U.S. patent application number 12/724566 was filed with the patent office on 2010-07-08 for antiviral compositions.
Invention is credited to Lieven Baert, Geert VERRECK.
Application Number | 20100172970 12/724566 |
Document ID | / |
Family ID | 8240674 |
Filed Date | 2010-07-08 |
United States Patent
Application |
20100172970 |
Kind Code |
A1 |
VERRECK; Geert ; et
al. |
July 8, 2010 |
ANTIVIRAL COMPOSITIONS
Abstract
The present invention is concerned with pharmaceutical
compositions of antiviral compounds which can be administered to a
mammal, in particular a human, suffering from a viral infection.
These compositions comprise particles obtainable by melt-extruding
a mixture comprising one or more antiviral compounds and one or
more appropriate water-soluble polymers and subsequently milling
said melt-extruded mixture.
Inventors: |
VERRECK; Geert; (Malle,
BE) ; Baert; Lieven; (Brugge, BE) |
Correspondence
Address: |
PHILIP S. JOHNSON;JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK
NJ
08933-7003
US
|
Family ID: |
8240674 |
Appl. No.: |
12/724566 |
Filed: |
March 16, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11733507 |
Apr 10, 2007 |
|
|
|
12724566 |
|
|
|
|
10088805 |
Mar 21, 2002 |
7241458 |
|
|
PCT/EP2000/008522 |
Aug 31, 2000 |
|
|
|
11733507 |
|
|
|
|
Current U.S.
Class: |
424/451 ;
424/464; 424/489; 424/490; 514/245; 514/272; 514/275 |
Current CPC
Class: |
A61K 31/53 20130101;
A61K 31/506 20130101; A61P 31/12 20180101; A61K 31/513 20130101;
A61K 9/146 20130101; A61P 31/18 20180101 |
Class at
Publication: |
424/451 ;
424/464; 424/489; 424/490; 514/245; 514/272; 514/275 |
International
Class: |
A61K 9/48 20060101
A61K009/48; A61K 9/20 20060101 A61K009/20; A61K 9/14 20060101
A61K009/14; A61K 9/16 20060101 A61K009/16; A61K 31/53 20060101
A61K031/53; A61K 31/505 20060101 A61K031/505; A61P 31/12 20060101
A61P031/12 |
Foreign Application Data
Date |
Code |
Application Number |
Sep 24, 1999 |
EP |
99203128.6 |
Claims
1. (canceled)
2. (canceled)
3. (canceled)
4. (canceled)
5. (canceled)
6. (canceled)
7. (canceled)
8. (canceled)
9. (canceled)
10. (canceled)
11. (canceled)
12. (canceled)
13. (canceled)
14. (canceled)
15. (canceled)
16. (canceled)
17. (canceled)
18. (canceled)
19. (canceled)
20. (canceled)
21. (canceled)
22. (canceled)
23. (canceled)
24. (canceled)
25. A particle consisting of a solid dispersion comprising (a) a
compound of formula ##STR00051## a N-oxide, a pharmaceutically
acceptable addition salt, a quaternary amine or a stereochemically
isomeric form thereof, wherein
-b.sup.1=b.sup.2-C(R.sup.2a)=b.sup.3-b.sup.4=represents a bivalent
radical of formula --CH.dbd.CH--C(R.sup.2a).dbd.CH--CH.dbd. (b-1);
--N.dbd.CH--C(R.sup.2a).dbd.CH--CH.dbd. (b-2);
--CH.dbd.N--C(R.sup.2a).dbd.CH--CH.dbd. (b-3);
--N.dbd.CH--C(R.sup.2a).dbd.N--CH.dbd. (b-4);
--N.dbd.CH--C(R.sup.2a).dbd.CH--N.dbd. (b-5);
--CH.dbd.N--C(R.sup.2a).dbd.N--CH.dbd. (b-6);
--N.dbd.N--C(R.sup.2a).dbd.CH--CH.dbd. (b-7); q is 0, 1, 2; or
where possible q is 3 or 4; R.sup.1 is hydrogen, aryl, formyl,
C.sub.1-6alkylcarbonyl, C.sub.1-6alkyl, C.sub.1-6alkyloxycarbonyl,
C.sub.1-6alkyl substituted with formyl, C.sub.1-6alkylcarbonyl,
C.sub.1-6alkyloxycarbonyl; R.sup.2a is cyano, aminocarbonyl, mono-
or di(methyl)aminocarbonyl, C.sub.1-6alkyl substituted with cyano,
aminocarbonyl or mono- or di(methyl)aminocarbonyl, C.sub.2-6alkenyl
substituted with cyano, or C.sub.2-6alkynyl substituted with cyano;
each R.sup.2 independently is hydroxy, halo, C.sub.1-6alkyl
optionally substituted with cyano or C(.dbd.O)R.sup.6,
C.sub.3-7cycloalkyl, C.sub.2-6alkenyl optionally substituted with
one or more halogen atoms or cyano, C.sub.2-6alkynyl optionally
substituted with one or more halogen atoms or cyano,
C.sub.1-6alkyloxy, C.sub.1-6alkyloxycarbonyl, carboxyl, cyano,
nitro, amino, mono- or di(C.sub.1-6alkyl)amino, polyhalomethyl,
polyhalomethyloxy, polyhalomethylthio, --S(.dbd.O).sub.pR.sup.6,
--NH--S(.dbd.O).sub.pR.sup.6, --C(.dbd.O)R.sup.6, --NHC(.dbd.O)H,
--C(.dbd.O)NHNH.sub.2, --NHC(.dbd.O)R.sup.6, --C(.dbd.NH)R.sup.6 or
a radical of formula ##STR00052## wherein each A independently is
N, CH or CR.sup.6; B is NH, O, S or NR.sup.6; p is 1 or 2; and
R.sup.6 is methyl, amino, mono- or dimethylamino or polyhalomethyl;
L is C.sub.1-10alkyl, C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.3-7cycloalkyl, whereby each of said aliphatic group may be
substituted with one or two substituents independently selected
from C.sub.3-7cycloalkyl, indolyl or isoindolyl, each optionally
substituted with one, two, three or four substituents each
independently selected from halo, C.sub.1-6alkyl, hydroxy,
C.sub.1-6alkyloxy, cyano, aminocarbonyl, nitro, amino,
polyhalomethyl, polyhalomethyloxy and C.sub.1-6alkylcarbonyl,
phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein
each of said aromatic rings may optionally be substituted with one,
two, three, four or five substituents each independently selected
from the substituents defined in R.sup.2; or L is --X--R.sup.3
wherein R.sup.3 is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or
pyridazinyl, wherein each of said aromatic rings may optionally be
substituted with one, two, three, four or five substituents each
independently selected from the substituents defined in R.sup.2;
and X is --NR.sup.1--, --NH--NH--, --N.dbd.N--, --O--,
--C(.dbd.O)--, --CHOH--, --S--, --S(.dbd.O)-- or
--S(.dbd.O).sub.2--; Q represents hydrogen, C.sub.1-6alkyl, halo,
polyhaloC.sub.1-6alkyl or NR.sup.4R.sup.5; and R.sup.4 and R.sup.5
are each independently selected from hydrogen, hydroxy,
C.sub.1-12alkyl, C.sub.1-12alkyloxy, C.sub.1-12alkylcarbonyl,
C.sub.1-12alkyloxycarbonyl, aryl, amino, mono- or
di(C.sub.1-12alkyl)amino, mono- or di(C.sub.1-12alkyl)aminocarbonyl
wherein each of the aforementioned C.sub.1-12alkyl groups may
optionally and each individually be substituted with one or two
substituents each independently selected from hydroxy,
C.sub.1-6alkyloxy, hydroxyC.sub.1-6alkyloxy, carboxyl,
C.sub.1-6alkyloxycarbonyl, cyano, amino, imino, mono- or
di(C.sub.1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy,
polyhalomethylthio, --S(.dbd.O).sub.pR.sup.6,
--NH--S(.dbd.O).sub.pR.sup.6, --C(.dbd.O)R.sup.6, --NHC(.dbd.O)H,
--C(.dbd.O)NHNH.sub.2, --NHC(.dbd.O)R.sup.6, --C(.dbd.NH)R.sup.6,
aryl and Het; or R.sup.4 and R.sup.5 taken together may form
pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or
di(C.sub.1-12alkyl)aminoC.sub.1-4alkylidene; Y represents hydroxy,
halo, C.sub.3-7cycloalkyl, C.sub.2-6alkenyl optionally substituted
with one or more halogen atoms, C.sub.2-6alkynyl optionally
substituted with one or more halogen atoms, C.sub.1-6alkyl
substituted with cyano or C(.dbd.O)R.sup.6, C.sub.1-6alkyloxy,
C.sub.1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or
di(C.sub.1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy,
polyhalomethylthio, --S(.dbd.O).sub.pR.sup.6,
--NH--S(.dbd.O).sub.pR.sup.6, --C(.dbd.O)R.sup.6, --NHC(.dbd.O)H,
--C(.dbd.O)NHNH.sub.2, --NHC(.dbd.O)R.sup.6, --C(.dbd.NH)R.sup.6 or
aryl; aryl is phenyl or phenyl substituted with one, two, three,
four or five substituents each independently selected from halo,
C.sub.1-6alkyl, C.sub.3-7cycloalkyl, C.sub.1-6alkyloxy, cyano,
nitro, polyhaloC.sub.1-6alkyl and polyhaloC.sub.1-6alkyloxy; Het is
an aliphatic or aromatic heterocyclic radical; said aliphatic
heterocyclic radical is selected from pyrrolidinyl, piperidinyl,
homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and
tetrahydrothienyl wherein each of said aliphatic heterocyclic
radical may optionally be substituted with an oxo group; and said
aromatic heterocyclic radical is selected from pyrrolyl, furanyl,
thienyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein
each of said aromatic heterocyclic radical may optionally be
substituted with hydroxy; and (b) one or more pharmaceutically
acceptable water-soluble polymers.
26. A particle according to claim 25 wherein the compound of
formula (I-B) is a compound wherein
-b.sup.1=b.sup.2-C(R.sup.2a)=b.sup.3-b.sup.4=is a radical of
formula (b-1); q is 0; R.sup.2a is cyano or --C(.dbd.O)NH.sub.2; Y
is cyano, --C(.dbd.O)NH.sub.2 or a halogen; Q is hydrogen or
--NR.sup.4R.sup.5; L is --X--R.sup.3 wherein R.sup.3 is substituted
phenyl.
27. A particle according to claim 25 wherein the compound of
formula (I-B) is a compound wherein R.sup.2a is cyano; Y is halo; Q
is NH.sub.2; L is X--R.sup.3 wherein X is NR.sup.1, O or S, and
R.sup.3 is phenyl substituted with C.sub.1-6alkyl, halogen or
cyano.
28. A particle according to claim 25 wherein the compound of
formula (I-B) is a compound wherein L is --X--R.sup.3 wherein
R.sup.3 is 2,4,6-trisubstituted phenyl, each substituent
independently selected from chloro, bromo, fluoro, cyano or
C.sub.1-4alkyl.
29. A particle according to claim 25 wherein the compound of
formula (I-B) is a compound wherein Y is chloro or bromo and Q is
hydrogen or amino
30. A particle according to claim 25 wherein the compound of
formula (I-B) is a compound wherein the moiety in the 2 position of
the pyrimidine ring is a 4-cyano-anilino group.
31. A particle according to claim 25 wherein the compound of
formula (I-B) is a compound wherein the moiety in the 2 position of
the pyrimidine ring is a 4-cyano-anilino group, L is --X--R.sup.3
wherein R.sup.3 is a 2,4,6-trisubstituted phenyl, Y is a halogen
and Q is hydrogen or NH.sub.2.
32. A particle according to claim 25 wherein the compound of
formula (I-B) is selected from
4-[[4-amino-5-chloro-6-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino-
]benzonitrile;
4-[[5-chloro-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzoni-
trile;
4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]ben-
zonitrile;
4-[[4-amino-5-chloro-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-py-
rimidinyl]amino]-benzonitrile;
4-[[5-bromo-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]ben-
zonitrile;
4-[[4-amino-5-chloro-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimi-
dinyl]amino]benzonitrile; and a N-oxide, a pharmaceutically
acceptable addition salt or a quaternary amine thereof.
33. A particle according to claim 25 wherein the water-soluble
polymer is a polymer that has an apparent viscosity of 1 to 5000
mPas when dissolved at 20.degree. C. in an aqueous solution at 2%
(w/v).
34. A particle according to claim 25 wherein the water-soluble
polymer is selected from the group comprising alkylcelluloses,
hydroxyalkylcelluloses, hydroxyalkyl alkylcelluloses,
carboxyalkylcelluloses, alkali metal salts of
carboxyalkylcelluloses, carboxyalkylalkylcelluloses,
carboxyalkylcellulose esters, starches, pectines, chitosan, di-,
oligo- or polysaccharides, polyacrylic acids and the salts thereof,
polymethacrylic acids, the salts and esters thereof, methacrylate
copolymers, polyvinylalcohol, polyalkylene oxides such as
polyethylene oxide and polypropylene oxide and copolymers of
ethylene oxide and propylene oxide.
35. A particle according to claim 34 wherein the water-soluble
polymer is selected from the group comprising methylcellulose;
hydroxymethylcellulose; hydroxyethylcellulose;
hydroxypropylcellulose; hydroxybutylcellulose; hydroxyethyl
methylcellulose; hydroxypropyl methylcellulose;
carboxymethylcellulose; sodium carboxymethylcellulose;
carboxymethylethylcellulose; sodium carboxymethylamylopectine;
chitosan; trehalose; cyclodextrins; alginic acid, alkali metal and
ammonium salts thereof; carrageenans; galactomannans; tragacanth;
agar-agar; gummi arabicum; guar gummi; xanthan gummi; polyethylene
oxide; polypropylene oxide; and copolymers of ethylene oxide and
propylene oxide.
36. A particle according to claim 34 wherein the water-soluble
polymer is selected from Eudragit E.RTM. and hydroxypropyl
methylcellulose.
37. A particle according to claim 34 wherein the water-soluble
polymer is an aminoalkyl methacrylate copolymer.
38. A particle according to claim 34 wherein the water-soluble
polymer is hydroxypropyl methylcellulose.
39. A particle according to claim 38 wherein the hydroxypropyl
methylcellulose has an apparent viscosity from about 1 to about 100
mPas when dissolved at 20.degree. C. in an aqueous solution at 2%
(w/v).
40. A particle according to claim 38 wherein the hydroxypropyl
methylcellulose has an apparent viscosity from about 3 to about 15
mPas when dissolved at 20.degree. C. in an aqueous solution at 2%
(w/v).
41. A particle according to claim 38 wherein the hydroxypropyl
methylcellulose has an apparent viscosity of about 5 mPas when
dissolved at 20.degree. C. in an aqueous solution at 2% (w/v).
42. A particle according to claim 38 wherein the hydroxypropyl
methylcellulose is hydroxypropyl methylcellulose HPMC 2910 5
mPas.
43. A particle according to claim 25 wherein the weight-by-weight
ratio of (a):(b) is in the range of 1:1 to 1:899.
44. A particle according to claim 43 wherein the weight-by-weight
ratio of (a):(b) is in the range of 1:1 to 1:100.
45. A particle according to claim 44 wherein the weight-by-weight
ratio of (a):(b) is in the range of 1:1 to 1:5.
46. A particle according to claim 42 wherein the weight-by-weight
ratio of (a):(b) is in the range of from about 1:1 to about
1:3.
47. A particle according to claim 46 wherein the weight-by-weight
ratio of (a):(b) is in the range of about 1:1.5.
48. A particle according to claim 25 wherein the compound of
formula (I-B) is in a non-crystalline phase.
49. A particle according to claim 25 wherein the solid dispersion
is in the form of a solid solution comprising (a) and (b), or in
the form of a dispersion wherein amorphous or microcrystalline (a)
or amorphous or microcrystalline (b) is dispersed more or less
evenly in a solid solution comprising (a) and (b).
50. A particle according to claim 25 having a particle size of less
than 1500 .mu.m.
51. A particle according to claim 25 having a particle size of less
than 250 .mu.m.
52. A particle according to claim 25 having a particle size of less
than 125 .mu.m.
53. A particle according to claim 25 further comprising one or more
pharmaceutically acceptable excipients.
54. A solid dispersion comprising (a) a compound of formula (I-B)
as defined in claim 25; and (b) one or more pharmaceutically
acceptable water-soluble polymers.
55. A solid dispersion according to claim 54 wherein the water
soluble polymer is a polymer that has an apparent viscosity of 1 to
5000 mPas when dissolved at 20.degree. C. in an aqueous solution at
2% (w/v).
56. A solid dispersion according to claim 54 wherein the
weight-by-weight ratio of components (a):(b) is 1:1 to 1:5.
57. A solid dispersion according to claim 54 which is in the form
of a solid solution comprising (a) and (b).
58. A solid dispersion according to claim 54 wherein the solid
dispersion is in the form of a solid solution comprising (a) and
(b), or in the form of a dispersion wherein amorphous or
microcrystalline (a) or amorphous or microcrystalline (b) is
dispersed more or less evenly in a solid solution comprising (a)
and (b).
59. A pharmaceutical dosage form comprising a therapeutically
effective amount of particles as claimed in claim 25.
60. A dosage form according to claim 59 which is a tablet.
61. A dosage form according to claim 60 for immediate release of a
compound of formula (I-B) upon oral ingestion wherein said
particles are homogeneously distributed throughout a mixture of a
diluent and a disintegrant.
62. A dosage form according to claim 59 surrounded by a film-coat
comprising a film-forming polymer, a plasticizer and optionally a
pigment.
63. A dosage form according to claim 61 wherein the diluent is a
spray-dried mixture of lactose monohydrate and microcrystalline
cellulose (75:25), and the disintegrant is crospovidone or
croscarmellose.
64. A dosage form according to claim 59 wherein the weight of said
particles is at least 40% of the total weight of the dosage
form.
65. A dosage form according to claim 59 containing from 200 to 400
mg of a compound of formula (I-B) per unit dosage form.
66. A dosage form according to claim 59 containing from 5 to 200 mg
of a compound of formula (I-B) per unit dosage form.
67. A process of preparing a particle according to claim 25
comprising spray-drying of a solution of the components (a) and
(b).
68. A process of preparing a particle according to claim 25
comprising blending the components (a) and (b), extruding said
blend at a temperature in the range of 20-300.degree. C. and
grinding the extrudate, and optionally sieving the particles.
69. A process of preparing a particle according to claim 25
comprising milling or grinding a solid dispersion comprising (a) a
compound of formula (I-B); and (b) one or more pharmaceutically
acceptable polymers.
70. A particle according to claim 25 consisting of a solid solution
comprising two parts by weight of a compound of formula (I-B) and
three parts by weight of hydroxypropyl methylcellulose HPMC 2910 5
mPas, obtainable by blending said components, extruding the blend
at a temperature in the range of 20.degree. C.-300.degree. C.,
grinding the extrudate, and optionally sieving the thus obtained
particles.
71. A process of preparing a solid dispersion according to claim 54
characterized by (a) spray-drying of a solution of the components
(a) and (b); (b) preparing a solution of the components (a) and
(b), pouring said solution onto a large surface so as to form a
thin film, and evaporating the solvent therefrom; or (c)
melt-extruding the components (a) and (b).
72. A process of preparing a pharmaceutical dosage form
characterized by blending a therapeutically effective amount of
particles according to claim 25 with pharmaceutically acceptable
excipients and compressing said blend into tablets or filling said
blend in capsules.
73. Particles according to claim 25 for use in preparing a
pharmaceutical dosage form for oral administration to a mammal
suffering from a viral infection.
74. Particles according to claim 25 for use in preparing a
pharmaceutical dosage form for oral administration to a mammal
suffering from a viral infection, wherein a single such dosage form
can be administered once daily to said mammal
75. A pharmaceutical package suitable for commercial sale
comprising a container, an oral dosage form of a compound of
formula (I-B) as claimed in claim 60, and associated with said
package written matter.
76. A particle according to claim 31 wherein the water-soluble
polymer is hydroxypropyl methylcellulose.
77. A particle according to claim 76 wherein the weight-by-weight
ratio of (a):(b) is in the range of from about 1:1 to about 1:3.
Description
[0001] The present invention concerns pharmaceutical compositions
of antiviral compounds which can be administered to a mammal, in
particular a human, suffering from a viral infection. These
compositions comprise particles obtainable by melt-extruding a
mixture comprising one or more antiviral compounds and one or more
appropriate water-soluble polymers and subsequently milling said
melt-extruded mixture.
[0002] The antiviral compounds constituting the pharmaceutical
compositions of the present invention are dispersed in a carrier by
melt-extrusion to obtain a solid dispersion in order to improve
their bio-availability.
[0003] Compounds structurally related to the present antiviral
compounds are disclosed in the prior art. [0004] Pharmazie (1990),
45(4), p 284 discloses trisubstituted derivatives of
2,4,6-trichloro-1,3,5-triazine having anti-bacterial activity.
[0005] Chem. Abstr. (1990), 112, no. 1 concerns synthesis of
fluorinated derivatives of 1,3,5-triazine as potential bactericidal
agents. [0006] Chem. Abstr. (1988), 108, no. 15 describes
2,4,6-mixed functional substituted 1,3,5-triazines as
anti-convulsives. [0007] Chem. Abstr. (1983), 98, no. 11 concerns
the preparation of
p-(2,4-diarylamino-6-S-triazinylamino)-benzaldehyde/acetophenone
thiosemicarbazones as potential tuberculostatic agents. [0008]
Chem. Abstr. (1981), 95, no. 4 describes the preparation of
polypyromellitimides containing dialkylamino-type melamine units.
[0009] Chem. Abstr. (1975), 83, no. 23 describes optically active
S-triazine derivatives. [0010] FR-A-2099730 concerns diamino-, and
dinitro-S-triazines, which can be used for the preparation of
polymeric material and colorants. [0011] EP-A-0795549 discloses
bis-aryloxy(amino)-triazinyl-oxy(amino)aryl derivatives as
antiviral agents. [0012] Ashley et al. (J. Chem. Soc. (1960),
January 1, pp 4525-4532) describes amidinoanilino-1,3,5-triazines
having potential trypanocidal activity. [0013] WO 91/18887
discloses diaminopyrimidines as gastric acid secretion inhibitors.
[0014] EP-A-0588762 concerns the use of N-phenyl-2-pyrimidinamine
derivatives as proteinkinase C-inhibitors and anticancer agents.
[0015] WO 95/10506 describes N-alkyl-N-aryl-pyrimidinamines and
derivatives thereof as Corticotropin Releasing Factor receptor
antagonists. [0016] EP-A-0270111 discloses pyrimidine derivatives
as fungicides in agricultural and horticultural compositions.
[0017] J. Med. Chem. (1969), 10, pp 974-975 describes
2,4-bis(arylamino)-5-methyl-pyrimidines and Chem. Abstr. (1981),
95, no. 11 describes 2,4-bis(arylamino)-6-methylpyrimidines as
antimicrobial agents. [0018] J. Med. Chem. (1996), 39, pp 4358-4360
deals with 4-anilino-6-aminopyrimidines as non-peptide high
affinity human Cortocotropin Releasing Factor.sub.1 receptor
antagonists. [0019] EP-0,834,507 discloses substituted diamino
1,3,5-triazine derivatives having HIV replication inhibiting
properties.
[0020] The particles of the present invention consist of a solid
dispersion comprising
(a) an antiviral compound of formula
##STR00001##
a N-oxide, a pharmaceutically acceptable addition salt or a
stereochemically isomeric form thereof, wherein [0021] Y is
CR.sup.5 or N; [0022] A is CH, CR.sup.4 or N; [0023] n is 0, 1, 2,
3 or 4; [0024] Q is --NR.sup.1R.sup.2 or when Y is CR.sup.5 then Q
may also be hydrogen; [0025] R.sup.1 and R.sup.2 are each
independently selected from hydrogen, hydroxy, C.sub.1-12alkyl,
C.sub.1-12alkyloxy, C.sub.1-12alkylcarbonyl,
C.sub.1-12alkyloxycarbonyl, aryl, amino, mono- or
di(C.sub.1-12alkyl)amino, mono- or di(C.sub.1-12alkyl)aminocarbonyl
wherein each of the aforementioned C.sub.1-12alkyl groups may
optionally and each individually be substituted with one or two
substituents each independently selected from hydroxy,
C.sub.1-6alkyloxy, hydroxyC.sub.1-6alkyloxy, carboxyl,
C.sub.1-6alkyloxycarbonyl, cyano, amino, imino, aminocarbonyl,
aminocarbonylamino, mono- or di(C.sub.1-6alkyl)amino, aryl and Het;
or [0026] R.sup.1 and R.sup.2 taken together may form pyrrolidinyl,
piperidinyl, morpholinyl, azido or mono- or
di(C.sub.1-12alkyl)aminoC.sub.1-4alkylidene; [0027] R.sup.3 is
hydrogen, aryl, C.sub.1-6alkylcarbonyl, C.sub.1-6alkyl,
C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkyl substituted with
C.sub.1-6alkyloxycarbonyl; and [0028] each R.sup.4 independently is
hydroxy, halo, C.sub.1-6alkyl, C.sub.1-6alkyloxy, cyano, amino
carbonyl, nitro, amino, trihalomethyl, trihalomethyloxy, or when Y
is CR.sup.5 then R.sup.4 may also represent C.sub.1-6alkyl
substituted with cyano or aminocarbonyl; [0029] R.sup.5 is hydrogen
or C.sub.1-4alkyl; [0030] L is --X.sup.1--R.sup.6 or
--X.sup.2-Alk-R.sup.7 wherein [0031] R.sup.6 and R.sup.7 each
independently are phenyl or phenyl substituted with one, two,
three, four or five substituents each independently selected from
halo, hydroxy, C.sub.1-6alkyl, C.sub.1-6alkyloxy,
C.sub.1-6alkylcarbonyl, C.sub.1-6alkyloxycarbonyl, formyl, cyano,
nitro, amino, and trifluoromethyl; or when Y is CR.sup.5 then
R.sup.6 and R.sup.2 may also be selected from phenyl substituted
with one, two, three, four or five substituents each independently
selected from aminocarbonyl, trihalomethyloxy and trihalomethyl; or
when Y is N then R.sup.6 and R.sup.7 may also be selected from
indanyl or indolyl, each of said indanyl or indolyl may be
substituted with one, two, three, four or five substituents each
independently selected from halo, hydroxy, C.sub.1-6alkyl,
C.sub.1-6alkyloxy, C.sub.1-6alkylcarbonyl,
C.sub.1-6alkyloxycarbonyl, formyl, cyano, nitro, amino, and
trifluoromethyl; when R.sup.6 is optionally substituted indanyl or
indolyl, it is preferably attached to the remainder of the molecule
via the fused phenyl ring. For instance, R.sup.6 is suitably 4-,
5-, 6- or 7-indolyl; [0032] X.sup.1 and X.sup.2 are each
independently --NR.sup.3--, --NH--NH--, --N.dbd.N--, --O--, --S--,
--S(.dbd.O)-- or --S(.dbd.O).sub.2--; [0033] Alk is
C.sub.1-4alkanediyl; or [0034] when Y is CR.sup.5 then L may also
be selected from C.sub.1-10alkyl, C.sub.3-10alkenyl,
C.sub.3-10alkynyl, C.sub.3-7cycloalkyl, or C.sub.1-10alkyl
substituted with one or two substituents independently selected
from C.sub.3-7cycloalkyl, indanyl, indolyl and phenyl, wherein said
phenyl, indanyl and indolyl may be substituted with one, two,
three, four or where possible five substituents each independently
selected from halo, hydroxy, C.sub.1-6alkyl, C.sub.1-6alkyloxy,
cyano, aminocarbonyl, C.sub.1-6alkyloxycarbonyl, formyl, nitro,
amino, trihalomethyl, trihalomethyloxy and C.sub.1-6alkylcarbonyl;
[0035] aryl is phenyl or phenyl substituted with one, two, three,
four or five substituents each independently selected from halo,
C.sub.1-6alkyl, C.sub.1-6alkyloxy, cyano, nitro and
trifluoromethyl; [0036] Het is an aliphatic or aromatic
heterocyclic radical; said aliphatic heterocyclic radical is
selected from pyrrolidinyl, piperidinyl, homopiperidinyl,
piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydrothienyl
wherein each of said aliphatic heterocyclic radical may optionally
be substituted with an oxo group; and said aromatic heterocyclic
radical is selected from pyrrolyl, furanyl, thienyl, pyridyl,
pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said
aromatic heterocyclic radical may optionally be substituted with
hydroxy; [0037] or [0038] an antiviral compound of formula
##STR00002##
[0038] the N-oxides, the pharmaceutically acceptable addition
salts, quaternary amines and the stereochemically isomeric forms
thereof, wherein [0039]
-b.sup.1=b.sup.2-C(R.sup.2a)=b.sup.3-b.sup.4=represents a bivalent
radical of formula
[0039] --CH.dbd.CH--C(R.sup.2a).dbd.CH--CH.dbd. (b-1);
--N.dbd.CH--C(R.sup.2a).dbd.CH--CH.dbd. (b-2);
--CH.dbd.N--C(R.sup.2a).dbd.CH--CH.dbd. (b-3);
--N.dbd.CH--C(R.sup.2a).dbd.N--CH.dbd. (b-4);
--N.dbd.CH--C(R.sup.2a).dbd.CH--N.dbd. (b-5);
--CH.dbd.N--C(R.sup.2a).dbd.N--CH.dbd. (b-6);
--N.dbd.N--C(R.sup.2a).dbd.CH--CH.dbd. (b-7); [0040] q is 0, 1, 2;
or where possible q is 3 or 4; [0041] R.sup.1 is hydrogen, aryl,
formyl, C.sub.1-6alkylcarbonyl, C.sub.1-6alkyl,
C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkyl substituted with formyl,
C.sub.1-6alkylcarbonyl, C.sub.1-6alkyloxycarbonyl; [0042] R.sup.2a
is cyano, aminocarbonyl, mono- or di(methyl)aminocarbonyl,
C.sub.1-6 alkyl substituted with cyano, aminocarbonyl or mono- or
di(methyl)aminocarbonyl, C.sub.2-6alkenyl substituted with cyano,
or C.sub.2-6 alkynyl substituted with cyano; [0043] each R.sup.2
independently is hydroxy, halo, C.sub.1-6alkyl optionally
substituted with cyano or --C(.dbd.O)R.sup.6, C.sub.3-7cycloalkyl,
C.sub.2-6alkenyl optionally substituted with one or more halogen
atoms or cyano, C.sub.2-6alkynyl optionally substituted with one or
more halogen atoms or cyano, C.sub.1-6alkyloxy,
C.sub.1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or
di(C.sub.1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy,
polyhalomethylthio, --S(.dbd.O).sub.pR.sup.6,
--NH--S(.dbd.O).sub.pR.sup.6, --C(.dbd.O)R.sup.6, --NHC(.dbd.O)H,
--C(.dbd.O)NHNH.sub.2, --NHC(.dbd.O)R.sup.6, --C(.dbd.NH)R.sup.6 or
a radical of formula
##STR00003##
[0043] wherein each A independently is N, CH or CR.sup.6; [0044] B
is NH, O, S or NR.sup.6; [0045] p is 1 or 2; and [0046] R.sup.6 is
methyl, amino, mono- or dimethylamino or polyhalomethyl; [0047] L
is C.sub.1-10alkyl, C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.3-7cycloalkyl, whereby each of said aliphatic group may be
substituted with one or two substituents independently selected
from [0048] C.sub.3-7cycloalkyl, [0049] indolyl or isoindolyl, each
optionally substituted with one, two, three or four substituents
each independently selected from halo, C.sub.1-6alkyl, hydroxy,
C.sub.1-6alkyloxy, cyano, aminocarbonyl, nitro, amino,
polyhalomethyl, polyhalomethyloxy and C.sub.1-6alkylcarbonyl,
[0050] phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl,
wherein each of said aromatic rings may optionally be substituted
with one, two, three, four or five substituents each independently
selected from the substituents defined in R.sup.2; or [0051] L is
--X--R.sup.3 wherein [0052] R.sup.3 is phenyl, pyridinyl,
pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said
aromatic rings may optionally be substituted with one, two, three,
four or five substituents each independently selected from the
substituents defined in R.sup.2; and [0053] X is --NR.sup.1--,
--NH--NH--, --N.dbd.N--, --O--, --C(.dbd.O)--, --CHOH--, --S--,
--S(.dbd.O)-- or --S(.dbd.O).sub.2--; [0054] Q represents hydrogen,
C.sub.1-6alkyl, halo, polyhaloC.sub.1-6alkyl or --NR.sup.4R.sup.5;
and [0055] R.sup.4 and R.sup.5 are each independently selected from
hydrogen, hydroxy, C.sub.1-12alkyl, C.sub.1-12alkyloxy,
C.sub.1-12alkylcarbonyl, C.sub.1-12alkyloxycarbonyl, aryl, amino,
mono- or di(C.sub.1-12alkyl)amino, mono- or
di(C.sub.1-12alkyl)aminocarbonyl wherein each of the aforementioned
C.sub.1-12alkyl groups may optionally and each individually be
substituted with one or two substituents each independently
selected from hydroxy, C.sub.1-6alkyloxy, hydroxyC.sub.1-6alkyloxy,
carboxyl, C.sub.1-6alkyloxycarbonyl, cyano, amino, imino, mono- or
di(C.sub.1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy,
polyhalomethylthio, --S(.dbd.O).sub.pR.sup.6,
--NH--S(.dbd.O).sub.pR.sup.6, --C(.dbd.O)R.sup.6, --NHC(.dbd.O)H,
--C(.dbd.O)NHNH.sub.2, --NHC(.dbd.O)R.sup.6, --C(.dbd.NH)R.sup.6,
aryl and Het; or [0056] R.sup.4 and R.sup.5 taken together may form
pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or
di(C.sub.1-12alkyl)aminoC.sub.1-4alkylidene; [0057] Y represents
hydroxy, halo, C.sub.3-7cycloalkyl, C.sub.2-6alkenyl optionally
substituted with one or more halogen atoms, C.sub.2-6alkynyl
optionally substituted with one or more halogen atoms,
C.sub.1-6alkyl substituted with cyano or --C(.dbd.O)R.sup.6,
C.sub.1-6alkyloxy, C.sub.1-6alkyloxycarbonyl, carboxyl, cyano,
nitro, amino, mono- or di(C.sub.1-6alkyl)amino, polyhalomethyl,
polyhalomethyloxy, polyhalomethylthio, --S(.dbd.O).sub.pR.sup.6,
--NH--S(.dbd.O).sub.pR.sup.6, --C(.dbd.O)R.sup.6, --NHC(.dbd.O)H,
--C(.dbd.O)NHNH.sub.2, --NHC(.dbd.O)R.sup.6, --C(.dbd.NH)R.sup.6 or
aryl; [0058] aryl is phenyl or phenyl substituted with one, two,
three, four or five substituents each independently selected from
halo, C.sub.1-6alkyl, C.sub.3-7cycloalkyl, C.sub.1-6alkyloxy,
cyano, nitro, polyhaloC.sub.1-6alkyl and polyhaloC.sub.1-6alkyloxy;
Het is an aliphatic or aromatic heterocyclic radical; said
aliphatic heterocyclic radical is selected from pyrrolidinyl,
piperidinyl, homopiperidinyl, piperazinyl, morpholinyl,
tetrahydrofuranyl and tetrahydrothienyl wherein each of said
aliphatic heterocyclic radical may optionally be substituted with
an oxo group; and said aromatic heterocyclic radical is selected
from pyrrolyl, furanyl, thienyl, pyridinyl, pyrimidinyl, pyrazinyl
and pyridazinyl wherein each of said aromatic heterocyclic radical
may optionally be substituted with hydroxy; Het is meant to include
all the possible isomeric forms of the heterocycles mentioned in
the definition of Het, for instance, pyrrolyl also includes
2H-pyrrolyl; the Het radical may be attached to the remainder of
the molecule of formula (I-B) through any ring carbon or heteroatom
as appropriate, thus, for example, when the heterocycle is
pyridinyl, it may be 2-pyridinyl, 3-pyridinyl or 4-pyridinyl. or
[0059] an antiviral compound of formula
##STR00004##
[0059] the N-oxides, the pharmaceutically acceptable addition
salts, quaternary amines and the stereochemically isomeric forms
thereof, wherein [0060] -a.sup.1=a.sup.2-a.sup.3=a.sup.4-
represents a bivalent radical of formula
[0060] --CH.dbd.CH--CH.dbd.CH-- (a-1);
--N.dbd.CH--CH.dbd.CH-- (a-2);
--N.dbd.CH--N.dbd.CH-- (a-3);
--N.dbd.CH--CH.dbd.N-- (a-4);
--N.dbd.N--CH.dbd.CH-- (a-5); [0061] n is 0, 1, 2, 3 or 4; and in
case -a.sup.1=a.sup.2-a.sup.3=a.sup.4- is (a-1), then n may also be
5; [0062] R.sup.1 is hydrogen, aryl, formyl,
C.sub.1-6alkylcarbonyl, C.sub.1-6alkyl, C.sub.1-6alkyloxycarbonyl,
C.sub.1-6alkyl substituted with formyl, C.sub.1-6alkylcarbonyl,
C.sub.1-6alkyloxycarbonyl; and [0063] each R.sup.2 independently is
hydroxy, halo, C.sub.1-6alkyl optionally substituted with cyano or
--C(.dbd.O)R.sup.4, C.sub.3-7cycloalkyl, C.sub.2-6alkenyl
optionally substituted with one or more halogen atoms or cyano,
C.sub.2-6alkynyl optionally substituted with one or more halogen
atoms or cyano, C.sub.1-6alkyloxy, C.sub.1-6alkyloxycarbonyl,
carboxyl, cyano, nitro, amino, mono- or di(C.sub.1-6alkyl)amino,
polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, [0064]
--S(.dbd.O).sub.pR.sup.4, --NH--S(.dbd.O).sub.pR.sup.4,
--C(.dbd.O)R.sup.4, --NHC(.dbd.O)H, --C(.dbd.O)NHNH.sub.2,
--NHC(.dbd.O)R.sup.4, --C(.dbd.NH)R.sup.4 or a radical of
formula
##STR00005##
[0064] wherein each A independently is N, CH or CR.sup.4; [0065] B
is NH, O, S or NR.sup.4; [0066] p is 1 or 2; and [0067] R.sup.4 is
methyl, amino, mono- or dimethylamino or polyhalomethyl; [0068] L
is C.sub.1-10alkyl, C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.3-7cycloalkyl, whereby each of said aliphatic group may be
substituted with one or two substituents independently selected
from [0069] C.sub.3-7cycloalkyl, [0070] indolyl or isoindolyl, each
optionally substituted with one, two, three or four substituents
each independently selected from halo, C.sub.1-6alkyl, hydroxy,
C.sub.1-6alkyloxy, cyano, aminocarbonyl, nitro, amino,
polyhalomethyl, polyhalomethyloxy and C.sub.1-6alkylcarbonyl,
[0071] phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl,
wherein each of said aromatic rings may optionally be substituted
with one, two, three, four or five substituents each independently
selected from the substituents defined in R.sup.2; or [0072] L is
--X--R.sup.3 wherein [0073] R.sup.3 is phenyl, pyridinyl,
pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said
aromatic rings may optionally be substituted with one, two, three,
four or five substituents each independently selected from the
substituents defined in R.sup.2; and [0074] X is --NR.sup.1--,
--NH--NH--, --N.dbd.N--, --O--, --C(.dbd.O)--, --CHOH--, --S--,
--S(.dbd.O)-- or --S(.dbd.O).sub.2--; [0075] aryl is phenyl or
phenyl substituted with one, two, three, four or five substituents
each independently selected from halo, C.sub.1-6alkyl,
C.sub.3-7cycloalkyl, C.sub.1-6alkyloxy, cyano, nitro,
polyhaloC.sub.1-6alkyl and polyhaloC.sub.1-6alkyloxy; [0076] with
the proviso that compounds wherein [0077] L is C.sub.1-3alkyl;
R.sup.1 is selected from hydrogen, ethyl and methyl;
-a.sup.1=a.sup.2-a.sup.3=a.sup.4- represents a bivalent radical of
formula (a-1); n is 0 or 1 and R.sup.2 is selected from fluoro,
chloro, methyl, trifluoromethyl, ethyloxy and nitro; or [0078] L is
--X--R.sup.3, X is --NH--; R.sup.1 is hydrogen;
-a.sup.1=a.sup.2-a.sup.3=a.sup.4- represents a bivalent radical of
formula (a-1); n is 0 or 1 and R.sup.2 is selected from chloro,
methyl, methyloxy, cyano, amino and nitro and R.sup.3 is phenyl,
optionally substituted with one substituent selected from chloro,
methyl, methyloxy, cyano, amino and nitro; [0079] and the compounds
[0080] N,N'-dipyridinyl-(1,3,5)-triazine-2,4-diamine; [0081]
(4-chloro-phenyl)-(4(1-(4-isobutyl-phenyl)-ethyl)-(1,3,5)
triazin-2-yl)-amine are not included; and (b) one or more
pharmaceutically acceptable water-soluble polymers.
[0082] As used in the foregoing definitions and hereinafter halo
defines fluoro, chloro, bromo and iodo; polyhalomethyl as a group
or part of a group is defined as mono- or polyhalosubstituted
methyl, in particular methyl with one or more fluoro atoms, for
example, difluoromethyl or trifluoromethyl; polyhaloC.sub.1-6alkyl
as a group or part of a group is defined as mono- or
polyhalosubstituted C.sub.1-6alkyl, for example, the groups defined
in halomethyl, 1,1-difluoro-ethyl and the like; in case more than
one halogen atoms are attached to an alkyl group within the
definition of polyhalomethyl or polyhaloC.sub.1-6alkyl, they may be
the same or different; C.sub.1-4alkyl as a group or part of a group
encompasses the straight and branched chained saturated hydrocarbon
radicals having from 1 to 4 carbon atoms such as, for example,
methyl, ethyl, propyl, butyl and the like; C.sub.1-6alkyl as a
group or part of a group encompasses the straight and branched
chained saturated hydrocarbon radicals as defined in C.sub.1-4alkyl
as well as the higher homologues thereof containing 5 or 6 carbon
atoms such as, for example pentyl or hexyl; C.sub.1-10alkyl as a
group or part of a group group encompasses the straight and
branched chained saturated hydrocarbon radicals as defined in
C.sub.1-6alkyl as well as the higher homologues thereof containing
7 to 10 carbon atoms such as, for example, heptyl, octyl, nonyl or
decyl; C.sub.1-10alkyl as a group or part of a group encompasses
the straight and branched chained saturated hydrocarbon radicals as
defined in C.sub.1-10alkyl as well as the higher homologues thereof
containing 11 or 12 carbon atoms such as, for example, undecyl,
dodecyl and the like; C.sub.1-4alkylidene as a group or part of a
group defines bivalent straight and branched chained hydrocarbons
having from 1 to 4 carbon atoms such as, for example, methylene,
ethylidene, propylidene, butylidene and the like;
C.sub.1-4alkanediyl as a group or part of a group encompasses those
radicals defined under C.sub.1-4alkylidene as well as other
bivalent straight and branched chained hydro-carbons having from 1
to 4 carbon atoms such as, for example, 1,2-ethanediyl,
1,3-propanediyl, 1,4-butanediyl and the like; C.sub.3-7cycloalkyl
as a group or part of a group is generic to cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl;
C.sub.3-10alkenyl as a group or part of a group defines straight
and branch chained hydrocarbon radicals containing one double bond
and having from 3 to 10 carbon atoms such as, for example,
2-propenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl,
3-hexenyl, 3-heptenyl, 2-octenyl, 2-nonenyl, 2-decenyl and the
like, whereby the carbon atom attached to the pyrimidine ring is
preferably an aliphatic carbon atom; C.sub.3-10alkynyl as a group
or part of a group defines straight and branch chained hydrocarbon
radicals containing one triple bond and having from 3 to 10 carbon
atoms such as, for example, 2-propynyl, 2-butynyl, 2-pentynyl,
3-pentynyl, 3-methyl-2-butynyl, 3-hexynyl, 3-heptynyl, 2-octynyl,
2-nonynyl, 2-decynyl and the like, whereby the carbon atom attached
to the pyrimidine ring is preferably an aliphatic carbon atom;
C.sub.2-6alkenyl defines straight and branched chain hydrocarbon
radicals having from 2 to 6 carbon atoms containing a double bond
such as ethenyl, propenyl, butenyl, pentenyl, hexenyl and the like;
C.sub.2-10alkenyl defines straight and branched chain hydrocarbon
radicals having from 2 to 10 carbon atoms containing a double bond
such as the groups defined for C.sub.2-6alkenyl and heptenyl,
octenyl, nonenyl, decenyl and the like; C.sub.2-6alkynyl defines
straight and branched chain hydrocarbon radicals having from 2 to 6
carbon atoms containing a triple bond such as ethynyl, propynyl,
butynyl, pentynyl, hexynyl and the like; C.sub.2-10alkynyl defines
straight and branched chain hydrocarbon radicals having from 2 to
10 carbon atoms containing a triple bond such as the groups defined
for C.sub.2-6alkynyl and heptynyl, octynyl, nonynyl, decynyl and
the like; C.sub.1-3alkyl as a group or part of a group encompasses
the straight and branched chain saturated hydrocarbon radicals
having from 1 to 3 carbon atoms such as, methyl, ethyl and propyl;
C.sub.4-10alkyl encompasses the straight and branched chain
saturated hydrocarbon radicals as defined above, having from 4 to
10 carbon atoms. The term C.sub.1-6alkyloxy defines straight or
branched chain saturated hydrocarbon radicals such as methoxy,
ethoxy, propyloxy, butyloxy, pentyloxy, hexyloxy, 1-methylethyloxy,
2-methyl-propyloxy, 2-methylbutyloxy and the like;
C.sub.3-6cycloalkyloxy is generic to cyclopropyloxy, cyclobutyloxy,
cyclopentyloxy and cyclohexyloxy.
[0083] As used herein before, the term (.dbd.O) forms a carbonyl
moiety when attached to a carbon atom, a sulfoxide group when
attached once to a sulfur atom, and a sulfonyl group when attached
twice to a sulfur atom.
[0084] When any variable (e.g. aryl, R.sup.3, R.sup.4 in formula
(I-A) etc.) occurs more than one time in any constituent, each
definition is independent.
[0085] Lines drawn into ring systems from substituents indicate
that the bond may be attached to any of the suitable ring atoms.
For instance for compounds of formula (I-A), R.sup.4 can be
attached to any available carbon atom of the phenyl or pyridyl
ring.
[0086] The addition salts as mentioned herein are meant to comprise
the therapeutically active addition salt forms which the compounds
of formula (I-A), (I-B) or (I-C) are able to form with appropriate
acids, such as, for example, inorganic acids such as hydrohalic
acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric;
phosphoric and the like acids; or organic acids such as, for
example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic,
malonic, succinic, maleic, fumaric, malic, tartaric, citric,
methane-sulfonic, ethanesulfonic, benzenesulfonic,
p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic
and the like acids.
[0087] The pharmaceutically acceptable addition salts as mentioned
hereinabove are also meant to comprise the therapeutically active
non-toxic base, in particular, a metal or amine addition salt forms
which the compounds of the present invention are able to form. Said
salts can conveniently be obtained by treating the compounds of the
present invention containing acidic hydrogen atoms with appropriate
organic and inorganic bases such as, for example, the ammonium
salts, the alkali and earth alkaline metal salts, e.g. the lithium,
sodium, potassium, magnesium, calcium salts and the like, salts
with organic bases, e.g. the benzathine, N-methyl-D-glucamine,
hydrabamine salts, and salts with amino acids such as, for example,
arginine, lysine and the like. Conversely said salt forms can be
converted by treatment with an appropriate base or acid into the
free acid or base form.
[0088] The term addition salts also comprises the hydrates and the
solvent addition forms which the compounds of formula (I-A), (I-B)
or (I-C) are able to form. Examples of such forms are e.g.
hydrates, alcoholates and the like.
[0089] The term stereochemically isomeric forms of the compounds of
formula (I-A), (I-B) or (I-C), as used hereinbefore, defines all
possible compounds made up of the same atoms bonded by the same
sequence of bonds but having different three-dimensional structures
which are not interchangeable, which the compounds of the present
invention may possess. Unless otherwise mentioned or indicated, the
chemical designation of a compound encompasses the mixture of all
possible stereochemically isomeric forms which said compound may
possess. Said mixture may contain all diastereomers and/or
enantiomers of the basic molecular structure of said compound. All
stereochemically isomeric forms of the compounds of formula (I-A),
(I-B) or (I-C) both in pure form or in admixture with each other
are intended to be embraced within the scope of the present
invention.
[0090] Some of the compounds of formula (I-A), (I-B) or (I-C) may
also exist in their tautomeric forms. Such forms although not
explicitly indicated in the above formula are intended to be
included within the scope of the present invention.
[0091] Whenever used hereinafter, the term compound of formula
(I-A), (I-B) or (I-C) is meant to include any subgroup thereof,
also the N-oxides, the pharmaceutically acceptable addition salts,
the quaternary amines and all stereoisomeric forms.
[0092] Suitable compounds of formula (I-A) are those wherein Y is
CR.sup.5 or N; A is CH, CR.sup.4 or N; n is 0, 1, 2, 3 or 4; Q is
--NR.sup.1R.sup.2; R.sup.1 and R.sup.2 are each independently
selected from hydrogen, hydroxy, C.sub.1-12alkyl,
C.sub.1-12alkyloxy, C.sub.1-12alkylcarbonyl,
C.sub.1-12alkyloxy-carbonyl, aryl, amino, mono- or
di(C.sub.1-12alkyl)amino, mono- or
di(C.sub.1-12alkyl)amino-carbonyl wherein each of the
aforementioned C.sub.1-12alkyl groups may optionally and each
individually be substituted with one or two substituents each
independently selected from hydroxy, C.sub.1-6alkyloxy,
hydroxyC.sub.1-6alkyloxy, carboxyl, C.sub.1-6alkyloxy-carbonyl,
cyano, amino, imino, aminocarbonyl, aminocarbonylamino, mono- or
di(C.sub.1-6alkyl)amino, aryl and Het; or R.sup.1 and R.sup.2 taken
together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or
mono- or di(C.sub.1-12alkyl)aminoC.sub.1-4alkylidene; R.sup.3 is
hydrogen, aryl, C.sub.1-6alkylcarbonyl, C.sub.1-6alkyl,
C.sub.1-6alkyloxycarbonyl, C.sub.1-6alkyl substituted with
C.sub.1-6alkyloxycarbonyl; each R.sup.4 independently is hydroxy,
halo, C.sub.1-6alkyl, C.sub.1-6alkyloxy, cyano, aminocarbonyl,
nitro, amino, trihalomethyl, trihalo-methyloxy; R.sup.5 is hydrogen
or C.sub.1-4alkyl; L is --X.sup.1--R.sup.6 or --X.sup.2-Alk-R.sup.7
wherein R.sup.6 and R.sup.7 each independently are phenyl or phenyl
substituted with one, two, three, four or five substituents each
independently selected from halo, hydroxy, C.sub.1-6alkyl,
C.sub.1-6alkyloxy, C.sub.1-6alkylcarbonyl,
C.sub.1-6alkyloxycarbonyl, formyl, cyano, nitro, amino, and
trifluoromethyl, X.sup.1 and X.sup.2 are each independently
--NR.sup.3--, --NH--NH--, --N.dbd.N--, --O--, --S--, --S(.dbd.O)--
or --S(.dbd.O).sub.2--, and Alk is C.sub.1-4alkanediyl; aryl is
phenyl or phenyl substituted with one, two, three, four or five
substituents each independently selected from halo, C.sub.1-6alkyl,
C.sub.1-6alkyloxy, cyano, nitro and trifluoromethyl; Het is an
aliphatic or aromatic heterocyclic radical; said aliphatic
heterocyclic radical is selected from pyrrolidinyl, piperidinyl,
homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and
tetrahydrothienyl wherein each of said aliphatic heterocyclic
radical may optionally be substituted with an oxo group; and said
aromatic heterocyclic radical is selected from pyrrolyl, furanyl,
thienyl, pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein
each of said aromatic heterocyclic radical may optionally be
substituted with hydroxy.
[0093] Most preferred compounds of formula (I-A) are [0094]
4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-2-pyrimidinyl]amino]benzonitri-
le (*1.B1; comp. 1); [0095]
6-[(2,6-dichlorophenyl)methyl]-N2-(4-fluorophenyl)-2,4-pyrimidinediamine
(*1.B1; comp. 2); [0096]
4-[[4-[(2,4-dichlorophenyl)methyl]-6-[(4-hydroxybutyl)amino]-2-pyrimidiny-
l]amino]-benzonitrile (*1.B2; comp. 3); [0097]
4-[[4-[(2,6-dichlorophenyl)methyl]-6-[(3-hydroxypropyl)amino]-2-pyrimidin-
yl]-amino]benzonitrile (*1.B1; comp. 4); [0098]
N-[2-[(4-cyanophenyl)amino]-6-[(2,6-dichlorophenyl)methyl]-4-pyrimidinyl]-
acetamide (*1.B7; comp. 5); [0099]
N-[2-[(4-cyanophenyl)amino]-6-[(2,6-dichlorophenyl)methyl]-4-pyrimidinyl]-
-butanamide (*1.B7; comp. 6); [0100]
4-[[2-amino-6-(2,6-dichlorophenoxy)-4-pyrimidinyl]amino]benzonitrile
(*1.B1; comp. 7); [0101]
4-[[4-[(2,6-dichlorophenyl)methyl]-6-[(2-hydroxy-2-phenylethyl)amino]-2-p-
yrimidinyl]amino]benzonitrile (*1.B2; comp. 8); [0102]
4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[3-(2-oxo-1-pyrrolidinyl)propyl]ami-
no]-2-pyrimidinyl]amino]benzonitrile (*1.B2; comp. 9); [0103]
4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[2-(2-hydroxyethoxy)ethyl]amino]-2--
pyrimidinyl]amino]benzonitrile monohydrochloride (*1.B2; comp. 10);
[0104]
4-[[4-[(2,6-dichlorophenyl)methyl]-6-[(2,3-dihydroxypropyl)amino]-2-pyrim-
idinyl]-amino]benzonitrile (*1.B2; comp. 11); [0105]
4-[[4-[(2,6-dichlorophenyl)methyl]-6-(hydroxyamino)-2-pyrimidinyl]amino]--
benzonitrile (*1.B4; comp. 12); [0106]
4-[[4-[(2-cyanoethyl)amino]-6-[(2,6-dichlorophenyl)methyl]-2-pyrimidinyl]-
amino]-benzonitrile (*1.B3; comp. 13); [0107]
4-[[4-[(2,6-dichlorophenyl)methyl]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-p-
yrimidinyl]-amino]benzonitrile (*1.B3; comp. 14); [0108]
4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2-pyrimidinyl]amino]--
benzonitrile (*1.B1; comp. 15); [0109]
N2-(4-bromophenyl)-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2,4-pyrimidine-
diamine (*1.B1; comp. 16); [0110]
4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile
(*1.B8a; comp. 17); [0111]
4-[[2-[(2,4,6-trimethylphenyl)amino]-4-pyrimidinyl]amino]benzonitrile
(*1.B9a; comp. 18); [0112]
4-[[4-[(2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile
(*1.B9a; comp. 19); [0113]
4-[[4-(2,4,6-trimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile
(*1.B10; comp. 20); [0114]
4-[[4-[(2,6-dichlorophenyl)thio]-2-pyrimidinyl]amino]benzonitrile
(*1.B10; comp. 21); [0115]
4-[[4-[[2,6-dibromo-4-(1-methylethyl)phenyl]amino]-2-pyrimidinyl]amino]be-
nzonitrile (*1.B9a; comp. 22); [0116]
4-[[4-[[2,6-dichloro-4-(trifluoromethyl)phenyl]amino]-2-pyrimidinyl]amino-
]-benzonitrile (*1.B9c; comp. 23); [0117]
4-[[4-[(2,4-dichloro-6-methylphenyl)amino]-2-pyrimidinyl]amino]benzonitri-
le (*1.B9a; comp. 24); [0118]
4-[[2-[(cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylbenzonitrile
(*1.B8a or 1.B8b; comp. 25); [0119]
4-[[4-[(2,4-dibromo-6-fluorophenyl)amino]-2-pyrimidinyl]amino]benzonitril-
e (*1.B9c; comp. 26); [0120]
4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-5-methyl-2-pyrimidinyl]amino]--
benzeneacetonitrile (*1.B1; comp. 27); [0121]
4-[[4-[methyl(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitri-
le (*1.B9c; comp. 28); [0122]
4-[[4-[(2,4,6-trichlorophenyl)amino]-2-pyrimidinyl]amino]benzonitrile
(*1.B9c; comp. 29); [0123]
4-[[4-[(2,4,6-trimethylphenyl)thio]-2-pyrimidinyl]amino]benzonitrile
(*1.B10; comp. 30); [0124]
4-[[4-[(2,4,6-trimethylphenyl)amino-2-pyrimidinyl]amino]benzonitrile
(*1.B11; comp. 31); [0125]
4-[[4-amino-6-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonit-
rile (*1.B1; comp. 32); [0126]
4-[[2-amino-6-[(2,4,6-trimethylphenyl)amino]-4-pyrimidinyl]amino]benzonit-
rile (*1.B1; comp. 33); [0127]
4-[[4-(2-bromo-4-chloro-6-methylphenoxy)-2-pyrimidinyl]amino]benzonitrile
(*1.B10; comp. 34); [0128]
4-[[4-[(4-chloro-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitri-
le (*1.B9c; comp. 35); [0129]
3,5-dichloro-4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]benzonitril-
e (*1.B9a; comp. 36); [0130]
4-[[4-[[2,6-dichloro-4-(trifluoromethoxy)phenyl]amino]-2-pyrimidinyl]amin-
o]-benzonitrile (*1.B9c; comp. 37); [0131]
4-[[4-[(2,4-dibromo-3,6-dichlorophenyl)amino]-2-pyrimidinyl]amino]benzoni-
trile (*1.B9c; comp. 38); [0132]
4-[[4-[(2,6-dibromo-4-propylphenyl]amino]-2-pyrimidinyl]amino]benzonitril-
e (*1.B9c; comp. 39); [0133]
4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide
(*1.B11; comp. 40); [0134]
4-[[4-[(4-(1,1-dimethylethyl)-2,6-dimethylphenyl)amino]-2-pyrimidinyl]ami-
no]-benzonitrile (*1.B9a; comp. 41); [0135]
4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile
(*1.B10; comp. 42); [0136]
4-[[4-[(4-chloro-2,6-dimethylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]--
benzonitrile (*1.B9c; comp. 43); [0137]
4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino-3,5-dimethylben-
zonitrile (*1.B9b; comp. 44); [0138]
4-[[4-[[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]amino]-5-methyl-2-pyrimi-
dinyl]-amino]benzonitrile (*1.B9c; comp. 45); [0139]
4-[[4-[(4-bromo-2,6-dimethylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]-b-
enzonitrile (*1.B9c; comp. 46); [0140]
4-[[5-methyl-4-[(2,4,6-trimethylphenyl)thio]-2-pyrimidinyl]amino]benzonit-
rile (*1.B9c; comp. 47); [0141]
4-[[4-[(2,6-dibromo-4-propylphenyl)amino]-5-methyl-2-pyrimidinyl]amino]-b-
enzonitrile (*1.B9a; comp. 48); [0142]
4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide,
N3-oxide (*1.B12; comp. 49); [0143]
N2-(4-chlorophenyl)-N-4-(2,4,6-trimethylphenyl)-2,4-pyrimidinediamine
(*1.B8a; comp. 50); [0144]
4-[[4-[[2,6-dibromo-4-(1-methylethyl)phenyl]amino]-5-methyl-2-pyrimidinyl-
]amino]-benzonitrile (*1.B9a; comp. 51); [0145]
4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethyl
Benzonitrile (*1.B9b; comp. 52); [0146]
4-[[4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]benzonitrile (comp.
53); [0147]
4-[[4-amino-6-(2,6-dimethylphenoxy)-1,3,5-triazin-2-yl]amino]benzo-
nitrile (*1.B15; comp. 54); [0148]
4-[[4-amino-6-[(2-chloro-6-methylphenyl)amino]-1,3,5-triazin-2-yl]amino]b-
enzonitrile (*1.B13a; comp. 55); [0149]
4-[[4-amino-6-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazin-2-yl]amino]ben-
zonitrile (*1.B13a or 1.B13b; comp. 56); [0150]
4-[[4-(hydroxyamino)-6-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazin-2-yl]-
amino]-benzonitrile (*1.B14; comp. 57); [0151]
4-[[4-amino-6-[(2-ethyl-6-methylphenyl)amino]-1,3,5-triazin-2-yl]amino]be-
nzonitrile (*1.B13b; comp. 58); [0152]
4-[[4-amino-6-[(2,6-dichlorophenyl)thio]-1,3,5-triazin-2-yl]amino]benzoni-
trile (*1.B13b; comp. 59); [0153]
4-[[4-(hydroxyamino)-6-[(2,4,6-trichlorophenyl)amino]-1,3,5-triazin-2-yl]-
amino]-benzonitrile (*1.B14; comp. 60); [0154]
4-[[4-amino-6-(2,4,6-trimethylphenoxy)-1,3,5-triazin-2-yl]amino]benzonitr-
ile (*1.B13b; comp. 61); [0155]
4-[[4-(hydroxyamino)-6-(2,4,6-trimethylphenoxy)-1,3,5-triazin-2-yl]amino]-
-benzonitrile (*1.B14; comp. 62); [0156]
4-[[4-amino-6-[(2,4-dichloro-6-methylphenyl)amino]-1,3,5-triazin-2-yl]ami-
no]-benzonitrile (*1.B13b; comp. 63); [0157]
4-[[4-[(2,4-dichloro-6-methylphenyl)amino]-6-(hydroxyamino)-1,3,5-triazin-
-2-yl]-amino]benzontrile (*1.B14; comp. 64); [0158]
4-[[4-(hydroxyamino)-6-(2,4,6-trichlorophenoxy)-1,3,5-triazin-2-yl]amino]-
benzonitrile trifluoroacetate (1:1) (*1.B14; comp. 65); [0159]
4-[[4-(4-acetyl-2,6-dimethylphenoxy)-6-amino-1,3,5-triazin-2-yl]amino]ben-
zonitrile (*1.B16; comp. 66); [0160]
4-[[4-amino-6-(2,4,6-tribromophenoxy)-1,3,5-triazin-2-yl]amino]benzonitri-
le (*1.B17; comp. 67); [0161]
4-[[4-amino-6-(4-nitro-2,6-dimethylphenoxy)-1,3,5-triazin-2-yl]amino]benz-
onitrile (*1.B17; comp. 68); [0162]
4-[[4-amino-6-(2,6-dibromo-4-methylphenoxy)-1,3,5-triazin-2-yl]amino]benz-
onitrile (*1.B17; comp. 69); [0163]
4-[[4-amino-6-(4-formyl-2,6-dimethylphenoxy)-1,3,5-triazin-2-yl]amino]ben-
zonitrile (*1.B17; comp. 70); [0164]
4-[[4-amino-6-[(2,4-dichlorophenyl)thio]-1,3,5-triazin-2-yl]amino]benzoni-
trile (*1.B17; comp. 71); [0165]
4-[[4-[(5-acetyl-2,3-dihydro-7-methyl-1H-inden-4-yl)oxy]-6-amino-1,3,5-tr-
iazin-2-yl]-amino]benzonitrile (*1.B20; comp. 72); [0166]
4-[[4-amino-6-[(4-bromo-2-chloro-6-methylphenyl)amino]-1,3,5-triazin-2-yl-
]amino]-benzonitrile (*1.B20; comp. 73); [0167]
4-[[4-amino-6-[(2-chloro-4,6-dimethylphenyl)amino]-1,3,5-triazin-2-yl]ami-
no]-benzonitrile (*1.B20; comp. 74); [0168]
4-[[4-amino-6-[[2,4-dichloro-6-(trifluoromethyl)phenyl]amino]-1,3,5-triaz-
in-2-yl]-amino]benzonitrile (*1.B13; comp. 75); [0169]
4-[[4-amino-6-[methyl(2,4,6-trimethylphenyl)amino]-1,3,5-triazin-2-yl]ami-
no]-benzonitrile (*1.B18; comp. 76); [0170]
4-[[4-amino-6-[(2,6-dibromo-4-methylphenyl)amino]-1,3,5-triazin-2-yl]amin-
o]-benzonitrile (*1.B13b; comp. 77); [0171]
4-[[4-amino-6-[[2,6-dibromo-4-(1-methylethyl)phenyl]amino]-1,3,5-triazin--
2-yl]-amino]benzonitrile (*1.B13b; comp. 78); the N-oxides, the
pharmaceutically acceptable addition salts and the stereochemically
isomeric forms thereof (* indicates the example number of the
preparation procedure listed in the experimental part according to
which the compound of formula (I-A) was synthesized).
[0172] Suitable compounds of formula (I-B) are those wherein one or
more of the following restrictions apply: [0173] i)
-b.sup.1=b.sup.2-C(R.sup.2a)=b.sup.3-b.sup.4= is a radical of
formula (b-1); [0174] ii) q is 0; [0175] iii) R.sup.2a is cyano or
--C(.dbd.O)NH.sub.2, preferably R.sup.2a is cyano; [0176] iv) Y is
cyano, --C(.dbd.O)NH.sub.2 or a halogen, preferably a halogen;
[0177] v) Q is hydrogen or --NR.sup.4R.sup.5 wherein R.sup.4 and
R.sup.5 are preferably hydrogen; [0178] vi) L is --X--R.sup.3
wherein X is preferably NR.sup.1, O or S, most preferably X is NH,
and R.sup.3 is substituted phenyl with C.sub.1-6alkyl, halogen and
cyano as preferred substituents.
[0179] Another interesting group of compounds of formula (I-B) are
those compounds of formula (I-B) wherein L is --X--R.sup.3 wherein
R.sup.3 is 2,4,6-trisubstituted phenyl, each substituent
independently selected from chloro, bromo, fluoro, cyano or
C.sub.1-4 alkyl.
[0180] Also interesting are those compounds of formula (I-B)
wherein Y is chloro or bromo and Q is hydrogen or amino.
[0181] Particular compounds of formula (I-B) are those compounds of
formula (I-B) wherein the moiety in the 2 position of the
pyrimidine ring is a 4-cyano-anilino group.
[0182] Preferred compounds of formula (I-B) are those compounds of
formula (I-B) wherein the moiety in the 2 position of the
pyrimidine ring is a 4-cyano-anilino group, L is --X--R.sup.3
wherein R.sup.3 is a 2,4,6-trisubstituted phenyl, Y is a halogen
and Q is hydrogen or NH.sub.2.
[0183] Most preferred compounds of formula (I-B) are: [0184]
4-[[4-amino-5-chloro-6-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino-
]-benzonitrile; [0185]
4-[[5-chloro-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzoni-
trile; [0186]
4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitr-
ile; [0187]
4-[[4-amino-5-chloro-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]-
amino]-benzonitrile; [0188]
4-[[5-bromo-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]-be-
nzonitrile; [0189]
4-[[4-amino-5-chloro-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amin-
o]-benzonitrile; and [0190]
4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino-
]-benzonitrile; the N-oxides, the pharmaceutically acceptable
addition salts, quaternary amines and the stereochemically isomeric
forms thereof.
[0191] An interesting group of compounds of formula (I-C) are those
compounds of formula (I-C) wherein one or more of the following
conditions are met: [0192] (i) n is 1; [0193] (ii)
-a.sup.1=a.sup.2-a.sup.3=a.sup.4- represents a bivalent radical of
formula (a-1); [0194] (iii) R.sup.1 is hydrogen or alkyl; [0195]
(iv) R.sup.2 is cyano; aminocarbonyl; mono- or
di(methyl)aminocarbonyl; C.sub.1-6alkyl substituted with cyano,
aminocarbonyl or mono- or di(methyl)aminocarbonyl; and more in
particular, R.sup.2 is on the 4 position relative to the
--NR.sup.1-- moiety; [0196] i) L is --X--R.sup.3 wherein X is
preferably --NR.sup.1--, --O-- or --S--, most preferably X is
--NH--, and R.sup.3 is substituted phenyl with C.sub.1-6alkyl,
halogen and cyano as preferred substituents.
[0197] Preferred compounds of formula (I-C) are those compounds of
formula (I-C) wherein L is --X--R.sup.3 wherein R.sup.3 is a
disubstituted phenyl group or a trisubstituted phenyl group, each
substituent independently selected from chloro, bromo, fluoro,
cyano or C.sub.1-4alkyl.
[0198] Most preferred compound of formula (I-C) is
4-[[4-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazin-2-yl]amino]benzonitril-
e.
[0199] The compounds of formula (I-A) can be prepared according to
art-known procedures.
[0200] In particular, the compounds of formula (I-A) can generally
be prepared by reacting an intermediate of formula (II), wherein
W.sup.1 is a suitable leaving group such as, for example, a halo
atom with an amino derivative of formula (III) in a reaction inert
solvent such as, for example, 1,4-dioxane, tetrahydrofuran,
2-propanol, N-methyl-pyrrolidinone and the like, optionally in the
presence of a suitable base such as, for example, sodiumhydroxide,
sodiumhydride, triethylamine or N,N-di-isopropyl-ethylamine or the
like.
##STR00006##
[0201] In case Q is NR.sup.1R.sup.2 and R.sup.2 contains a hydroxy
moiety, it may be convenient to perform the above reaction with a
protected form of intermediate (III) whereby the hydroxy moiety
bears a suitable protecting group P being, for instance, a benzyl,
and subsequently removing the protective group according to
art-known methodologies, such as, for example, reacting with
BBr.sub.3 in dichloromethane under nitrogen atmosphere.
[0202] Compounds of formula (I-A) wherein Y is CR.sup.5, said
compounds being represented by formula (I-A-a), may also be
prepared by reacting an intermediate of formula (IV) wherein
W.sup.1 is a suitable leaving group such as, for example, a halo
atom, with an amino derivative of formula (V), optionally in a
solvent such as, for example, water, 2-propanol, diethylether,
1-methyl-2-pyrrolidinone and the like, and optionally in the
presence of an acid such as, for example, 1 N hydrochloric acid in
diethylether. It may be convenient to perform the reaction under a
reaction-inert atmosphere such as, for example, oxygen free argon
or nitrogen.
##STR00007##
[0203] Compounds of formula (I-A-a) wherein L is
--X.sup.1--R.sup.6, said compounds being represented by formula
(I-A-a-1), can also be prepared by reacting an intermediate of
formula (VI) with an intermediate of formula (VII) in a suitable
solvent such as, for example, 1,4-dioxane.
##STR00008##
[0204] Depending on the nature of X.sup.1 a suitable base or acid
may be used to improve the reaction rate. For instance, in case
X.sup.1 is --O--, sodium hydride may be used as suitable base; or
in case X.sup.1 is --NR.sup.3--, HCl may be used as a suitable
acid.
[0205] The compounds of formula (I-A), wherein Y is N, said
compounds being represented by formula (I-A-b), can also
conveniently be prepared using solid phase synthesis techniques. In
general, solid phase synthesis involves reacting an intermediate in
a synthesis with a polymer support. This polymer supported
intermediate can then be carried on through a number of synthetic
steps. After each step, impurities are removed by filtering the
resin and washing it numerous times with various solvents. At each
step the resin can be split up to react with various intermediates
in the next step thus allowing for the synthesis of a large number
of compounds. After the last step in the procedure the resin is
treated with a reagent or process to cleave the resin from the
sample.
[0206] Suitable polymer supports include for instance Rink Amide
resin (Calbiochem-Novabiochem Corp., San Diego, Calif.).
[0207] For instance, the compounds of formula (I-A-b) wherein n is
1 and the R.sup.4 substituent is placed in the meta position of A,
and NR.sup.1R.sup.2 is NH.sub.2, said compounds being represented
by formula (I-A-b-1), were prepared according to the procedure
depicted in Scheme 1.
##STR00009##
[0208] In scheme 1, Rink Amide resin is reacted in a suitable
solvent such as, for example N,N-dimethylformamide in the presence
of piperidine to obtain the primary amine of formula (VIII-a) which
can then further be reacted with an intermediate of formula (IX)
wherein W.sup.1 is a suitable leaving group such as, for example, a
halo atom, in the presence of a base such as for example,
N,N-diisopropylethylamine, in a suitable solvent such as, for
example, dimethylsulfoxide. Impurities can be removed by washing
numerous times with various solvents such as, for example,
N,N-dimethylformamide, dichloromethane, dimethylsulfoxide and the
like. The resulting polymer-bound intermediate of formula (VIII-b)
was then further reacted with L-H (X). To facilitate this
transformation, silver triflate, sodium hexamethyldisilazide or
cesium carbonate may be used. The resin is finally treated with a
cleavage reagent such as for example trifluoroacetic acid in
tetrahydrofuran, thus obtaining compounds of formula (I-A-b-1).
[0209] In this and the following preparations, the reaction
products may be isolated from the reaction medium and, if
necessary, further purified according to methodologies generally
known in the art such as, for example, extraction, crystallization,
distillation, trituration and chromatography.
[0210] The compounds of formula (I-A) may further be prepared by
converting compounds of formula (I-A) into each other according to
art-known group transformation reactions.
[0211] The compounds of formula (I-A) may be converted to the
corresponding N-oxide forms following art-known procedures for
converting a trivalent nitrogen into its N-oxide form. Said
N-oxidation reaction may generally be carried out by reacting the
starting material of formula (I-A) with an appropriate organic or
inorganic peroxide. Appropriate inorganic peroxides comprise, for
example, hydrogen peroxide, alkali metal or earth alkaline metal
peroxides, e.g. sodium peroxide, potassium peroxide; appropriate
organic peroxides may comprise peroxy acids such as, for example,
benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic
acid, e.g. 3-chlorobenzenecarboperoxoic acid, peroxoalkanoic acids,
e.g. peroxoacetic acid, alkylhydroperoxides, e.g. t.butyl
hydro-peroxide. Suitable solvents are, for example, water, lower
alcohols, e.g. ethanol and the like, hydrocarbons, e.g. toluene,
ketones, e.g. 2-butanone, halogenated hydrocarbons, e.g.
dichloromethane, and mixtures of such solvents.
[0212] For instance, compounds of formula (I-A-a) wherein Q is
NR.sup.1R.sup.2 and R.sup.1 and R.sup.2 are taken together to form
mono- or di(C.sub.1-12alkyl)aminoC.sub.1-4alkylidene, said
compounds being represented by formula (I-A-a-2), may be prepared
by reacting a compound of formula (I-A-a) wherein R.sup.1 and
R.sup.2 are hydrogen, said compound being represented by formula
(I-A-a-3), with an intermediate of formula (X.sup.1) or a
functional derivative thereof.
##STR00010##
[0213] Also, compounds of formula (I-A-a) wherein Q is
NR.sup.1R.sup.2 and R.sup.1 and R.sup.2 are hydrogen may further be
reacted with an acyl halide or an alkyl chloroformate in a
reaction-inert solvent such as, for example dichloromethane, in the
presence of a suitable base, such as, for example, pyridine, to
form the corresponding amide, respectively, carbamate
derivative.
[0214] Some of the compounds of formula (I-A) and some of the
intermediates in the present invention may contain an asymmetric
carbon atom. Pure stereochemically isomeric forms of said compounds
and said intermediates can be obtained by the application of
art-known procedures. For example, diastereoisomers can be
separated by physical methods such as selective crystallization or
chromatographic techniques, e.g. counter current distribution,
liquid chromatography and the like methods. Enantiomers can be
obtained from racemic mixtures by first converting said racemic
mixtures with suitable resolving agents such as, for example,
chiral acids, to mixtures of diastereomeric salts or compounds;
then physically separating said mixtures of diastereomeric salts or
compounds by, for example, selective crystallization or
chromatographic techniques, e.g. liquid chromatography and the like
methods; and finally converting said separated diastereomeric salts
or compounds into the corresponding enantiomers. Pure
stereochemically isomeric forms may also be obtained from the pure
stereochemically isomeric forms of the appropriate intermediates
and starting materials, provided that the intervening reactions
occur stereospecifically.
[0215] An alternative manner of separating the enantiomeric forms
of the compounds of formula (I-A) and intermediates involves liquid
chromatography, in particular liquid chromatography using a chiral
stationary phase.
[0216] Some of the intermediates and starting materials are known
compounds and may be commercially available or may be prepared
according to art-known procedures.
[0217] Intermediates of formula (II), wherein Y is CR.sup.5, said
intermediates being represented by formula (II-a), can be prepared
by reacting an intermediate of formula (XII) with an intermediate
of formula (V) analogously to the preparation of compounds of
formula (I-a).
##STR00011##
[0218] A particular subgroup of the intermediates of formula (II-a)
is represented by formula
##STR00012##
wherein n' is 0, 1, 2, or 3.
[0219] Particular intermediates of formula (II'-a) are those
wherein W.sup.1 is a halo atom, more in particular, a chloro
atom.
[0220] Intermediates of formula (II), wherein Y is N, R.sup.4 is
placed in paraposition of NR.sup.3, and n is 1, said intermediates
being represented by formula (II-b-1) can be prepared by reacting
an intermediate of formula (XIII) wherein W.sup.1 is a suitable
leaving group such as, for example, a halogen, with an amine
derivative of formula (XIV) in a reaction-inert solvent such as,
for example, tetrahydrofuran, 1,4-dioxane or the like, in the
presence of a suitable base such as, for example, triethylamine;
and subsequently reacting the thus obtained intermediate of formula
(XV) with an intermediate of formula (XVI) in a reaction-inert
solvent such as, for example, acetonitrile, 1,4-dioxane or the
like, in the presence of a base such as, for example, potassium
carbonate, sodium hydride, N,N-diisopropyl-ethylamine or the
like.
##STR00013##
[0221] The order of the above reaction scheme may also be reversed,
i.e. first an intermediate of formula (XIII) may be reacted with an
intermediate of formula (XVI), and then, the resulting intermediate
of formula (XVII) may further be reacted with an amine derivative
of formula (XIV); thus forming an intermediate of formula
(II-b-1).
##STR00014##
[0222] Particular intermediates are those intermediates of formula
(II-b-1) wherein R.sup.4 is cyano, amino, carbonyl, nitro or
trifluoromethyl, R.sup.3 is hydrogen, A is CH, W.sup.1 is a halogen
such as, chloro and bromo, and L is as defined in the compounds of
formula (I) provided that R.sup.6 is other than p-cyano-phenyl,
p-nitro-phenyl, p-methoxy-phenyl and p-aminocarbonyl-phenyl, and
R.sup.7 is other than 2-(4-hydroxyphenyl)ethyl]amino; more in
particular, R.sup.3, A and W.sup.1 are as defined above, R.sup.4 is
cyano and L is X.sup.1--R.sup.6 or X.sup.2-Alk-R.sup.7; wherein
R.sup.6 and R.sup.7 each independently are indanyl, indolyl or
phenyl; each of said indanyl, indolyl or phenyl may be substituted
with two, three, four or five substituents each independently
selected from halo, C.sub.1-6alkyl, C.sub.1-6alkyloxy, hydroxy,
C.sub.1-6alkylcarbonyl, C.sub.1-6alkyloxycarbonyl, formyl, cyano,
nitro, amino and trifluoromethyl.
[0223] Intermediates of formula (IV) wherein Q is NR.sup.1R.sup.2,
said intermediates being represented by formula (IV-a), can be
prepared by reacting a pyrimidine derivative of formula (XVIII)
wherein W.sup.1 is a suitable leaving group such as, for example, a
halo atom, with an intermediate of formula (III) in a reaction
inert solvent such as, for example, 1,4-dioxane, 2-propanol or the
like. Different regio-specific isomers may be formed and can be
separated from one another using suitable separation techniques
such as, for example, chromatography.
##STR00015##
[0224] Intermediates of formula (XVIII) whereby L is L'-CH.sub.2
and is attached in the 2 position of the pyrimidine ring and
W.sup.1 is chloro, said intermediates being represented by formula
(XVIII-a), can be prepared by reacting an imidamide of formula
(XIX) with a propanedioic acid ester of formula (XX) in a solvent
such as, for example, ethanol, and in the presence of, for
instance, sodium, and subsequently reacting the thus formed
intermediate of formula (XXI) with a suitable reagent such as, for
example, phosphoryl chloride.
##STR00016##
[0225] Intermediates of formula (XVIII) whereby L is L'-CH.sub.2
and is attached in the 4 or 6 position of the pyrimidine ring and
W.sup.1 is chloro, said intermediates being represented by formula
(XVIII-b), can be prepared by reacting an intermediate of formula
(XXII) with urea or a functional derivative thereof, in a solvent
such as, for example, ethanol, and in the presence of, for
instance, sodium, and subsequently reacting the thus formed
intermediate of formula (XXIII) with a suitable reagent such as,
for example, phosphoryl chloride.
##STR00017##
[0226] Intermediates of formula (XVIII) wherein L is L'-CH.sub.2
and is attached anywhere on the pyrimidine ring, said intermediates
being represented by formula (XVIII-c), can be prepared by reacting
an intermediate of formula (XXIV), wherein W.sup.1 is a suitbale
leaving group such as, for example, a halo atom, with an
intermediate of formula (XXV) wherein W.sup.2 is a suitable leaving
group such as, for example, a halogen, according to the procedure
of a Grignard reaction.
##STR00018##
[0227] Intermediates of formula (XVIII) wherein L is --Z--R.sup.6,
--Z-- representing therein --O-- or --NH--, and --Z--R.sup.6 is
attached in the 4 or 6 position of the pyrimidine ring, said
intermediates being represented by formula (XVIII-d), can be
prepared by reacting an intermediate of formula (XXVI) with an
intermediate of formula (XXVII) wherein W.sup.1 is a suitable
leaving group such as, for example, a halo atom, in a
reaction-inert solvent such as, for example, tetrahydrofuran or
1,4-dioxane, and in the presence of a suitable base such as, for
example, potassium hydroxide or diisopropyl ethaneamine, or sodium
hydride.
##STR00019##
[0228] Compounds of formula (I-A) and some of the intermediates may
have one or more stereogenic centers in their structure, present in
a R or a S configuration.
[0229] In general, compounds of formula (I-B) can be prepared by
reacting an intermediate of formula (II(b)) wherein W.sup.1 is a
suitable leaving group such as, for example, a halogen, hydroxy,
triflate, tosylate, thiomethyl, methylsulfonyl,
trifluoromethylsulfonyl and the like, with an amino derivative of
formula (III(b)) optionally under solvent-free conditions or in a
reaction-inert solvent such as, for example, ethanol,
1-methyl-2-pyrrolidinone, N,N-dimethylformamide, 1,4-dioxane,
tetrahydrofuran, dimethyl sulfoxide, tetraline, sulfolane,
acetonitrile and the like, under a reaction-inert atmosphere such
as, for example, oxygen free argon or nitrogen, and optionally in
the presence of an acid such as, for example, 1 N hydrochloric acid
in diethyl ether or the like. This reaction can be performed at a
temperature ranging between 50.degree. C. and 250.degree. C.
##STR00020##
[0230] In this and the following preparations, the reaction
products may be isolated from the reaction medium and, if
necessary, further purified according to methodologies generally
known in the art such as, for example, extraction, crystallization,
distillation, trituration and chromatography.
[0231] The compounds of formula (I-B) wherein L is a radical of
formula --NR.sup.1--R.sup.3, said compounds being represented by
formula (I-B-1), can be prepared by reacting an intermediate of
formula (IV(b)) wherein W.sup.2 is a suitable leaving group such
as, for example, a halogen or a triflate, with an intermediate of
formula (V(b)) under solvent-free conditions or in an appropriate
solvent such as, for example, ethanol, 1-methyl-2-pyrrolidinone,
N,N-dimethylformamide, 1,4-dioxane, tetrahydrofuran, dimethyl
sulfoxide, tetraline, sulfolane, acetonitrile and the like, under a
reaction-inert atmosphere such as, for example, oxygen free argon
or nitrogen, and optionally in the presence of an acid such as, for
example, 1 N hydrochloric acid in diethyl ether. This reaction can
be performed at a temperature ranging between 50.degree. C. and
250.degree. C.
##STR00021##
[0232] The compounds of formula (I-B) wherein L is a radical of
formula --O--R.sup.3, said compounds being represented by formula
(I-B-2), can be prepared by reacting an intermediate of formula
(IV(b)) wherein W.sup.2 is a suitable leaving group such as, for
example a halogen or a triflate, with an intermediate of formula
(VI(b)) in an appropriate solvent such as, for example,
1,4-dioxane, dimethyl sulfoxide, tetraline, sulfolane and the like
under a reaction-inert atmosphere such as, for example, oxygen free
argon or nitrogen, and in the presence of a base such as, for
example, sodium hydride, potassium hydride, sodium hydroxide or the
like. This reaction can be performed at a temperature ranging
between 50.degree. C. and 250.degree. C.
##STR00022##
[0233] The compounds of formula (I-B) may further be prepared by
converting compounds of formula (I-B) into each other according to
art-known group transformation reactions.
[0234] The compounds of formula (I-B) may be converted to the
corresponding N-oxide forms by the procedures described
hereinabove.
[0235] For instance, the compounds of formula (I-B) wherein Q is a
halogen may be converted to the corresponding compounds wherein Q
is --NR.sup.4H using NH.sub.2R.sup.4 as a reagent in a reaction
inert solvent such as, for example, 1,4-dioxane and the like,
optionally in the presence of a suitable base such as, for example,
triethylamine or N,N-diisopropyl-ethylamine or the like. In case
R.sup.4 contains a hydroxy moiety, it may be convenient to perform
the above reaction with a protected form of NH.sub.2R.sup.4 whereby
the hydroxy moiety bears a suitable protecting group P being, for
instance, a trialkylsilyl group, and subsequently removing the
protective group according to art-known methodologies.
[0236] Some of the compounds of formula (I-B) and some of the
intermediates in the present invention may contain an asymmetric
carbon atom. Pure stereochemically isomeric forms of said compounds
and said intermediates can be obtained by the application of
art-known procedures. For example, diastereoisomers can be
separated by physical methods such as selective crystallization or
chromatographic techniques, e.g. counter current distribution,
liquid chromatography and the like methods. Enantiomers can be
obtained from racemic mixtures by first converting said racemic
mixtures with suitable resolving agents such as, for example,
chiral acids, to mixtures of diastereomeric salts or compounds;
then physically separating said mixtures of diastereomeric salts or
compounds by, for example, selective crystallization or
chromatographic techniques, e.g. liquid chromatography and the like
methods; and finally converting said separated diastereomeric salts
or compounds into the corresponding enantiomers. Pure
stereochemically isomeric forms may also be obtained from the pure
stereochemically isomeric forms of the appropriate intermediates
and starting materials, provided that the intervening reactions
occur stereospecifically.
[0237] An alternative manner of separating the enantiomeric forms
of the compounds of formula (I-B) and intermediates involves liquid
chromatography, in particular liquid chromatography using a chiral
stationary phase.
[0238] Some of the intermediates and starting materials are known
compounds and may be commercially available or may be prepared
according to art-known procedures.
[0239] Intermediates of formula (II(b)) wherein L is --X--R.sup.3,
said intermediates being represented by formula (II(b)-1), can be
prepared by reacting a pyrimidine derivative of formula (VII(b))
wherein each W.sup.1 is as defined previously, with HXR.sup.3
(VIII(b)) in a reaction inert solvent such as, for example,
1,4-dioxane, 2-propanol or the like, and in the presence of a base
such as, for example, triethylamine or N,N-diisopropylethyl-amine
or the like. Different regio-specific isomers may be formed and can
be separated from one another using suitable separation techniques
such as, for example, chromatography.
##STR00023##
[0240] Intermediates of formula (IV(b)) can be prepared by reacting
an intermediate of formula (VII(b)-a) wherein W.sup.2 is a suitable
leaving group such as, for example, a halogen, with an intermediate
of formula (IX(b)) in a suitable solvent such as, for example,
1-methyl-2-pyrrolidinone, 1,4-dioxane or the like, in the presence
of an acid such as, for example, 1 N hydrochloric acid in diethyl
ether. This reaction can be performed at a temperature ranging
between 50.degree. C. and 250.degree. C.
##STR00024##
[0241] Alternatively, intermediates of formula (IV(b)) can be
prepared by reacting an intermediate of formula (X(b)) with
phosphorous oxychloride, triflic anhydride or a functional
derivative thereof under a reaction-inert atmosphere such as, for
example, oxygen free argon or nitrogen. This reaction can be
performed at a temperature ranging between 20.degree. C. and
150.degree. C.
##STR00025##
[0242] Intermediates of formula (X(b)) can be prepared by reacting
an intermediate of formula (XI(b)) or a functional derivative
thereof, with an intermediate of formula (IX(b)). This reaction may
be performed under solvent-free conditions or in an appropriate
solvent such as, for example, diglyme, tetraline or the like under
a reaction-inert atmosphere such as, for example, oxygen free argon
or nitrogen, and optionally in the presence of a base such as, for
example, sodium hydride, potassium hydride or the like. This
reaction can be performed at a temperature ranging between
100.degree. C. and 250.degree. C.
##STR00026##
[0243] Intermediates of formula (X(b)) can also be prepared by
reacting an intermediate of formula (XII(b)), wherein W.sup.2 is a
suitable leaving group and Y and Q are defined as described for a
compound of formula (I-B), with an intermediate of formula
(XIII(b)) in an appropriate solvent such as, for example, ethanol,
or the like, and in the presence of a base such as, for example,
sodium ethoxide or the like, under a reaction-inert atmosphere such
as, for example, oxygen free argon or nitrogen. The reaction can be
performed at a temperature ranging between 20.degree. C. and
125.degree. C.
##STR00027##
[0244] A convenient way of preparing an intermediate of formula
(IV(b)) wherein Y is a bromine or chloro atom, said intermediates
being represented by formula (IV(b)-1), involves the introduction
of a bromine or chloro atom to an intermediate of formula (XIV(b))
using N-bromosuccinimide or N-chlorosuccinimide in a reaction-inert
solvent such as, for example, chloroform, carbon tetrachloride or
the like. This reaction can be performed at a temperature ranging
between 20.degree. C. and 125.degree. C.
##STR00028##
[0245] Analogous to the conversion of compounds of formula (I-B)
wherein Q is a halogen to compounds of formula (I-B) wherein Q is
--NHR.sup.4, the intermediates of formula (II(b)), (IV(b)) and
(VII(b)) can also be converted.
[0246] Compounds of formula (I-C) wherein L is a radical of formula
--X--R.sup.3, said compounds are represented by formula (I-C-a),
can be prepared by reacting an intermediate of formula (II(c))
wherein W.sup.1 is a suitable leaving group, for example, a
halogen, with an amine derivative of formula (III(c)) in a
reaction-inert solvent, for example, tetrahydrofuran, 1,4-dioxane
or the like, in the presence of a suitable base such as,
triethylamine; and subsequently reacting the thus obtained
intermediate of formula (IV(c)) with an intermediate of formula
(V(c)) in a reaction-inert solvent such as acetonitrile,
1,4-dioxane or the like, in the presence of a base such as
potassium carbonate, sodium hydride, N,N-diisopropyl-ethylamine or
the like.
##STR00029##
[0247] The order of the above reaction scheme may also be reversed,
i.e. first an intermediate of formula (II(c)) may be reacted with
an intermediate of formula (V(c)), and then, the resulting
intermediate may further be reacted with an amine derivative of
formula (III(c)); thus forming a compound of formula (I-C-a).
[0248] The reaction products may be isolated from the reaction
medium and, if necessary, further purified according to
methodologies generally known in the art such as, extraction,
crystallization, distillation, trituration and chromatography.
[0249] Compounds of formula (I-C) wherein L is an optionally
substituted C.sub.1-10alkyl, C.sub.2-10alkenyl, C.sub.2-10alkynyl,
C.sub.3-7cycloalkyl, said compounds are represented by formula
(I-C-b), can be prepared by first making a Grignard reagent of an
intermediate of formula (VI(c)) wherein W.sup.2 is a suitable
substituent such as, a halogen, e.g. bromine, in the presence of
magnesium in a reaction-inert solvent such as, diethyl ether, and
subsequently reacting said Grignard reagent with an intermediate of
formula (II(c)) wherein W.sup.1 is a suitable leaving group such
as, a halogen, e.g. chlorine, in a reaction-inert solvent, for
example, benzene, thus forming an intermediate of formula (VII(c)).
It may be convenient to perform the above reaction under a inert
atmosphere, for instance, argon. Intermediate (VII(c)) may be
isolated from its reaction medium, or may be in situ further
reacted with an intermediate of formula (III(c)) in a
reaction-inert solvent such as, 1,4-dioxane, and in the presence of
a suitable base such as, diisopropylethylamine or the like, thus
forming a compound of formula (I-C-b).
##STR00030##
[0250] The compounds of formula (I-C) may further be prepared by
converting compounds of formula (I-C) into each other according to
art-known group transformation reactions.
[0251] The compounds of formula (I-C) may be converted to the
corresponding N-oxides by the procedures as described
hereinabove.
[0252] Some of the intermediates as mentioned hereinabove are
commercially available or can be prepared according to art-known
procedures.
[0253] Compounds of formula (I-C) and some of the intermediates may
have one or more stereogenic centers in their structure, present in
a R or a S configuration.
[0254] The compounds of formula (I-A), (I-B) or (I-C) as prepared
in the hereinabove described processes may be synthesized as a
mixture of stereoisomeric forms, in particular in the form of
racemic mixtures of enantiomers which can be separated from one
another following art-known resolution procedures. The racemic
compounds of formula (I-A), (I-B) or (I-C) may be converted into
the corresponding diastereomeric salt forms by reaction with a
suitable chiral acid. Said diastereomeric salt forms are
subsequently separated, for example, by selective or fractional
crystallization and the enantiomers are liberated therefrom by
alkali. An alternative manner of separating the enantiomeric forms
of the compounds of formula (I-A), (I-B) or (I-C) involves liquid
chromatography using a chiral stationary phase. Said pure
stereochemically isomeric forms may also be derived from the
corresponding pure stereochemically isomeric forms of the
appropriate starting materials, provided that the reaction occurs
stereospecifically. Preferably if a specific stereoisomer is
desired, said compound will be synthesized by stereospecific
methods of preparation. These methods will advantageously employ
enantiomerically pure starting materials.
[0255] It will be appreciated by those skilled in the art that in
the processes described above the functional groups of intermediate
compounds to prepare compounds of formula (I-A), (I-B) or (I-C) may
need to be blocked by protecting groups.
[0256] Functional groups which it is desirable to protect include
hydroxy, amino and carboxylic acid. Suitable protecting groups for
hydroxy include trialkylsilyl groups (e.g. tert-butyldimethylsilyl,
tert-butyldiphenylsilyl or trimethylsilyl), benzyl and
tetrahydropyranyl. Suitable protecting groups for amino include
tert-butyloxycarbonyl or benzyloxycarbonyl. Suitable protecting
groups for carboxylic acid include C.sub.1-6alkyl or benzyl
esters.
[0257] The protection and deprotection of functional groups may
take place before or after a reaction step.
[0258] The use of protecting groups is fully described in
`Protective Groups in Organic Chemistry`, edited by J W F McOmie,
Plenum Press (1973), and `Protective Groups in Organic Synthesis`
2.sup.nd edition, T W Greene & P G M Wutz, Wiley Interscience
(1991).
[0259] The compounds of formula (I-A), (I-B) and (I-C) and the
intermediates of formula (II'-a) unexpectedly show antiretroviral
properties, in particular against Human Immunodeficiency Virus
(HIV), which is the aetiological agent of Acquired Immune
Deficiency Syndrome (AIDS) in humans. The HIV virus preferentially
infects human T-4 cells and destroys them or changes their normal
function, particularly the coordination of the immune system. As a
result, an infected patient has an everdecreasing number of T-4
cells, which moreover behave abnormally. Hence, the immunological
defense system is unable to combat infections and neoplasms and the
HIV infected subject usually dies by opportunistic infections such
as pneumonia, or by cancers. Other conditions associated with HIV
infection include thrombocytopaenia, multiple sclerosis, Kaposi's
sarcoma and infection of the central nervous system characterized
by progressive demyelination, resulting in dementia and symptoms
such as, progressive dysarthria, ataxia and disorientation. HIV
infection further has also been associated with peripheral
neuropathy, progressive generalized lymphadenopathy (PGL) and
AIDS-related complex (ARC).
[0260] The compounds of formula (I-A), (I-B) and (I-C) also show
activity against HIV-1 strains that have acquired resistance to
art-known non-nucleoside reverse transcriptase inhibitors. They
also have little or no binding affinity to human .alpha.-1 acid
glycoprotein.
[0261] Those of skill in the treatment of HIV-infection could
determine the effective daily amount from the test results
presented here. In general it is contemplated that an effective
daily amount would be from 0.01 mg/kg to 50 mg/kg body weight, more
preferably from 0.1 mg/kg to 10 mg/kg body weight. It may be
appropriate to administer the required dose as two, three, four or
more sub-doses at appropriate intervals throughout the day. Said
sub-doses may be formulated as unit dosage forms, for example,
containing 1 to 1000 mg, in particular 5 to 600 mg of active
ingredient per unit dosage form, and more in particular from 200 to
400 mg per unit dosage form or from 5 to 200 mg of active
ingredient per unit dosage form depending on the particular
compound being used.
[0262] The exact dosage and frequency of administration depends on
the particular compound of formula (I-A), (I-B) or (I-C) used, the
particular condition being treated, the severity of the condition
being treated, the age, weight and general physical condition of
the particular patient as well as other medication the individual
may be taking, as is well known to those skilled in the art.
Furthermore, it is evident that said effective daily amount may be
lowered or increased depending on the response of the treated
subject and/or depending on the evaluation of the physician
prescribing the compounds of the instant invention. The effective
daily amount ranges mentioned hereinabove are therefore only
guidelines and are not intended to limit the scope or use of the
invention to any extent.
[0263] The compounds of formula (I-A), (I-B) or (I-C) can also be
used in the present invention in combination with another compound
of formula (I-A), (I-B) or (I-C) or with another antiretroviral
compound. Thus, the present invention also relates to a
pharmaceutical composition containing (a) a compound of formula
(I-A), (I-B) or (I-C), (b) another compound of formula (I-A), (I-B)
or (I-C) or another antiretroviral compound, and (c) one or more
water-soluble polymers, as a combined preparation for anti-HIV
treatment. Said other antiretroviral compounds may be known
antiretroviral compounds such as nucleoside reverse transcriptase
inhibitors, e.g. zidovudine (3'-azido-3'-deoxythymidine, AZT),
didanosine (dideoxy inosine; ddI), zalcitabine (dideoxycytidine,
ddC) or lamivudine (3'-thia-2'-3'-dideoxycytidine, 3TC) and the
like; non-nucleoside reverse transciptase inhibitors such as
suramine, foscarnet-sodium (trisodium phosphono formate),
nevirapine
(11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4]diaz-
epin-6-one), sustiva (efavirenz), tacrine (tetrahydroaminoacridine)
and the like; compounds of the TIBO
(tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepine-2(1H)-one and
thione)-type e.g.
(S)-8-chloro-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo-[4-
,5,1-jk][1,4]benzodiazepine-2(1H)-thione; compounds of the
.alpha.-APA (.alpha.-anilino phenyl acetamide) type e.g.
.alpha.-[(2-nitro-phenyl)amino]-2,6-dichlorobenzene-acetamide and
the like; TAT-inhibitors, e.g. RO-5-3335 and the like; protease
inhibitors e.g. indinavir, ritanovir, saquinovir and the like; NMDA
receptor inhibitors e.g. pentamidine; .alpha.-glycosidase inhibitor
e.g. castanospermine and the like; Rnase H inhibitor e.g. dextran
(dextran sulfate) and the like; or immunomodulating agents, e.g.
levamisole, thymopentin and the like.
[0264] The term "a solid dispersion" defines a system in a solid
state (as opposed to a liquid or gaseous state) comprising at least
two components, wherein one component is dispersed more or less
evenly throughout the other component or components. When said
dispersion of the components is such that the system is chemically
and physically uniform or homogenous throughout or consists of one
phase as defined in thermo-dynamics, such a solid dispersion will
be called "a solid solution" hereinafter. Solid solutions are
preferred physical systems because the components therein are
usually readily bioavailable to the organisms to which they are
administered. This advantage can probably be explained by the ease
with which said solid solutions can form liquid solutions when
contacted with a liquid medium such as gastric juice. The ease of
dissolution may be attributed at least in part to the fact that the
energy required for dissolution of the components from a solid
solution is less than that required for the dissolution of
components from a crystalline or microcrystalline solid phase.
[0265] The term "a solid dispersion" also comprises dispersions
which are less homogenous throughout than solid solutions. Such
dispersions are not chemically and physically uniform throughout or
comprise more than one phase. For example, the term "a solid
dispersion" also relates to particles having domains or small
regions wherein amorphous, microcrystalline or crystalline (a), or
amorphous, microcrystalline or crystalline (b), or both, are
dispersed more or less evenly in another phase comprising (b), or
(a), or a solid solution comprising (a) and (b). Said domains are
regions within the particles distinctively marked by some physical
feature, small in size compared to the size of the particle as a
whole, and evenly and randomly distributed throughout the
particle.
[0266] As described hereinabove, the particles of the present
invention also comprise one or more water-soluble polymers.
[0267] The water-soluble polymer in the particles according to the
present invention is a polymer that preferably has an apparent
viscosity, when dissolved at 20.degree. C. in an aqueous solution
at 2% (w/v), of 1 to 5000 mPas more preferably of 1 to 700 mPas,
and most preferred of 1 to 100 mPas. For example, the water-soluble
polymer can be selected from the group comprising [0268]
alkylcelluloses such as methylcellulose, [0269]
hydroxyalkylcelluloses such as hydroxymethylcellulose,
hydroxyethylcellulose, hydroxypropylcellulose and
hydroxybutylcellulose, [0270] hydroxyalkyl alkylcelluloses such as
hydroxyethyl methylcellulose and hydroxypropyl methylcellulose,
[0271] carboxyalkylcelluloses such as carboxymethylcellulose,
[0272] alkali metal salts of carboxyalkylcelluloses such as sodium
carboxymethylcellulose, [0273] carboxyalkylalkylcelluloses such as
carboxymethylethylcellulose, [0274] carboxyalkylcellulose esters,
[0275] starches, [0276] pectines such as sodium
carboxymethylamylopectine, [0277] chitin derivates such as
chitosan, [0278] di-, oligo- and polysaccharides such as trehalose,
cyclodextrins and derivatives thereof, alginic acid, alkali metal
and ammonium salts thereof, carrageenans, galactomannans,
tragacanth, agar-agar, gummi arabicum, guar gummi and xanthan
gummi, [0279] polyacrylic acids and the salts thereof, [0280]
polymethacrylic acids, the salts and esters thereof, methacrylate
copolymers, [0281] polyvinylalcohol, [0282] polyalkylene oxides
such as polyethylene oxide and polypropylene oxide and copolymers
of ethylene oxide and propylene oxide.
[0283] Preferred water-soluble polymers are Eudragit E.RTM. and
hydroxypropyl methylcelluloses (HPMC).
[0284] Said Eudragit E.RTM. (Rohm GmbH, Germany) is an aminoalkyl
methacrylate copolymer, more in particular poly(butyl methacrylate,
(2-dimethylaminoethyl)methacrylate, methyl methacrylate) (1:2:1).
This basic polymethacrylate is soluble in gastric fluid up to pH 5.
Eudragit E.RTM. 100, which is a solvent-free Eudragit E.RTM. solid
substance is preferred.
[0285] Said HPMC contains sufficient hydroxypropyl and methoxy
groups to render it water-soluble. HPMC having a methoxy degree of
substitution from about 0.8 to about 2.5 and a hydroxypropyl molar
substitution from about 0.05 to about 3.0 are generally
water-soluble. Methoxy degree of substitution refers to the average
number of methyl ether groups present per anhydroglucose unit of
the cellulose molecule. Hydroxypropyl molar substitution refers to
the average number of moles of propylene oxide which have reacted
with each anhydroglucose unit of the cellulose molecule.
Hydroxypropyl methylcellulose is the United States Adopted Name for
hypromellose (see Martindale, The Extra Pharmacopoeia, 29th
edition, page 1435). In the four digit number "2910", the first two
digits represent the approximate percentage of methoxyl groups and
the third and fourth digits the approximate percentage composition
of hydroxypropoxyl groups; 5 mPas is a value indicative of the
apparent viscosity of a 2% aqueous solution at 20.degree. C.
[0286] The molecular weight of the HPMC normally affects both the
release profile of the milled extrudate as well as its physical
properties. A desired release profile can thus be designed by
choosing an HPMC of an appropriate molecular weight; for immediate
release of the active ingredient from the particles, a low
molecular weight polymer is preferred. High molecular weight HPMC
is more likely to yield a sustained release pharmaceutical dosage
form. The molecular weight of a water-soluble cellulose ether is
generally expressed in terms of the apparent viscosity at
20.degree. C. of an aqueous solution containing two percent by
weight of said polymer. Suitable HPMC include those having a
viscosity from about 1 to about 100 mPas, in particular form about
3 to about 15 mPas, preferably about 5 mPas The most preferred type
of HPMC having a viscosity of 5 mPas., is the commercially
available HPMC 2910 5 mPas, because this yields particles from
which superior oral dosage forms of compounds of formula (I-A),
(I-B) or (I-C) can be prepared as will be discussed hereunder and
in the experimental part.
[0287] The weight-by-weight ratio of (a) (i.e. the antiviral
compound):(b) (i.e. the water-soluble polymer) is in the range of
1:1 to 1:899, preferably 1:1 to 1:100, more preferably 1:1 to 1:5.
In the case of (compound of formula (I-A), (I-B) or (I-C)): (HPMC
2910 5 mPas), said ratio preferably ranges from about 1:1 to about
1:3, and optimally is about 1:1.5 (or 2:3). The most appropriate
weight by weight ratio of a compound of formula (I-A), (I-B) or
(I-C) to water-soluble polymer(s) may be determined by a person
skilled in the art by straightforward experimentation. The lower
limit is determined by practical considerations. Indeed, given the
therapeutically effective amount of a compound of formula (I-A),
(I-B) or (I-C) (from about 1 mg to about 1000 mg per unit dosage
form, preferably about 200 mg to 400 mg or 5 to 200 mg per unit
dosage form), the lower limit of the ratio is determined by the
maximum amount of mixture that can be processed into one dosage
form of practical size. When the relative amount of water-soluble
polymer is too high, the absolute amount of mixture needed to reach
the therapeutic level will be too high to be processed into one
capsule or tablet. Tablets, for example, have a maximum weight of
about 1 g, and the extrudate can account for maximally about 90%
(w/w) thereof. Consequently, the lower limit of the amount of a
compound of formula (I-A), (I-B) or (I-C) over water-soluble
polymer will be about 1:899 (1 mg of a compound of formula (I-A),
(I-B) or (I-C)+899 mg water-soluble polymer).
[0288] On the other hand, if the ratio is too high, this means the
amount of the compound of formula (I-A), (I-B) or (I-C) is
relatively high compared to the amount of water-soluble polymer,
then there is the risk that the compound of formula (I-A), (I-B) or
(I-C) will not dissolve sufficiently in the water-soluble polymer,
and thus the required bioavailability will not be obtained. The
degree to which a compound has dissolved into a water-soluble
polymer can often be checked visually: if the extrudate is clear
then it is very likely that the compound will have dissolved
completely in the water-soluble polymer. It will be appreciated
that the upper limit of 1:1 may be underestimated for particular
compounds of formula (I-A), (I-B) or (I-C) and particular
water-soluble polymers. Since this can be established easily but
for the experimentation time involved, solid dispersions wherein
the ratio (a):(b) is larger than 1:1 are also meant to be comprised
within the scope of the present invention.
[0289] The particles according to the present invention can be
prepared by first preparing a solid dispersion of the components,
and then optionally grinding or milling that dispersion. Various
techniques exist for preparing solid dispersions including
melt-extrusion, spray-drying and solution-evaporation,
melt-extrusion being preferred.
[0290] The melt-extrusion process comprises the following
steps:
a) mixing the components (a) and (b), b) optionally blending
additives with the thus obtained mixture, c) heating the thus
obtained blend until one obtains a homogenous melt, d) forcing the
thus obtained melt through one or more nozzles; and e) cooling the
melt till it solidifies.
[0291] The terms "melt" and "melting" should be interpreted
broadly. For our purposes, these terms not only mean the alteration
from a solid state to a liquid state, but can also refer to a
transition to a glassy state or a rubbery state, and in which it is
possible for one component of the mixture to get embedded more or
less homogeneously into the other. In particular cases, one
component will melt and the other component(s) will dissolve in the
melt thus forming a solution, which upon cooling may form a solid
solution having advantageous dissolution properties.
[0292] One of the most important parameters of melt extrusion is
the temperature at which the melt-extruder is operating. It was
found that the operating temperature can easily range between about
20.degree. C. and about 300.degree. C., more preferably about
70.degree. C. and 250.degree. C. The lower temperature limit
depends on the solubility of a compound of formula (I-A), (I-B) or
(I-C) in the water-soluble polymer and on the viscosity of the
mixture. When the compound of formula (I-A), (I-B) or (I-C) is not
completely dissolved in the water-soluble polymer, the extrudate
will not have the required bioavailability; when the viscosity of
the mixture is too high, the process of melt extrusion will be
difficult. At temperatures of more than 300.degree. C. the
water-soluble polymer may decompose to an unacceptable level. It
may be noted that there is no need to fear decomposition of a
compound of formula (I-A), (I-B) or (I-C) at temperatures up to
300.degree. C. A person skilled in the art will easily recognize
the most appropriate temperature range to be used.
[0293] The throughput rate is also of importance because even at
relatively low temperatures the water-soluble polymer may start to
decompose when it remains too long in contact with the heating
element.
[0294] It will be appreciated that the person skilled in the art
will be able to optimize the parameters of the melt extrusion
process within the above given ranges. The working temperatures
will also be determined by the kind of extruder or the kind of
configuration within the extruder that is used. Most of the energy
needed to melt, mix and dissolve the components in the extruder can
be provided by the heating elements.
[0295] However, the friction of the material within the extruder
may also provide a substantial amount of energy to the mixture and
aid in the formation of a homogenous melt of the components.
[0296] A person skilled in the art will easily recognize the most
appropriate extruder, such as, for example, a single screw, a twin
screw extruder or a multi-screw extruder, for the preparation of
the subject-matter of the present invention.
[0297] Spray-drying of a solution of the components also yields a
solid dispersion of said components and may be a useful alternative
to the melt-extrusion process, particularly in those cases where
the water-soluble polymer is not sufficiently stable to withstand
the extrusion conditions and where residual solvent can effectively
be removed from the solid dispersion. Yet another possible
preparation consists of preparing a solution of the components,
pouring said solution onto a large surface so as to form a thin
film, and evaporating the solvent therefrom.
[0298] The solid dispersion product is milled or ground to
particles having a particle size of less than 1500 .mu.m,
preferably less than 400 .mu.m, more preferably less than 250
.mu.m, and most preferably less than 125 .mu.m. The particle size
proves to be an important factor determining the speed with which a
particular dosage form can be manufactured on a large scale. For
instance, for capsules, the particle size may range preferably from
100 to 1500 .mu.m; for tablets the particle size is preferably less
than 250 .mu.m. The smaller the particles, the faster the
tabletting speed can be without detrimental effects on their
quality. The particle size distribution is such that more than 70%
of the particles (measured by weight) have a diameter ranging from
about 50 .mu.m to about 1400 .mu.m, in particular from about 50
.mu.m to about 200 .mu.m, more in particular from about 50 .mu.m to
about 150, and most in particular from about 50 .mu.m to about 125
.mu.m. Particles of the dimensions mentioned herein can be obtained
by sieving them through nominal standard test sieves as described
in the CRC Handbook, 64.sup.th ed., page F-114. Nominal standard
sieves are characterized by the mesh/hole width (.mu.m), DIN 4188
(mm), ASTM E 11-70 (No), Tyler.RTM. (mesh) or BS 410 (mesh) values.
Throughout this description, and in the claims hereinafter,
particle sizes are designated by reference to the mesh/hole width
in .mu.m and to the corresponding Sieve No. in the ASTM E11-70
standard.
[0299] Preferred are particles wherein the compound of formula
(I-A), (I-B) or (I-C) is in a non-crystalline phase as these have
an intrinsically faster dissolution rate than those wherein part or
all of the compound of formula (I-A), (I-B) or (I-C) is in a
microcrystalline or crystalline form.
[0300] Preferably, the solid dispersion is in the form of a solid
solution comprising (a) and (b). Alternatively, it may be in the
form of a dispersion wherein amorphous or microcrystalline (a) or
amorphous or microcrystalline (b) is dispersed more or less evenly
in a solid solution comprising (a) and (b).
[0301] Preferred particles are those obtainable by melt-extrusion
of the components and grinding, and optionally sieving. More in
particular, the present invention concerns particles consisting of
a solid solution comprising two parts by weight of a compound of
formula (I-A), (I-B) or (I-C) and three parts by weight of
hydroxypropyl methylcellulose HPMC 2910 5 mPas, obtainable by
blending said components, melt-extruding the blend at a temperature
in the range of 20.degree. C.-300.degree. C., grinding the
extrudate, and optionally sieving the thus obtained particles. The
preparation is easy to perform and yields particles of a compound
of formula (I-A), (I-B) or (I-C) that are free of organic
solvent.
[0302] The particle as described hereinabove may further comprise
one or more pharmaceutically acceptable excipients such as, for
example, plasticizers, flavors, colorants, preservatives and the
like. Said excipients should not be heat-sensitive, in other words,
they should not show any appreciable degradation or decomposition
at the working temperature of the melt-extruder.
[0303] In the current formulations (compound of formula (I-A),
(I-B) or (I-C): HPMC 2910 5 mPas), the amount of plasticizer is
preferably small, in the order of 0% to 15% (w/w), preferably less
than 5% (w/w). With other water-soluble polymers though,
plasticizers may be employed in much different, often higher
amounts because plasticizers as mentioned hereinbelow lower the
temperature at which a melt of (a), (b) and plasticizer is formed,
and this lowering of the melting point is advantageous where the
polymer has limited thermal stability. Suitable plasticizers are
pharmaceutically acceptable and include low molecular weight
polyalcohols such as ethylene glycol, propylene glycol, 1,2
butylene glycol, 2,3-butylene glycol, styrene glycol; polyethylene
glycols such as diethylene glycol, triethylene glycol,
tetraethylene glycol; other polyethylene glycols having a molecular
weight lower than 1,000 g/mol; polypropylene glycols having a
molecular weight lower than 200 g/mol; glycol ethers such as
monopropylene glycol monoisopropyl ether; propylene glycol
monoethyl ether; diethylene glycol monoethyl ether; ester type
plasticizers such as sorbitol lactate, ethyl lactate, butyl
lactate, ethyl glycolate, allyl glycollate; and amines such as
monoethanolamine, diethanolamine, triethanolamine,
monoisopropanolamine; triethylenetetramine,
2-amino-2-methyl-1,3-propanediol and the like. Of these, the low
molecular weight polyethylene glycols, ethylene glycol, low
molecular weight polypropylene glycols and especially propylene
glycol are preferred.
[0304] Once the extrudate is obtained, it can be milled and sieved,
and it can be used as ingredient to make pharmaceutical dosage
forms.
[0305] The particles of the present invention can be formulated
into pharmaceutical dosage forms comprising a therapeutically
effective amount of particles. Although, at first instance,
pharmaceutical dosage forms for oral administration such as tablets
and capsules are envisaged, the particles of the present invention
can also be used to prepare pharmaceutical dosage forms e.g. for
rectal administration. Preferred dosage forms are those adapted for
oral administration shaped as a tablet. They can be produced by
conventional tabletting techniques with conventional ingredients or
excipients and with conventional tabletting machines. As mentioned
above, an effective antiviral dose of a compound of formula (I-A),
(I-B) or (I-C) ranges from about 1 mg to about 1000 mg per unit
dosage form, and preferably is about 200 to 400 mg or 5 to 200 mg
per unit dosage form depending on the particular compound being
used. When one considers that the weight-by-weight ratio of (a):(b)
is maximally about 1:1, then it follows that one dosage form will
weigh at least 10 to 800 mg. In order to facilitate the swallowing
of such a dosage form by a mammal, it is advantageous to give the
dosage form, in particular tablets, an appropriate shape. Tablets
that can be swallowed comfortably are therefore preferably
elongated rather than round in shape. Especially preferred are
biconvex oblate tablets. As discussed hereunder in more detail, a
film coat on the tablet further contributes to the ease with which
it can be swallowed.
[0306] Tablets that give an immediate release of a compound of
formula (I-A), (I-B) or (I-C) upon oral ingestion and that have
good bioavailability are designed in such a manner that the tablets
disintegrate rapidly in the stomach (immediate release) and that
the particles which are liberated thereby are kept away from one
another so that they do not coalesce, give local high
concentrations of a compound of formula (I-A), (I-B) or (I-C) and
the chance that the drug precipitates (bioavailability). The
desired effect can be obtained by distributing said particles
homogeneously throughout a mixture of a disintegrant and a
diluent.
[0307] Suitable disintegrants are those that have a large
coefficient of expansion. Examples thereof are hydrophilic,
insoluble or poorly water-soluble crosslinked polymers such as
crospovidone (crosslinked polyvinylpyrrolidone) and croscarmellose
(crosslinked sodium carboxymethylcellulose). The amount of
disintegrant in immediate release tablets according to the present
invention may conveniently range from about 3 to about 15% (w/w)
and preferably is about 7 to 9%, in particular about 8.5% (w/w).
This amount tends to be larger than usual in tablets in order to
ensure that the particles are spread over a large volume of the
stomach contents upon ingestion. Because disintegrants by their
nature yield sustained release formulations when employed in bulk,
it is advantageous to dilute them with an inert substance called a
diluent or filler.
[0308] A variety of materials may be used as diluents or fillers.
Examples are spray-dried or anhydrous lactose, sucrose, dextrose,
mannitol, sorbitol, starch, cellulose (e.g. micro-crystalline
cellulose Avicel.TM.), dihydrated or anhydrous dibasic calcium
phosphate, and others known in the art, and mixtures thereof.
Preferred is a commercial spray-dried mixture of lactose
monohydrate (75%) with microcrystalline cellulose (25%) which is
commercially available as Microcelac.TM.. The amount of diluent or
filler in the tablets may conveniently range from about 20% to
about 40% (w/w) and preferably ranges from about 25% to about 32%
(w/w).
[0309] The tablet may include a variety of one or more other
conventional excipients such as binders, buffering agents,
lubricants, glidants, thickening agents, sweetening agents,
flavors, and colors. Some excipients can serve multiple
purposes.
[0310] Lubricants and glidants can be employed in the manufacture
of certain dosage forms, and will usually be employed when
producing tablets. Examples of lubricants and glidants are
hydrogenated vegetable oils, e.g hydrogenated Cottonseed oil,
magnesium stearate, stearic acid, sodium lauryl sulfate, magnesium
lauryl sulfate, colloidal silica, talc, mixtures thereof, and
others known in the art. Interesting lubricants and glidants are
magnesium stearate, and mixtures of magnesium stearate with
colloidal silica. A preferred lubricant is hydrogenated vegetable
oil type I, most preferably hydrogenated, deodorized Cottonseed oil
(commercially available from Karlshamns as Akofine NF.TM. (formerly
called Sterotex.TM.)). Lubricants and glidants generally comprise
0.2 to 7.0% of the total tablet weight.
[0311] Other excipients such as coloring agents and pigments may
also be added to the tablets of the present invention. Coloring
agents and pigments include titanium dioxide and dyes suitable for
food. A coloring agent is an optional ingredient in the tablet of
the present invention, but when used the coloring agent can be
present in an amount up to 3.5% based on the total tablet
weight.
[0312] Flavors are optional in the composition and may be chosen
from synthetic flavor oils and flavoring aromatics or natural oils,
extracts from plants leaves, flowers, fruits and so forth and
combinations thereof. These may include cinnamon oil, oil of
wintergreen, peppermint oils, bay oil, anise oil, eucalyptus, thyme
oil. Also useful as flavors are vanilla, citrus oil, including
lemon, orange, grape, lime and grapefruit, and fruit essences,
including apple, banana, pear, peach, strawberry, raspberry,
cherry, plum, pineapple, apricot and so forth, The amount of flavor
may depend on a number of factors including the organoleptic effect
desired. Generally the flavor will be present in an amount from
about 0% to about 3% (w/w).
[0313] As known in the art, tablet blends may be dry-granulated or
wet-granulated before tabletting. The tabletting process itself is
otherwise standard and readily practised by forming a tablet from
desired blend or mixture of ingredients into the appropriate shape
using a conventional tablet press.
[0314] Tablets of the present invention may further be film-coated
to improve taste, to provide ease of swallowing and an elegant
appearance. Many suitable polymeric film-coating materials are
known in the art. A preferred film-coating material is
hydroxypropyl methylcellulose HPMC, especially HPMC 2910 5 mPas.
Other suitable film-forming polymers also may be used herein,
including, hydroxypropylcellulose, and acrylate-methacrylate
copolymers. Besides a film-forming polymer, the film coat may
further comprise a plasticizer (e.g. propylene glycol) and
optionally a pigment (e.g. titanium dioxide). The film-coating
suspension also may contain talc as an anti-adhesive. In immediate
release tablets according to the invention, the film coat is small
and in terms of weight accounts for less than about 3% (w/w) of the
total tablet weight.
[0315] Preferred dosage forms are those wherein the weight of the
particles is at least 40% of the total weight of the total dosage
form, that of the diluent ranges from 20 to 40%, and that of the
disintegrant ranges from 3 to 10%, the remainder being accounted
for by one or more of the excipients described hereinabove.
[0316] The present invention further concerns a process of
preparing particles as described hereinbefore, characterized by
blending the components, extruding said blend at a temperature in
the range of 20-300.degree. C., grinding the extrudate, and
optionally sieving the particles.
[0317] The invention also concerns solid dispersions obtainable by
melt-extrusion of [0318] (a) a compound of formula (I-A), (I-B) or
(I-C) or one of its stereoisomers or a mixture of two or more of
its stereoisomers, and [0319] (c) one or more pharmaceutically
acceptable water-soluble polymers.
[0320] It is another object of the invention to provide a process
of preparing a pharmaceutical dosage form as described
hereinbefore, characterized by blending a therapeutically effective
amount of particles as described hereinbefore, with
pharmaceutically acceptable excipients and compressing said blend
into tablets or filling said blend in capsules.
[0321] Further, this invention concerns particles as described
hereinbefore, for use in preparing a pharmaceutical dosage form for
oral administration to a mammal suffering from a viral infection,
wherein preferably a single such dosage form can be administered
once daily to said mammal
[0322] The present invention also concerns the use of particles
according to as described hereinbefore, for the preparation of a
pharmaceutical dosage form for oral administration to a mammal
suffering from a viral infection, wherein preferably a single such
dosage form can be administered once daily to said mammal
[0323] The invention also relates to a method of treating a viral
infection in a mammal which comprises administering to said mammal
an effective antiviral amount of a compound of formula (I-A), (I-B)
or (I-C), preferably in a single oral dosage form which can be
administered once daily.
[0324] The invention also relates to a pharmaceutical package
suitable for commercial sale comprising a container, an oral dosage
form of a compound of formula (I-A), (I-B) or (I-C) as described
hereinbefore, and associated with said package written matter.
[0325] The following examples are intended to illustrate the
present invention.
EXPERIMENTAL PART
1. Compounds of Formula (I-A)
1.A. Preparation of Intermediate Compounds
Example 1.A1
[0326] a) A solution of 2,6-dichlorobenzylchloride (0.102 mol) in
1,1-diethylether (10 ml) was added dropwise to magnesium (0.102
mol) in 1,1-diethylether (60 ml). The reaction was initiated by
adding 2 drops of 1,2-dibromoethane. After most of magnesium
disappeared, 2,4,6-trichloropyrimidine (0.051 mol) in
1,1-diethylether (30 ml) was added. The mixture was stirred
overnight at room temperature. The solvent was evaporated and the
residue was purified by flash column chromatography over silica gel
(eluent: CH.sub.2Cl.sub.2/hexane 1/2). The desired fractions were
collected and the solvent was evaporated, yielding 3.3 g of (21%)
2,4-dichloro-6-[(2,6-dichloro-phenyl)methyl]pyrimidine (interm. 1;
melting point (mp.): 106-107.degree. C.).
[0327] b) Intermediate (1) (0.0081 mol) in 2-propanol (100 ml) was
heated until complete dissolution. The solution was then
transferred into a pressure tube and NH.sub.3 gas was bubbled into
it for 20 minutes. Then the mixture was heated to 80.degree. C. for
16 hours. The solvent was evaporated, yielding a residue of two
compounds:
2-chloro-6-[(2,6-di-chloro-phenyl)methyl]-4-pyrimidinamine (interm.
2) and 4-chloro-6-[(2,6-dichloro-phenyl)methyl]-2-pyrimidinamine
(interm. 3).
Example 1.A2
[0328] a) Urea (0.03 mol) was added to a mixture of (.+-.)-ethyl
2,6-dichloro-phenyl-.alpha.-methyl-.beta.-oxobutanoate (0.02 mol)
in NaOC.sub.2H.sub.5 in ethanol, (1M; 0.040 mol; 40 ml). The
reaction mixture was stirred and refluxed overnight. The solvent
was evaporated, water was added and the mixture was neutralized
with 0.3 N HOAc. The precipitate was filtered off and was further
triturated with ether and then H.sub.2O, then filtered off and
dried, yielding 2.2 g (39%) of
6-[(2,6-dichloro-phenyl)methyl]-5-methyl-2,4(1H,3H)-pyrimidinedione
(interm. 4).
[0329] b) A mixture of intermediate (4) (0.0095 mol) in phosphoryl
chloride (50 ml) was stirred and refluxed overnight. Excess of
phosphoryl chloride was then evaporated. Ice-water was added to the
residue. A white precipitate was formed, filtered off and dried.
The residue was purified by flash column chromatography over silica
gel (eluent: CH.sub.2Cl.sub.2). The desired fractions were
collected and the solvent was evaporated, yielding 2.06 g (67%) of
2,4-dichloro-6-[(2,6-dichloro-phenyl)methyl]-5-methylpyrimidine
(interm. 5).
[0330] c)
4-chloro-6-[(2,6-dichloro-phenyl)methyl]-5-methyl-2-pyrimidinami-
ne (interm. 6) and
2-chloro-6-[(2,6-dichloro-phenyl)methyl]-5-methyl-4-pyrimidinamine
(interm. 7) were prepared from intermediate 5 following the
procedures as described in example A1b.
Example 1.A3
[0331] a) To the stirred solution of
2,6-dichlorobenzeneethanimidamide HCl (1:1), (0.0042 mol) in
ethanol (20 ml), a solution of sodium (0.013 mol) in ethanol (10
ml) was added dropwise first and then propanedioic acid, diethyl
ester (0.0109 mol) was added. The reaction mixture was stirred and
refluxed for 4 hours and then stirred at room temperature overnight
After adding another equivalent of propanedioic acid, diethyl ester
(stirring and refluxing it overnight), the solvent was evaporated
and the residue was dissolved in water and acidified with 1 N HCl.
The solid was filtered off, washed with water and dried, yielding
0.87 g (76.4%) of
2-[(2,6-dichloro-phenyl)methyl]-4,6-pyrimidinediol (interm. 8).
[0332] b) 6-chloro-2-[(2,6-dichloro-phenyl)methyl]-4-pyrimidinamine
(interm. 9) was prepared starting from intermediate 8 according to
the procedures described in example A1b), A2b) & A2c).
Example 1.A4
[0333] 4-Amino-1-butanol (1.57 ml) was added to a solution of
intermediate (1) (0.008 mol) in 1,4-dioxane (20 ml) under Argon.
The reaction mixture was stirred for 2 hours at room temperature.
The solvent was evaporated. The residue was purified by flash
column chromatography over silica gel (eluent gradient:
CH.sub.2Cl.sub.2/CH.sub.3OH: from 100/0 to 98/2). The pure
fractions were collected and the solvent was evaporated, yielding
2.05 g of a mixture of
4-[[2-chloro-6-[(2,6-dichloro-phenyl)methyl]-4-pyrimidinyl]-amino]-1-buta-
nol (interm. 10) and
4-[[4-chloro-6-[(2,6-dichloro-phenyl)methyl]-2-pyrimidinyl]amino]-1-butan-
ol (interm. 11).
Example 1.A5
[0334] a) Potassium hydroxide/ethanol (10%; 0.035 mol) was added to
a solution of 2,6-dichlorophenol (0.035 mol) in tetrahydrofuran
(100 ml). The mixture was stirred and 2,4,6-trichloropyrimidine
(0.044 mol) was added. The mixture was stirred overnight at
60.degree. C. The reaction was quenched with NaOH 1N solution. The
aqueous layers were extracted with EtOAc several times and then the
organic layers were combined and washed with NaOH 3N and saturated
NaCl, dried and concentrated. The residue was recrystallized from
CH.sub.2Cl.sub.2/hexane. The precipitate was filtered off and
dried, yielding 5.98 g
2,4-dichloro-6-(2,6-dichlorophenoxy)pyrimidine (55%) (interm.
12).
[0335] b) Reaction under Argon atmosphere. 2,4,6-trimethylaniline
(0.0678 mol) was added to 2,4-dichloropyrimidine (0.0664 mol) in
1,4-dioxane (100 ml). N,N-di(1-methylethyl)-ethaneamine (0.0830
mol) was added. The reaction mixture was stirred and refluxed for 4
days and the solvent was evaporated. The residue was dissolved in
CH.sub.2Cl.sub.2, washed with a saturated NaHCO.sub.3 solution,
then dried (Na.sub.2SO.sub.4), filtered and the solvent was
evaporated to give 17.1 g solid residue. This solid was dissolved
in CH.sub.2Cl.sub.2:hexane (1:1; 150 ml), and the resulting
solution was concentrated to 100 ml, then filtered. The residue was
purified by column chromatography on KP-Sil (eluent:
CH.sub.2Cl.sub.2). The desired fractions were collected and the
solvent was evaporated. The less polar fraction was stirred in
CH.sub.2Cl.sub.2 for 3 hours and filtered, yielding 0.44 g
4-chloro-N-(2,4,6-trimethylphenyl)-2-pyrimidinamine (intermediate
10). A second fraction was recrystallized from acetonitrile,
filtered off and dried, yielding
2-chloro-N-(2,4,6-trimethyl-phenyl)-4-pyrimidinamine (intermediate
14).
Example 1.A6
[0336] Pyridine (1 ml) was added to a mixture of
4-[[4-amino-6-[(2,6-dichloro-phenyl)-methyl]-2-pyrimidinyl]amino]benzonit-
rile (0.00135 mol) in CH.sub.2Cl.sub.2 (19 ml). A solution of
chloroethanoyl chloride (0.001375 mol) in CH.sub.2Cl.sub.2 (0.5 ml)
was added dropwise on an ice bath. The mixture was stirred at room
temperature for 2 hours. More chloroethanoyl chloride (0.00625 mol)
in CH.sub.2Cl.sub.2 (0.5 ml) was added. The mixture stood in the
refrigerator overnight. The solvent was evaporated. The residue was
treated with a saturated Na.sub.2CO.sub.3 solution and the mixture
was extracted with CH.sub.2Cl.sub.2. The separated organic layer
was dried, filtered and concentrated. The residue was purified by
flash column chromatography over silica gel (eluent:
CH.sub.2Cl.sub.2/CH.sub.3OH/NH.sub.4OH 99/1/0.1). The desired
fractions were collected and the solvent was evaporated, yielding
0.22 g (36.5%) of
2-chloro-N-[6-[(2,6-dichloro-phenyl)methyl]-2-[(4-cyano-phenyl)amino]-4-p-
yrimidinyl]acetamide (interm. 13).
Example 1.A7
[0337] A mixture of 4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile
(0.005 mol) and nitryl tetrafluoroborate (0.0025 mol) in
acetonitrile (5 ml) was stirred at room temperature for 4 h. The
material was quenched with saturated bicarbonate (50 ml) on cracked
ice. The mixture was allowed to reach room temperature, and the
yellow solid was filtered off. The solid was adsorbed onto silica
and purified by column chromatography (eluent: 30%, 50%, 60%, 70%
CH.sub.2Cl.sub.2 in hexanes). The solvent of the desired fraction
was evaporated and the residue was dried, yielding 0.89 g (64%) of
3-nitro-4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile. (interm.
15)
Example 1.A8
[0338] A mixture of
2,6-dichloro-N-(2,4,6-trimethylphenyl)-4-pyrimidinamine (0.00376
mol) in a 2.0 M solution of NH.sub.3 in 2-propanol (25 ml) and a
0.5 M solution of NH.sub.3 in dioxane (25 ml) was heated in a
pressure sample at 110-115.degree. C. for 24 hours. The solvent was
evaporated, and the residue was chromatographed on Biotage (eluent:
1:1 CH.sub.2Cl.sub.2:hexane). The desired fractions were collected
and the solvent was evaporated, yielding a mixture of 0.523 g of
2-chloro-N4-(2,4,6-trimethylphenyl)-4,6-pyrimidine-diamine (interm.
53) and 0.101 g of
6-chloro-N4-(2,4,6-trimethylphenyl)-2,4-pyrimidinediamine (interm.
16)
Example 1.A9
[0339] a) 2,4,6-trichloro-1,3,5-triazine (0.07440 mol) and
tetrahydrofuran (100 ml) were combined and cooled to -75.degree. C.
under Ar atmosphere. 4-Aminobenzonitrile (0.07440 mol) was added
and the solution was stirred for 4 hours at -75.degree. C.
Triethyl-amine (0.07440 mol) was added dropwise and the reaction
mixture was allowed to warm up slowly to room temperature and
stirred for 3 days. After adding 1,4-dioxane (100 ml), the
resulting precipitate was collected by filtration, washed with
tetrahydrofuran, and dried, yielding 12.74 g
4-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]benzonitrile (interm.
17).
[0340] b) NaH (0.0113 mol), CH.sub.3CN (30 ml) and
2,6-dichlorophenol (0.0113 mol) were combined and stirred for 15
minutes under Ar atmosphere. Intermediate (17) (0.0113 mol) was
added and the reaction mixture was stirred at room temperature for
16 hours. The reaction mixture was quenched with ice water (30 ml)
and filtered. A precipitate formed in the filtrate and was filtered
off. The resulting solid was washed with H.sub.2O and CH.sub.3CN,
then dried, yielding 0.62 g (14.0%) of
4-[[4-chloro-6-(2,6-dichloro-phenoxy)-1,3,5-triazin-2-yl]amino]benzoni-
trile (interm. 18).
[0341] c) N,N-Diisopropylethylamine (0.00714 mol) was added to a
solution of 2-chloro-6-methylbenzenamine (0.00714 mol) in
1,4-dioxane (20 ml) under Ar flow. A solution of intermediate (17)
(0.00714 mol) in 1,4-dioxane (5 ml) was added. The reaction mixture
was stirred and refluxed for 24 hours. The solvent was evaporated
and CH.sub.2Cl.sub.2 was added. The organic layer was washed with a
saturated aqueous NaHCO.sub.3 solution, and the resulting
precipitate was filtered, yielding 0.56 g (21.1%) of
4-[[4-chloro-6-[(2-chloro-6-methylphenyl)amino]-1,3,5-triazin-2-yl]amino]-
benzonitrile (interm. 19).
Example 1.A10
[0342] a) 2,4,6-Trichloro-1,3,5-triazine (0.0266 mol) was added to
1,4-dioxane (50 ml) under Ar atmosphere. The solution was stirred
until it became homogeneous, then 2,6-dichlorobenzenamine (0.0266
mol) and K.sub.2CO.sub.3 (0.0362 mol) were added. The reaction
mixture was stirred at room temperature for 3 days. The solvent was
evaporated. Water was added to the residue and the aqueous phase
was extracted with CH.sub.2Cl.sub.2. The separated organic layer
was washed with brine, dried with potassium carbonate, filtered and
the filtrate was evaporated, yielding 7.52 g (91.2%) of
N-(2,6-dichlorophenyl)-4,6-dichloro-1,3,5-triazin-2-amine (interm.
20).
[0343] b) 1,4-Dioxane (50 ml), 4-cyanoaniline (0.0243 mol), and
N,N-diisopropylethylamine (0.0243 mol) were added to intermediate
(20) (0.0243 mol) under Ar atmosphere. The reaction mixture was
stirred and refluxed for 1 week. The reaction was cooled, the
solvent was evaporated and the residue was dissolved in ethyl
acetate. The organic phase was washed with a saturated NaHCO.sub.3
solution and with brine, dried with potassium carbonate, filtered,
and the solvent was evaporated. The residue was stirred in a
mixture of CH.sub.2Cl.sub.2 and saturated NaHCO.sub.3, and the
precipitate filtered, yielding 2.26 g (23.8%) of
4-[[4-chloro-6-[(2,6-dichlorophenyl)amino]-1,3,5-triazin-2-yl]amino]benzo-
nitrile (interm. 21).
Example 1.A11
[0344] Rink Amide resin (15 g; Calbiochem-Novabiochem Corp., San
Diego, Calif.; Product No. 01-64-0013) was washed in a reaction
vessel with CH.sub.2Cl.sub.2 (100 ml), N,N-dimethylformamide (200
ml), and N,N-dimethylformamide:piperidine (150 ml:50 ml) was added.
The mixture was agitated for 2 hours, washed with
N,N-dimethyl-formamide, CH.sub.2Cl.sub.2, and dimethylsulfoxide.
Intermediate (17) (0.06 mol), N,N-diisopropylethylamine (10.5 ml)
and dimethylsulfoxide (200 ml) were added and the reaction mixture
was agitated for three days, then washed with N,N-dimethylformamide
and CH.sub.2Cl.sub.2, yielding the resin bound intermediate
(17).
1.B. Preparation of Compounds of Formula (I-A)
Example 1.B1
[0345] A mixture of
##STR00031##
(*1.A4) (0.004 mol) and 4-amino-benzonitrile (0.0084 mol) were
combined in a sealed tube and heated for 16 hours at 160.degree. C.
under Argon. The reaction mixture was allowed to cool to room
temperature and dissolved in CH.sub.2Cl.sub.2/CH.sub.3OH 90/10 (20
ml) and 5 g of silica gel was added. After evaporating the solvent,
the residue was purified by flash column chromatography over silica
gel (eluent gradient: CH.sub.2Cl.sub.2/CH.sub.3OH: from 100/0 to
97/3). The desired fraction was collected and the solvent was
evaporated, yielding 0.31 g (18.1%) of
4-[[4-[(2,6-dichloro-phenyl)methyl]-6-[(3-hydroxypropyl)amino]-2-pyrimidi-
nyl]amino]benzonitrile (comp. 4). (* indicates the example number
according to which the intermediate was synthesized)
Example 1.B2
##STR00032##
[0346] (0.00399 mol) and 4-aminobenzonitrile (0.0012 mol) in
1-methyl-2-pyrrolidinone (3 ml) was stirred for 16 hours at
130.degree. C. under Argon. Then, the reaction mixture was cooled
to room temperature and quenched with H.sub.2O (200 ml). A
precipitate formed, which was stirred for 16 hours, and separated
by filtration over Celite. The residue was dissolved in
CH.sub.3OH/CH.sub.2Cl.sub.2 (10%, 200 ml), dried over
K.sub.2CO.sub.3, filtered, and evaporated. This resulting material
was further purified by flash column chromatography over silica gel
(gradient eluent: CH.sub.2Cl.sub.2/CH.sub.3OH from 100/0 to 95/5).
The desired fraction was collected and the solvent was evaporated,
yielding 0.43 g (21.7%) of
4-[[6-[(2,6-dichlorophenyl)methyl]-2-[[3-(2-oxo-1-pyrrolidinyl)propyl]-am-
ino]-4-pyrimidinyl]amino]benzonitrile (mp. 104-114.degree. C.).
Example 1.B3
[0347] HCl/diethyl ether (1N; 2.77 ml) was stirred into a solution
of
##STR00033##
(4 ml) under N.sub.2 atmosphere. The reaction mixture was heated
for 5 minutes. Next, 4-aminobenzonitrile (0.0061 mol) was added and
the reaction was heated at 100.degree. C. for 16 hours. Then, the
reaction mixture was cooled to room temperature and diluted with
ethylacetate (10 ml). The organic layer was washed with NaOH (1 N;
2.times.100 ml), H.sub.2O (2.times.100 ml), brine (50 ml),
respectively, dried, filtered and the filtrate was evaporated. The
crude material was purified by flash chromatography (eluent:
2.5-7.5% of CH.sub.3OH containing 10% NH.sub.4OH in
CH.sub.2Cl.sub.2). The desired fractions were collected and the
solvent was evaporated. The residue was dried, yielding 0.160 g
(12.0%) of
4-[[4-[(2,6-dichloro-phenyl)methyl]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-
-2-pyrimidinyl]amino]benzonitrile (comp. 14; mp. 80-85.degree.
C.).
Example 1.B4
[0348] A slurry of
##STR00034##
(150 ml) was stirred rapidly and cooled to 0.degree. C. under
nitrogen. BBr.sub.3 (0.015 mol) was introduced by syringe. The
reaction mixture was stirred rapidly for two hours. The reaction
mixture was recooled to 0.degree. C. and quenched with NaOH (aq. 1
N, 25 ml). The biphasic partial quench mixture gives a precipitate
which was filtered off and dried, yielding 2.5 g (91%) of
4-[[4-[(2,6-dichloro-phenyl)methyl]-6-(hydroxyamino)-2-pyrimidinyl]amino]-
benzonitrile dihydrobromide.pentahydrate (comp. 12; mp.
240-244.degree. C.).
Example 1.B5
[0349] 1,1-Dimethoxy-N,N-dimethylmethanamine (0.152 mol) was added
to
4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-2-pyrimidinyl]amino]benzonitri-
le (0.0008 mol). The mixture was stirred at room temperature for 2
days and then concentrated. The crude product was purified by flash
chromatography over silica gel (eluent: CH.sub.2Cl.sub.2/CH.sub.3OH
99/1). The desired fraction was collected and the solvent was
evaporated. The resulting residue was triturated with hexane,
yielding 0.15 g (42%) of
N'-[2-[(4-cyano-phenyl)amino]-6-[(2,6-dichlorophenyl)methyl]-4-pyrimid-
inyl]-N,N-dimethylmethanimidamide (mp. 175-180.degree. C.).
Example 1.B6
[0350] Piperidine (0.12 ml) was added to a mixture of intermediate
(13) (0.00047 mol) in terahydrofuran (20 ml). The mixture was
stirred at room temperature for 4 hours. More piperidine (0.14 ml)
was added. The mixture was stirred for another 2 hours. The solvent
was evaporated. The residue was purified by flash column
chromatography over silica gel
(CH.sub.2Cl.sub.2/CH.sub.3OH/NH.sub.4OH 99/1/0.1). The desired
fractions were collected and the solvent was evaporated, yielding
0.05 g (21.5%) of
N-[6-[(2,6-di-chloro-phenyl)methyl]-2-[(4-cyano-phenyl)amino]-4-pyrimidin-
yl]-1-piperidine-acetamide (mp. 175-180.degree. C.).
Example 1.B7
[0351] Pyridine (0.014 mol) was added to a mixture of
4-[[4-amino-6-[(2,6-dichlorophenyl)-methyl]-2-pyrimidinyl]amino]benzonitr-
ile (0.0013 mol) in CH.sub.2Cl.sub.2. A solution of octanoyl
chloride (1.5 equiv) in CH.sub.2Cl.sub.2 (0.5 ml) was added
dropwise. The mixture was stirred at room temperature for 2 hours.
More octanoyl chloride (3.5 equiv) in CH.sub.2Cl.sub.2 was added
dropwise. The mixture was stirred. The solvent was then evaporated.
The residue was treated with a saturated aqueous NaHCO.sub.3
solution and the mixture was extracted with CH.sub.2Cl.sub.2. The
separated organic layer was dried, filtered and the solvent was
evaporated to give the crude product. The residue was
recrystallized from CHCl.sub.3 and hexane, yielding 0.443 g (68.6%)
of
N-[6-[(2,6-dichloro-phenyl)-methyl]-2-[(4-cyano-phenyl)amino]-4-pyrimidin-
yl]octanamide (mp. 135-137.degree. C.).
Example 1.B8
[0352] a) A mixture of intermediate 14 (0.082 mol) and 5.4 N HCl in
2-propanol (0.086 mol) in water (300 ml) was stirred and warmed to
40-45.degree. C. over 30 minutes. 4-Amino-benzonitrile (0.242 mol)
was added at 40-45.degree. C. The reaction mixture was stirred and
refluxed for 4.5 hours, then cooled to room temperature. The
mixture was alkalized by portionwise addition of NaHCO.sub.3. This
mixture was extracted with ethylacetate. The organic layer was
separated, washed with brine, dried, filtered and the solvent was
evaporated. This fraction was stirred in ethanol p.a. (100 ml),
filtered off, washed with ethanol (50 ml), then dried, yielding
23.1 g (86%)
4-[[4-[(2,4,6-trimethylphenyl)-amino]-2-pyrimidinyl]amino]benzonitrile
(comp. 17).
[0353] b) A mixture of
4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile (0.021 mol) and HCl
in 2-propanol (0.0095 mol) in water (30 ml) was stirred for one
hour at 45.degree. C. 4-amino-3,5-dimethyl-benzonitrile (0.025 mol)
was added and the reaction mixture was stirred and refluxed
overnight. The mixture was cooled to room temperature, then
neutralized with NaHCO.sub.3. This mixture was extracted with
ethylacetate. The separated organic layer was washed with brine,
dried, filtered and the solvent evaporated. The residue was
crystallized from CH.sub.3CN, filtered off and dried. The residue
was stirred in boiling CH.sub.2Cl.sub.2 (20 ml), then filtered off
and dried. The residue was crystallized from methyl isobutyl keton,
filtered off and dried, yielding 0.3 g of
4-[[2-[(cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethylbenz-
onitrile (comp. 25).
Example 1.B9
[0354] a) 4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile (0.003
mol), 2,6-dibromo-4-methyl-benzenamine (0.006 mol) and 1 M HCl in
diethyl ether (4.5 ml) in 1,4-dioxane (10 ml) were combined in a
tube and heated under Ar until all diethyl ether had evaporated.
The tube was sealed and heated at 170.degree. C. for 2.5 days.
Silica gel was added, and the solvent was evaporated. The residue
was purified by flash column chromatography over silica gel (eluent
gradient: CH.sub.2Cl.sub.2:CH.sub.3OH:NH.sub.4OH 100:0:0 to
99:0.9:0.1). The desired fractions were collected and the solvent
was evaporated. The residue was recrystallized from acetonitrile,
filtered off and dried, yielding 0.22 g (15.9%) of
4-[[4-[(2,6-dibromo-4-methylphenyl)amino]-2-pyrimidinyl]amino]benzonitril-
e.
[0355] b)
4-[[4-[(4-chloro-5-methyl-2-pyrimidinyl]amino]benzonitrile (0.01541
mol), 4-amino-3,5-dimethyl-benzonitrile (0.00219 mol),
1-methyl-2-pyrrolidinone (4 ml), 1,4-dioxane (15 ml) and
diisopropylethylamine (0.0154 mol) were combined in a flask under a
stream of argon and heated at 160-230.degree. C. for 16 hours.
CH.sub.2Cl.sub.2 and 1N NaOH were added, and the mixture was
stirred 1 hour and filtered to give a brown solid (!). The
CH.sub.2Cl.sub.2 filtrate was separated and was evaporated and
purified by flash column chromatography (eluent: 2%
CH.sub.3OH/CH.sub.2Cl.sub.2). The desired fractions were combined,
evaporated and the residue was stirred in CH.sub.2Cl.sub.2. The
solid precipitate was filtered off, combined with the brown solid
(!) and recrystallized from CH.sub.3CN. The precipitate was
filtered off and dried, yielding 1.57 g (29%) of
4-[[2-[(4-cyanophenyl)amino]-5-methyl-4-pyrimidinyl]amino]-3,5-dimethylbe-
nzonitrile (comp. 52).
[0356] c) 2-[(4-cyanophenyl)amino]-4-pyrimidinyl
trifluoromethanesulfonate (0.0022 mol) and
2,6-dichloro-4-(trifluoromethyl)-benzenamine (0.0044 mol) were
combined in 1,4-dioxane (2.5 ml) and heated in a sealed tube under
Ar at 170.degree. C. for 40 hours. The reaction mixture was allowed
to cool to room temperature. Silica gel was added, and the solvent
was evaporated. The residue was purified by flash column
chromatography over silica gel (eluent gradient:
CH.sub.2Cl.sub.2:CH.sub.3OH:NH.sub.4OH 100:0:0 to 97:2.7:0.3). The
desired fractions were collected and the solvent was evaporated.
The residue was recrystallized from CH.sub.3CN, filtered off and
dried, yielding 0.086 g (9.2%) of
4-[[4-[[2,6-dichloro-4-(trifluoromethyl)-phenyl]amino]-2-pyrimidinyl]amin-
o]benzonitrile (comp. 23).
Example 1.B10
[0357] To a suspension of NaH (0.006 mol) in 1,4-dioxane (30 ml),
2,4,6-trimethyl-phenol (0.006 mol) was added. The mixture was
stirred for 15 minutes at room temperature, and a clear solution
formed. 4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile (0.004 mol)
was added, and the reaction mixture was heated to reflux under
Argon for 15 hours. The reaction mixture was allowed to cool to
room temperature, 0.5 ml of water was added, followed by 4 g of
silica gel, and the solvent was evaporated. The residue was
purified by flash column chromatography over silica gel (eluent
gradient: CH.sub.2Cl.sub.2:CH.sub.3OH 100:0:0 to 97:3). The pure
fractions were collected and the solvent was evaporated, yielding
1.18 g (89.4%) of
4-[[4-(2,4,6-trimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile
(comp. 20).
Example 1.B11
[0358]
4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitri-
le (0.0015 mol) was stirred in boiling ethanol (8 ml). 6 M HCl in
2-propanol (0.0015 mol) was added and the salt was allowed to
crystallize out overnight at room temperature. The precipitate was
filtered off, washed with 2-propanol and dried, yielding 0.47 g
(86%) of
4-[[4-[(2,4,6-trimethyl-phenyl)amino]-2-pyrimidinyl]amino]benzonitrile
hydrochloride (1:1) (comp. 31).
Example 1.B12
[0359] A mixture of
4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile
(0.00303 mol) and NaBO.sub.3.4H.sub.2O (0.00911 mol) in CH.sub.3OH
(30 ml) and H.sub.2O (10 ml) was stirred and refluxed for 4 days.
The reaction mixture was cooled. The precipitate was filtered off
and the precipitate (!) was purified by flash column chromatography
over silica gel (eluent: CH.sub.2Cl.sub.2/CH.sub.3OH gradient from
100/0 to 95/5). The desired fractions were collected and the
solvent was evaporated, yielding 0.586 g (56%) of
4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide
(comp. 40). The filtrate (!) was purified by reversed-phase HPLC
(eluent gradient: ((0.5% ammoniumacetate in H.sub.2O)/CH.sub.3CN
90/10)/CH.sub.3OH/CH.sub.3CN (0 minutes) 75/25/0, (44 minutes)
0/50/50, (57 minutes) 0/0/100, (61.1-70 minutes) 75/25/0). Three
desired fraction groups were collected and their solvent was
evaporated, yielding 0.18 g of
4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzamide,
N3-oxide (comp. 49) and 0.030 g of
4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]-amino]benzamide,
N1-oxide.
Example 1.B13
[0360] a) A mixture of
4-[[4-chloro-6-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazin-2-yl]-amino]b-
enzonitrile (*A9c) (0.00137 mol) and NH.sub.3 in 1,4-dioxane (0.5
M; 0.00548 mol) was heated in a pressure vessel at 100.degree. C.
for 6 days. The solvent was evaporated and the residue was
dissolved in CH.sub.2Cl.sub.2, washed with a saturated aqueous
NaHCO.sub.3 solution, dried, filtered and the solvent was
evaporated. The residue was purified by column chromatography over
silica gel (eluent: CH.sub.2Cl.sub.2/CH.sub.3OH 100/0, 99/1 and
98/2). The desired fractions were collected and the solvent was
evaporated. The residue was recrystallized from toluene. The
precipitate was filtered and dried, yielding 0.29 g (61.4%) of
4-[[4-amino-6-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazin-2-yl]amino]-be-
nzonitrile.
[0361] b) As an alternative for the preparation of this compound, a
mixture of
4-[[4-chloro-6-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazin-2-yl]amino]be-
nzonitrile (0.0230 mol) in NH.sub.3 in 2-propanol (2.0 M; 60 ml)
and NH.sub.3 in 1,4-dioxane (0.5 M; 20 ml) was heated at 95.degree.
C. for 21 hours. The solvent was evaporated. The residue was
dissolved in ethyl acetate, washed with 1 N NaOH, water and brine,
dried, filtered and the filtrate was evaporated. The residue was
recrystallized with acetonitrile, yielding 5.25 g (66.1%) of
4-[[4-amino-6-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazin-2-yl]amino]ben-
zonitrile.
##STR00035##
(0.015 mol) were added into a pressure flask. The reaction mixture
was heated to 40.degree. C. After 5 days, the reaction was cooled
to room temperature. 2.0 M NH.sub.3 in 2-propanol (0.015 mol) was
added, and the reaction was returned to 40.degree. C. The reaction
was diluted with diethylether and extracted with cold 1 M NaOH. The
aqueous layer was extracted twice more, and the organic phases were
combined. The insoluble material was filtered off and washed with
diethylether, which dissolved most of the material into the
filtrate. The filtrate was combined with the organic phases and
this solution was dried, filtered and the solvent evaporated. The
residue was purified over silica gel flash chromatography, eluting
with 4:1 CH.sub.2Cl.sub.2:diethylether to 100% diethylether. The
resulting material was recrystallized in
tetrahydrofuran/CH.sub.3CN, filtered off and dried, yielding 0.36 g
(67%) of
4-[[4-amino-6-[(2,4,6-trimethylphenyl)azo]-1,3,5-triazin-2-yl]amino]be-
nzonitrile.
Example 1.B14
[0362] O-(Trimethylsilyl)-hydroxylamine (0.0282 mol) was added
to
##STR00036##
(*1.A10b) (0.00282 mol) in 1,4-dioxane (10 ml). The reaction
mixture was stirred at room temperature for 2 days. The solvent was
evaporated. The residue was dissolved in ethyl acetate, washed with
1 N HCl, washed with a saturated aqueous NaHCO.sub.3 solution and
with brine, dried, filtered and the solvent was evaporated. The
residue was purified by column chromatography over silica gel ((I)
eluent gradient: CH.sub.2Cl.sub.2/CH.sub.3OH 98/2 to 96/4 and (II)
eluent gradient: CH.sub.2Cl.sub.2/CH.sub.3OH 100/0, 99/1 and 98/2)
The desired fractions were collected and the solvent was
evaporated. The residue was recrystallized from acetonitrile. The
precipitate was filtered off and dried, yielding 0.32 g (29.2%) of
4-[[[6-(2,6-dichlorophenylamino)-4-(hydroxylamino)]-1,3,5-triazin-2-yl]am-
ino]benzonitrile.
Example 1.B15
[0363] Tetrahydrofuran (10 ml) and 2,5-dimethylphenol (0.00818 mol)
were added to NaH (0.00859 mol). The mixture was stirred for 30
minutes at room temperature. Then, a solution of intermediate (17)
(0.00818 mol) in tetrahydrofuran (100 ml) was added. The reaction
mixture was stirred for 16 hours. Then, the solvent was evaporated
and NH.sub.3 in 1,4-dioxane (50 ml) was added. The resulting
reaction mixture was stirred for 16 hours. The solvent was
evaporated; and, the resulting residue was treated with
H.sub.2O/CH.sub.2Cl.sub.2, stirred, and filtered. A precipitate
formed in the filtrate and was filtered off, yielding 0.42 g of
fraction 1. The resulting filtrate was dried over K.sub.2CO.sub.3
and concentrated. The residue was purified by flash column
chromatography (eluent: CH.sub.3OH/CH.sub.2Cl.sub.2 2.5/97.5). The
desired fractions were collected and the solvent was evaporated,
yielding 2.89 g of fraction 2. Fractions 1 and 2 were combined and
recrystallized from CH.sub.3CN. The precipitate was filtered off
and dried, yielding 1.16 g (42.7%) of
4-[[4-amino-6-(2,5-dimethylphenoxy)-1,3,5-triazin-2-yl]amino]benzonitrile-
.
Example 1.B16
[0364] To a reaction vessel under Ar were added resin bound
intermediate (17) as prepared in example A 11 (0.00015 mol), a
solution of silver triflate (0.075 g) in dimethylsulfoxide (1 ml),
4-bromo-2-chloro-6-methylphenol (0.0027 mol), dimethylsulfoxide (3
ml), and 1.0M sodium bis(trimethylsilyl)amide and disilazane
(1,1,1-trimethyl-N-(trimethylsilyl)-silanamine, sodium salt) (3
ml). The reaction mixture was heated at 95.degree. C. for 12 hours.
The sample was filtered, and the resin was washed with
N,N-dimethylformamide (3.times.), CH.sub.2Cl.sub.2,
N,N-dimethylformamide, CH.sub.3OH, and CH.sub.2Cl.sub.2 (3.times.).
The sample was cleaved twice with 10% trifluoroacetic acid in
CH.sub.2Cl.sub.2 (5 ml, then 3 ml). The solvent was evaporated
under N.sub.2. Purification by reverse phase HPLC yielded 0.0055 g
of
4-[[4-amino-6-(4-bromo-2-chloro-6-methylphenoxy)-1,3,5-triazin-2-yl]-amin-
o]benzonitrile.
Example 1.B17
[0365] To a flask under Ar were added the resin bound intermediate
(17) as prepared in example A 11 (0.00015 mol), CsCO.sub.3 (0.975
g), 4-chloro-2,6-dimethylphenol (0.0038 mol), dimethylsulfoxide (2
ml) and 1 ml of a solution of silver triflate (0.075 g) in
dimethylsulfoxide (1 ml). Ar was bubbled through the reaction
mixture for 1 minute. The flask was heated at 95.degree. C. for 20
hours. The sample was then filtered, and washed with
N,N-dimethylformamide (2.times.), water (3.times.),
N,N-dimethylformamide (2.times.), CH.sub.3OH (1.times.), and
CH.sub.2Cl.sub.2 (3.times.). The sample was then cleaved with 10%
trifluoroacetic acid in CH.sub.2Cl.sub.2 (3 ml), yielding 0.0043 g
of
4-[[4-amino-6-(4-chloro-2,6-dimethylphenoxy)-1,3,5-triazin-2-yl]amino]ben-
zonitrile.
Example 1.B18
[0366] To a flask under Ar were added intermediate (17) (0.00752
mol), N,2,4,6-tetramethyl-benzenamine (0.00752 mol) in 1,4-dioxane
(20 ml) and N,N-diisopropylethylamine (0.00752 mol). The reaction
mixture was stirred and refluxed for 20 hours and the solvent was
evaporated. The residue was transferred into a pressure vessel with
0.5M NH.sub.3 in 1,4-dioxane (0.005 mol) and 2.0M NH.sub.3 in
2-propanol (0.040 mol) and the mixture was heated at 115.degree. C.
for 24 hours. The solvent was evaporated, the residue dissolved in
CH.sub.2Cl.sub.2, washed with 1N NaOH and water, dried with
potassium carbonate, filtered, and the solvent evaporated. The
residue was recrystallized two times with acetonitrile, filtered
off and dried, yielding 1.0 g (37%) of
4-[[4-amino-6-[methyl-(2,4,6-trimethylphenyl)amino]-1,3,5-triazin-2-yl]am-
ino]benzonitrile (comp. 76).
Example 1.B19
[0367]
4,6-dichloro-N-(2,6-dibromo-4-methylphenyl)-1,3,5-triazin-2-amine
(0.00651 mol), was dissolved in 1,4-dioxane (30 ml). Sequentially,
4-aminobenzonitrile (0.0066 mol) and N,N-diisopropylethylamine
(0.0066 mol) were added, and the clear solution was heated to
reflux for 4 days. The reaction was allowed to cool to room
temperature overnight, and the mixture was diluted with ethyl
acetate and treated with cold 1 M NaOH. The layers were separated,
and the organic phase was re-extracted with fresh 1 M NaOH. The
combined aqueous phases were treated with solid NaOH to maintain pH
>10 and backwashed with ethyl acetate (2.times.). The combined
organic phases were dried, filtered and concentrated. The residue
was separated and purified by flash column chromatography over
silica gel (eluent: CH.sub.2Cl.sub.2). The desired fractions were
combined, treated with CH.sub.3CN, triturated with CH.sub.3CN,
filtered off and dried, yielding 0.30 g (8.0%) of
4-[[4-amino-6-[(2,6-dibromo-4-methylphenyl)-amino]-1,3,5-triazin-2-yl]ami-
no]benzonitrile.
Example 1.B20
[0368] Intermediate (17),
1-(2,3-dihydro-4-hydroxy-7-methyl-1H-inden-5-yl)-ethanone,
Cs.sub.2CO.sub.3, and 1,4-dioxane were added to a reaction vessel
under Ar and heated 100.degree. C. for 48 hours while the sample
was slightly vortexed. The sample was cooled, and NH.sub.3 in
isopropanol was added. The reaction was heated at 100.degree. C. in
a sealed tube for 48 hours. The reaction mixture was cooled and
water (3 ml) was added to dissolve Cs.sub.2CO.sub.3. The sample was
filtered and purified by HPLC, yielding
4-[[4-[(5-acetyl-2,3-dihydro-7-methyl-1H-inden-4-yl)oxy]-6-amino-1,3,5-tr-
iazin-2-yl]amino]benzonitrile.
1.C. HIV Activity of the Compounds of Formula (I-A)
Example 1.C.1
[0369] A rapid, sensitive and automated assay procedure was used
for the in vitro evaluation of anti-HIV agents. An HIV-1
transformed T4-cell line, MT-4, which was previously shown
(Koyanagi et al., Int. J. Cancer, 36, 445-451, 1985) to be highly
susceptible to and permissive for HIV infection, served as the
target cell line Inhibition of the HIV-induced cytopathic effect
was used as the end point. The viability of both HIV- and
mock-infected cells was assessed spectrophotometrically via the in
situ reduction of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).
The 50% cytotoxic concentration (CC.sub.50 in .mu.M) was defined as
the concentration of compound that reduced the absorbance of the
mock-infected control sample by 50%. The percent protection
achieved by the compound in HIV-infected cells was calculated by
the following formula:
( OD T ) HIV - ( OD C ) HIV ( OD C ) MOCK - ( OD C ) HIV expressed
in % , ##EQU00001##
whereby (OD.sub.T).sub.HIV is the optical density measured with a
given concentration of the test compound in HIV-infected cells;
(OD.sub.C).sub.HIV is the optical density measured for the control
untreated HIV-infected cells; (OD.sub.C).sub.MOCK is the optical
density measured for the control untreated mock-infected cells; all
optical density values were determined at 540 nm. The dose
achieving 50% protection according to the above formula was defined
as the 50% inhibitory concentration (IC.sub.50 in .mu.M). The ratio
of CC.sub.50 to IC.sub.50 was defined as the selectivity index
(SI). The compounds of formula (I-A) were shown to inhibit HIV-1
effectively. Particular IC.sub.50, CC.sub.50 and SI values are
listed in Table 1 hereinbelow.
TABLE-US-00001 TABLE 1 Co. IC.sub.50 CC.sub.50 No. (.mu.M) (.mu.M)
SI 3 0.027 49.7 1860 4 0.016 37.4 2558 8 0.315 >100 >317 9
0.094 56.2 598 10 0.020 24.4 1192 11 0.037 58.6 1587 14 0.005 7.8
1557 12 0.003 9.0 2857 13 0.006 53.6 8642 5 0.017 50.6 2910 6 0.035
12.2 346 1 0.001 47.9 59935 2 0.042 43.4 1038 15 0.004 >100
>27027 16 0.058 45.2 786 7 0.518 52.0 100 17 0.001 2.08 2314 31
0.0006 1.3 2111 19 0.0007 0.8 1153 20 0.0029 >100 >34482 21
0.0012 >100 >83333 22 0.0032 8.7 2716 23 0.0085 19.9 2347 24
0.001 1.4 1367 25 0.0004 4.7 11632 26 0.0006 5.8 9641 54 0.003 33.8
10899 55 0.005 49.9 10187 56 0.001 44.0 33826 57 0.001 6.3 4480 58
0.006 8.1 1372 59 0.004 40.6 11285 60 0.001 7.6 7614 66 0.001 32.1
24712 67 0.005 >10.0 >1851 68 0.002 12.2 6102 28 0.0063 45.8
7275 29 0.0007 0.5 705 30 0.0036 >100 >27777 34 0.010 >100
>9523 35 0.0021 1.9 911 36 0.0033 5.2 1580 37 0.0030 9.6 3188 38
0.0028 0.4 144 39 0.0031 4.8 1547 41 0.011 8.7 771 42 0.0011
>100 >90909 43 0.0026 0.4 151 44 0.0008 0.4 541 45 0.012 9.3
753 46 0.002 0.4 208 47 0.010 >100 >9803 48 0.0031 2.2 711 51
0.0027 2.1 767 52 0.0007 0.4 619 18 0.0035 48.1 13743 32 0.0022
11.1 5064 33 0.0006 7.7 12783 50 0.0031 5.8 1885 40 0.075 0.8 10 27
0.022 >100 4555 53 0.0034 18.6 5476 69 0.002 1.7 859 71 0.004
57.3 13349 73 0.003 48.0 16561 74 0.001 48.5 80824 75 0.010 8.2 860
76 0.003 51.7 16164 77 0.001 5.9 11848 78 0.003 47.0 17431 70 0.007
30.0 4534 72 0.001 54.1 45129
2. Compounds of Formula (I-B)
2.A. Preparation of the Intermediate Compounds
Example 2.A1
[0370] Reaction under argon atmosphere. A solution of
2,4,6-trimethylbenzenamine (0.00461 mol)
in 1,4-dioxane (5 ml) was added to a solution of
5-bromo-2,4-dichloropyrimidine (0.00439 mol) in 1,4-dioxane (5 ml).
N,N-bis(1-methylethyl)ethanamine (0.00548 mol) was added. The
reaction mixture was stirred and refluxed for 20 hours. The solvent
was evaporated. The residue was dissolved in ethyl acetate, washed
with a saturated aqueous sodium bicarbonate solution, water and
brine, dried with sodium sulfate, filtered, and the solvent was
evaporated. The residue was purified by column chromatography over
silica gel (eluent: 1:5, 1:2 and 1:1 CH.sub.2Cl.sub.2:hexane). Two
pure fraction groups were collected and their solvent was
evaporated, yielding 0.35 g (24%) of
5-bromo-4-chloro-N-(2,4,6-trimethylphenyl)-2-pyrimidinamine
(interm. 1) and 0.93 g (65%) of
5-bromo-2-chloro-N-(2,4,6-trimethylphenyl)-4-pyrimidinamine
(interm. 2).
Example 2.A2
[0371] a) 4-Hydroxy-5-chloro-2-methylthiopyrimidine (0.0156 mol)
and 4-aminobenzonitrile (0.078-mol) were combined as a melt and
stirred at 180-200.degree. C. for 6 hours. The reaction mixture was
cooled, and triturated sequentially with boiling CH.sub.2Cl.sub.2
and CH.sub.3CN to obtain 95% pure compound, which was dried,
yielding 1.27 g (33%) of
4-[(5-chloro-4-hydroxy-2-pyrimidinyl)amino]benzonitrile (interm. 3;
mp. >300.degree. C.).
[0372] b) POCl.sub.3 (10 ml) was added to intermediate (3) (0.0028
mol). The flask was equipped with a condenser and heated to
80.degree. C. for 35 minutes. The material was quenched on ice and
allowed and the resulting precipitate was collected and washed with
water (50 ml). The sample was dried. A fraction thereof was further
purified by column chromatography. The pure fractions were
collected and the solvent was evaporated, yielding
4-[(4,5-dichloro-2-pyrimidinyl)amino]benzonitrile (interm. 4).
[0373] c) The mixture of intermediate (4) (0.0132 mol) in
tetrahydrofuran (75 ml) and CH.sub.2Cl.sub.2 (10 ml) was stirred
for 15 min. HCl in diethyl ether (0.0145 mol) was added slowly, and
the mixture was stirred for 5 minutes. The solvent was removed
under reduced pressure, yielding 3.98 g of
4-[(4,5-dichloro-2-pyrimidinyl)amino]benzonitrile monohydrochloride
(interm. 5).
Example 2.A3
[0374] a) 2,4,5,6-tetrachloropyrimidine (0.0134 mol), 1,4-dioxane
(30 ml), 2,4,6-trimethyl aniline (0.0134 mol), and
N,N-bis(1-methylethyl)ethanamine (0.0136 mol) were added to a flask
under argon and stirred at 55.degree. C. for 16 hours. The solvent
was evaporated, and the residue was dissolved in CH.sub.2Cl.sub.2,
then purified by column chromatography over silica gel (eluent:
CH.sub.2Cl.sub.2/hexane 1/4, and 1/2). The desired fractions were
collected and their solvent was evaporated, yielding 0.15 g
4,5,6-trichloro-N-(2,4,6-trimethylphenyl)-2-pyrimidinamine (interm.
6) and 3.15 g
2,5,6-trichloro-N-(2,4,6-trimethylphenyl)-4-pyrimidinamine (interm.
7).
[0375] b) A mixture of intermediate 7 (0.00474 mol) in NH.sub.3,
(2.0 M in 2-propanol; 20 ml) was heated in a pressure vessel at
75-80.degree. C. for 40 hours. The temperature was increased to
110-115.degree. C. The solvent was evaporated to produce 1.85 g of
residue. The sample was heated with NH.sub.3, (0.5 M in
1,4-dioxane; 20 ml) at 125.degree. C. for 18 hours. The solvent was
evaporated, yielding 1.7 g of a mixture of two isomers, i.e.
2,5-dichloro-N4-(2,4,6-trimethylphenyl)-4,6-pyrimidinediamine
(interm. 8) and
5,6-dichloro-N4-(2,4,6-trimethylphenyl)-2,4-pyrimidinediamine
(interm. 9).
Example 2.A4
[0376] a) A mixture of
4-[(1,4-dihydro-4-oxo-2-pyrimidinyl)amino]benzonitrile, (0.12 mol)
in POCl.sub.3 (90 ml) was stirred and refluxed under Argon for 20
minutes. The reaction mixture was slowly poured onto 750 ml
ice/water, and the solid was separated by filtration. The solid was
suspended in 500 ml water, and the pH of the suspension was
adjusted to neutral by adding a 20% NaOH solution. The solid was
again separated by filtration, suspended in 200 ml 2-propanone, and
1000 ml CH.sub.2Cl.sub.2 was added. The mixture was heated until
all solid had dissolved. After cooling to room temperature, the
aqueous layer was separated, and the organic layer was dried.
During removal of the drying agent by filtration, a white solid
formed in the filtrate. Further cooling of the filtrate in the
freezer, followed by filtration, yielded 21.38 g (77.2%) of
4-[(4-chloro-2-pyrimidinyl)amino]benzonitrile (interm. 10).
[0377] b) Intermediate (10) (0.005 mol),
1-bromo-2,5-pyrrolidinedione (0.006 mol) and trichloromethane (10
ml) were combined in a sealed tube and heated at 100.degree. C.
overnight. The reaction mixture was allowed to cool to room
temperature. Silica gel (2 g) was added, and the solvent was
evaporated. The residue was purified by flash column chromatography
over silica gel (eluent: CH.sub.2Cl.sub.2/hexanes 9/1). The pure
fractions were collected and the solvent was evaporated, yielding
1.31 g (84.5%) of
4-[(5-bromo-4-chloro-2-pyrimidinyl)amino]benzonitrile (interm.
11).
Example 2.A5
[0378] To a flask under Argon was added
4-amino-2,5,6-trichloropyrimidine (0.08564 mol),
4-amino-benzonitrile (0.1071 mol), 1-methyl-2-pyrrolidinone (17 ml)
and HCl in diethylether (1M; 85.6 ml). The mixture was placed in an
oil bath at 130.degree. C. under a stream of nitrogen until the
ether was gone. An additional 10 ml of 1-methyl-2-pyrrolidinone was
added. The mixture was heated at 145.degree. C. for 16 hours under
argon. 1,4-Dioxane was added. The mixture was refluxed, cooled,
then filtered. The filtrate was evaporated. The residue was
dissolved in CH.sub.2Cl.sub.2, washed with 1 N NaOH, then filtered.
The solid was dissolved in 2-propanone, evaporated onto silica gel,
and chromatographed using 1-3% 2-propanone in hexane as eluent. The
pure fractions were collected and the solvent was evaporated,
yielding 1.63 g (6.8%) of
4-[(4-amino-5,6-dichloro-2-pyrimidinyl)amino]benzonitrile (interm.
12).
2.B. Preparation of the Final Compounds of Formula (I-B)
Example 2.B1
[0379] a) To a flask under argon containing intermediate (1)
(0.00107 mol) was added ether. To this homogeneous solution was
added HCl/diethylether (1M; 0.00109 mol). The solvent was
evaporated and 1,4-dioxane (35 ml) and 4-aminobenzonitrile (0.00322
mol) were added. The reaction mixture was stirred and refluxed for
4 days. The solvent was evaporated. The residue was dissolved in
CH.sub.2Cl.sub.2, washed with a saturated sodium bicarbonate
solution, dried, filtered and the solvent was evaporated to give
0.79 g of amber oil. The oil was purified by reverse phase HPLC.
The desired fractions were collected and the solvent was
evaporated, yielding residues 1 and 2.
[0380] Residue 1 was purified by column chromatography over silica
gel (eluent: 0 and 2% CH.sub.3OH:CH.sub.2Cl.sub.2). The pure
fractions were collected and the solvent was evaporated, yielding
0.0079 g (2.0%) of
4-[[5-chloro-2-[(2,4,6-trimethylphenyl)amino]-4-pyrimidinyl]amino]benzoni-
trile (compound 1).
[0381] Residue 2 was purified by column chromatography over silica
gel (eluent: 0 and 2% CH.sub.3OH:CH.sub.2Cl.sub.2). The pure
fractions were collected and the solvent was evaporated, yielding
0.0044 g (1.0%) of
4-[[5-bromo-2-[(2,4,6-trimethylphenyl)amino]-4-pyrimidinyl]amino]benzonit-
rile (compound 2).
[0382] b) To a flask containing intermediate 2 (0.00285 mol) was
added ether. To this homogeneous solution was added HCl in diethyl
ether (1M; 0.00855 mol). The solvent was evaporated and 1,4-dioxane
(20 ml) was added. Finally, 4-aminobenzonitrile (0.00291 mol) and
1,4-dioxane (15 ml) were added and the reaction mixture was stirred
and refluxed for seven days. The solvent was evaporated, the
residue dissolved in CH.sub.2Cl.sub.2, washed with 1 M NaOH, and
the solvent evaporated. The residue was dissolved in
CH.sub.2Cl.sub.2 (10 ml) and the precipitate was filtered off and
dried, yielding 0.15 g (13%) of
4-[[5-bromo-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonit-
rile (comp. 3).
Example 2.B2
[0383] a) A 3:1 mixture of intermediate (8) and intermediate (9)
[as prepared in example A3b] and 4-aminobenzonitrile (0.01422 mol)
was heated in a pressure vessel at 180.degree. C. for 5 hours. The
sample was partitioned between CH.sub.2Cl.sub.2 and diluted
NaHCO.sub.3, dried over K.sub.2CO.sub.3, filtered, and evaporated.
CH.sub.3CN was stirred in, the resulting precipitate removed by
filtration. The filtrate was further purified by reverse phase
HPLC. The pure fractions were collected and the solvent was
evaporated, yielding 0.17 g of
4-[[4-amino-5-chloro-6-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino-
]benzonitrile trifluoroacetate (1:1) (comp. 4).
Example 2.B3
[0384] HCl in diethylether (1M; 0.0045 mol) was added to a
suspension of intermediate (4) (0.003 mol) in 1,4-dioxane (5 ml),
stirred under argon in a sealable tube. The mixture was warmed to
evaporate the diethylether, and 2,4,6-trimethylbenzenamine (0.009
mol) was added. The tube was sealed, and the reaction mixture was
heated to 150.degree. C. for 12 hours. The reaction mixture was
allowed to cool to room temperature. Sequentially, silica gel (2.2
g) and CH.sub.3OH (50 ml) were added. After evaporating the
solvent, the residue was purified by flash chromatography (eluent
gradient: CH.sub.2Cl.sub.2:CH.sub.3OH:NH.sub.4OH 99.5:0.45:0.05 up
to 99:0.9:0.1). The pure fractions were collected and the solvent
was evaporated. The residue was dried, yielding 0.80 g (73.4%) of
4-[[5-chloro-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzoni-
trile (comp. 5).
Example 2.B4
[0385] A mixture of intermediate (5) (0.0025 mol) and
2,6-dibromo-4-methylbenzenamine (0.0075 mol) in 1,3-dioxane (5.0
ml) in a sealed tube under argon was heated and stirred at
160.degree. C. for 16 hours. The reaction mixture was concentrated
by rotary evaporation onto silica gel (2.0 g). The material was
purified by flash chromatography (eluent 1:1
hexanes:CH.sub.2Cl.sub.2; neat CH.sub.2Cl.sub.2; 0.5%, 1% (10%
NH.sub.4OH in CH.sub.3OH) in CH.sub.2Cl.sub.2) for 90% purity.
Recrystallization afforded 0.15 g (12.2%) of
4-[[5-chloro-4-[(2,6-dibromo-4-methylphenyl)amino]-2-pyrimidinyl]amino]be-
nzonitrile (comp. 10; 95% purity).
Example 2.B5
[0386] NaH (0.0075 mol; 60% suspension in oil) was added to a
suspension of 2,4,6-trimethylphenol (0.0075 mol) in 1,4-dioxane (5
ml) in a sealable tube under argon. The mixture was stirred for 15
minutes, and intermediate (4) (0.0025 mol) was added. The tube was
sealed, and the reaction mixture was heated to 150.degree. C. for
15 hours. The reaction was allowed to cool to room temperature.
After silica gel (2.0 g) was added, the solvent was evaporated. The
residue was purified by flash column chromatography over silica gel
(eluent gradient: CH.sub.2Cl.sub.2: hexanes 9:1 up to 100:0; then
CH.sub.2Cl.sub.2:CH.sub.3OH:NH.sub.4OH 100:0:0 up to 97:2.7:0.3).
The pure fractions were collected and the solvent was evaporated.
The residue was dried, yielding 0.73 g of (80.2%)
4-[[5-chloro-4-(2,4,6-trimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile
(comp. 6).
Example 2.B6
[0387] NaH, 60% suspension in oil (0.003 mol) and
1-methyl-2-pyrrolidinone (3 ml) were added to a suspension of
4-hydroxy-3,5-dimethylbenzonitrile (0.003 mol) in 1,4-dioxane (3
ml) in a sealable tube under argon. After the H.sub.2 had evolved,
intermediate (11) (0.001 mol) was added. The tube was sealed and
the reaction mixture was heated to 160.degree. C. for 16 hours. The
mixture was cooled to room temperature, transferred to a beaker and
diluted with methanol (20 ml). Water (200 ml) was added dropwise.
The aqueous mixture was extracted with CH.sub.2Cl.sub.2/CH.sub.3OH
90/10 (3.times.300 ml). The organic layer was separated, dried,
filtered and adsorbed onto silica gel (1 g). The solvent was
evaporated and the residue was purified by flash column
chromatography over silica gel (eluent:
CH.sub.2Cl.sub.2/CH.sub.3OH/NH.sub.4OH from 100/0/0 to 98/1.8/0.2).
The desired fractions were collected and the solvent was
evaporated. The residue was triturated with hot CH.sub.3CN,
filtered off, then dried, yielding 0.20 g (47.6%) of
4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitr-
ile (comp. 17).
Example 2.B7
[0388] To a pressure vessel under argon was added intermediate 12
(0.00286 mol), 4-cyano-2,6-dimethylaniline (0.00571 mol), 1M HCl in
diethyl ether (0.00140 mol) and 1,4-dioxane (8 ml). The reaction
mixture was heated in an oil bath under a stream of nitrogen until
all the solvents had evaporated. 1-methyl-2-pyrrolidinone (3 ml)
was added, and the reaction mixture heated at 220-240.degree. C.
for 3 hours. Heating was continued at 210-220.degree. C. for 6
hours. The residue was dissolved in 1,4-dioxane, evaporated,
partitioned between CH.sub.2Cl.sub.2 and 1 N NaOH, filtered, dried
organic layers with potassium carbonate and evaporated. The desired
compound was isolated and purified by preparative reverse phase
chromatography. The pure fractions were collected and the solvent
was evaporated, yielding 0.0165 g (1.1% after lyophilization) of
4-[[4-amino-5-chloro-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]-
amino]benzonitrile trifluoroacetate (1:1) (comp. 19).
Example 2.B8
[0389] A mixture of intermediate (11) (0.0011 mol),
2,6-dimethyl-4-(2-propyl)benzenamine (0.0011 mol),
N,N,N',N'-tetramethyl-1,8-naphthalenediamine (0.0022 mol) and 1 M
HCl in ether (2.3 ml) (0.0023 mol) in 1,4-dioxane (25 ml) was
stirred and heated to 95.degree. C. for 16 hours. Solvent was
removed by rotary evaporation and the residue was purified by
reverse phase preparatory HPLC. The combined fractions containing
the desired material were lyophilized to yield 0.23 g of (48%);
##STR00037##
(48%);
[0390] mp. 198-201.degree. C. (comp.)
Example 2.B9
[0391] N,N-di(methylethyl)ethanamine (0.0024 mol) was added to
4-amino-2,5-dimethyl-3,4-benzonitrile (0.00219 mol) and
4-[[(5-bromo-4,6-dichloro)-2-pyrimidinyl]amino]-benzonitrile
(0.00218 mol). The reaction vial was sealed and heated to
155-160.degree. C. with stirring for 1.5 days. The sample was
cooled to room temperature. The sample was treated with flash
column chromatography over silica gel (eluent: CH.sub.2Cl.sub.2).
Purification was completed through preparative HPLC to yield 0.05 g
of
4-[[5-bromo-4-chloro-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]-
amino]benzonitrile (5.0%); mp. 259-260.degree. C.
Example 2.B10
[0392] Sequentially 2,4,6-trimethylbenzenamine (0.0022 mol) and
N,N-di(methylethyl)-ethanamine (0.0024 mol) were added to a
solution of and
4-[[(5-bromo-4,6-dichloro)-2-pyrimidinyl]amino]benzonitrile
(0.00218 mol) in 1,4-dioxane (10 ml). The tube was sealed and the
suspension was heated to 120-130.degree. C. in an oil bath while
stirring for 90 hours. The mixture was cooled to room temperature.
More N,N-di(methylethyl)-ethanamine (15 ml) was added, and the
sample was reheated to 120-130.degree. C. for 64 hours. The
reaction was heated at 150.degree. C. for 6 days. The sample was
cooled to room temperature. The sample was diluted with
ethylacetate and extracted with cold 1M NaOH. The aqueous phase was
backwashed with ethylacetate. The combined organic phases were
dried and concentrated. Flash column chromatography over silica gel
(eluent: CH.sub.2Cl.sub.2). The sample was further purified by
preparatory HPLC to yield 0.53 g of
4-[[5-bromo-4-chloro-6-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino-
]-benzonitrile (54.9%); mp. 220-221.degree. C.
Example 2.B11
[0393] A mixture of 4-aminobenzonitrile (0.0043 mol) and
##STR00038##
(0.0021 mol) in 1,4-dioxane (30 ml) was stirred at 100.degree. C.
for 16 hours. The solvent was removed by rotary evaporation. The
solid residue was triturated and the residue was dried in vacuo at
40.degree. C. for 16 hours, yielding 0.452 g of
##STR00039##
(55%); mp. >300.degree. C.
Example 2.B12
[0394] To a pressure vessel was added
##STR00040##
(0.00567 mol), 4-aminobenzonitrile (0.01163 mol) and
1-methyl-2-pyrrolidinone (20 ml). The reaction mixture was heated
at 140.degree. C. for 16 hours. The reaction mixture was cooled to
room temperature and acetonitrile and water were added. The
resulting precipitate was filtered, and the solid recrystallized
with acetonitrile to give 1.27 g of
4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-6-methyl-2-pyrimidinyl]amino]-
benzonitrile (52); mp. 260-262.degree. C.
Example 2.B13
[0395] Intermediate (11) (0.001 mol) and
2,6-dimethyl-4-aminobenzonitrile (0.00473 mol) were combined and
heated to 150.degree. C. while stirring for 16 hours. The sample
was dissolved in CH.sub.3OH and evaporated onto silica gel (1 g)
and eluted with 1:1 hexanes: CH.sub.2Cl.sub.2, 4:1
CH.sub.2Cl.sub.2:hexanes, and neat CH.sub.2Cl.sub.2 (2 L). The
desired fractions were evaporated and the residue was dried in
vacuo for 16 hours at 45.degree. C. The thus obtained was
transferred to a 4 ml vial in CH.sub.2Cl.sub.2 and the solvent was
evaporated, yielding 0.120 g of
4-[[5-bromo-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]-amino]be-
nzonitrile (28.6%); mp. 277-280.degree. C.
Example 2.B14
[0396]
4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-6-chloro-2-pyrimidinyl]-
amino]-benzonitrile (0.00250 mol) and NH.sub.3/1,4-dioxane 0.5M
(0.015 mol) were heated in a pressure vessel at 150.degree. C. for
4 days. The sample was allowed to sit at ambient conditions for 2
days. Water was added slowly to the mixture until a precipitate
formed. The mixture was stirred for 2 hours and filtered. The solid
was recrystallized from CH.sub.3CN to obtain 0.58 g (fraction 1).
The filtrate was evaporated (fraction 2). Both fractions were
combined and purified by column chromatography, eluting with
CH.sub.2Cl.sub.2. The resulting residue of the desired fraction was
recrystallized from CH.sub.3CN to yield 0.44 g of
4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]am-
ino]benzonitrile (40.5%). The sample was dried at 80.degree. C. for
16 hours at 0.2 mm Hg.
Example 2.B15
[0397]
4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-6-chloro-2-pyrimidinyl]-
amino]-benzonitrile (0.000660 mol), tetrahydrofuran (1 ml), and
1-pyrrolidineethanamine (0.00198 mol) were added to a pressure
vessel. The mixture was heated at 75.degree. C. for 16 hours.
CH.sub.2Cl.sub.2 was added, and the mixture was washed with water,
dried, filtered and the filtrate was evaporated. Purification using
flash column chromatography eluting with 1:9 methanol:methylene
chloride produced a solid which was redissolved in CH.sub.3CN.
HCl/diethylether 1.0M (0.48 ml) was added, and the mixture was
cooled in ice. Filtration yielded 0.19 g of
4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-6-[(1-pyrrolidinyl)ethylamino-
]-2-pyrimidinyl]amino]benzonitrile hydrochloride (1:1) (50.6%); mp.
208-210.degree. C.
Example 2.B16
[0398] To a pressure vessel was added
4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-6-chloro-2-pyrimidinyl]amino]-
benzonitrile (0.00064 mol), tetrahydrofuran (3 ml),
O-methylhydroxylamine (0.06 g), tetrahydrofuran and NaOH 1N
(0.00067 mol). The reaction mixture was stirred for 3 days at room
temperature, then for 1 day at 75.degree. C., for 1 day at
90.degree. C. and for 2 days at 110.degree. C. To
O-methylhydroxylamine (0.60 g) was added tetrahydrofuran (4 ml) and
NaOH 50% (0.00719 mol). The liquid was decanted into the reaction
flask and the reaction mixture was heated at 110.degree. C. for 3
days. The solvent was evaporated. The residue was dissolved in
CH.sub.2Cl.sub.2, washed with a saturated NaHCO.sub.3 solution and
water, dried (Na.sub.2SO.sub.4), filtered and the solvent was
evaporated.
[0399] The residue was purified by column chromatography over
silica gel (eluent: CH.sub.2Cl.sub.2/CH.sub.3OH 98/2). The pure
fractions were collected and the solvent was evaporated. The
residue was crystallized from CH.sub.3CN, filtered off and dried,
yielding 0.15 g of
4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-6-(methoxyamino)-2-pyrimidiny-
l]amino]benzonitrile (51%); mp. 185-186.degree. C. The sample was
dried (0.2 mm Hg, 80.degree. C., 16 hours).
Example 2.B17
[0400] a) n-Butyllithium (2.0 1, 0.005 mol) was added to a
0.degree. C. stirred solution of 1-(methyl-ethyl)-2-propanamine
(0.70 ml, 0.005 mol) and tetrahydrofuran (300 ml). After stirring
cold for 30 min, compound (17) (0.005 mol) was added. The resulting
mixture was stirred cold for 30 min at which point
1,1-dimethylethyl bromoacetate (1.5 ml, 10 mmol) was added and the
temperature was allowed to rise to room temperature and the
reaction was stirred for three. In a separate flask n-butyllithium
(2.0 ml, 5 mmol) was added to a stirred 0.degree. C. solution of
1-(methylethyl)-2-propanamine (0.70 ml, 5 mmol) in tetrahydrofuran
(50 ml) and allowed to react for 30 min at which time it was
transferred to the room temperature reaction. This procedure was
repeated. Quenched with 0.5 ml H.sub.2O, the sample was
concentrated by rotary evaporation onto silica gel, and purified by
flash chromatography (eluting with 0, 10, 20% ethylacetate in
hexanes) to give a white solid of
##STR00041##
mp. 195-197.degree. C.
[0401] b) A suspension of compound (17) in 40 ml of
N,N-dimethylformamide was treated with 0.24 g of NaH. The
effervescent mixture was stirred for 90. A solution of
1,4-dichloro-1,4-butanedione in 10 ml N,N-dimethylformamide was
prepared and cooled in an ice bath. The mixture prepared from
compound (17) was transferred to the cold solution of
1(methylethyl)-1-propanamine and was warmed to room temperature
with stirring for 42 hours. Another 0.24 g of NaH was added, the
reaction was stirred for 3 days, and diluted with ether and poured
into ice. Precipitation was removed by filtration. The 2 phase
filtrate was separated and the acidic aqueous fraction was
extracted twice more with ether. The combined ether fractions were
washed with small volumes of distilled water and dried. The solvent
was evaporated and the residue was subjected to silica gel column
chromatography. Reverse phase prep HPLC with immediate cooling for
lyophilization of the appropriate fractions provided 0.07 g of
##STR00042##
(7.8%); mp. 232-233.degree. C.
[0402] c) To a flask under argon was added NaH 60% and
tetrahydrofuran. The reaction was stirred at room temperature for
10 min and compound (17) added. After stirring for 1 hr ethyl
carbonochloridate was added. The reaction mixture was stirred at
room temperature for another 16 hrs and the solvent evaporated. The
residue was partially dissolved in dimethylsulfoxide and filtered.
The filtrate was purified by reverse phase Chromatography and
lyophilized to give 0.47 g (18%) of
##STR00043##
[0403] d) A mixture of
4-[[5-amino-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-amino]benzonit-
rile (0.00147 mol) in ethanoic acid anhydride (10 ml) and
2-propanone (10 ml) was stirred at room temperature for 16 hours.
The mixture was then heated to 55.degree. C., and more ethanoic
acid anhydride (3 ml) was added. The mixture was removed from heat
after 18 hours and stirred for 6 days at room temperature. The
sample was concentrated by rotary evaporation to a solid.
Purification by column chromatography (eluting with 0, 0.5, 1, 1.5,
2% (10% NH.sub.4OH in CH.sub.3OH) in methylene chloride)
yielded
##STR00044##
; mp. 290-295.degree. C. The solid was dried in vacuo for 16 hours
at 60.degree. C.
Example 2.B18
[0404] A mixture of
4-[[4-(4-cyano-2,6-dimethylphenoxy)-5-nitro-2-pyrimidinyl]amino]-benzonit-
rile (0.0005 mol) in tetrahydrofuran (20 ml) was hydrogenated
overnight with Pd/C 10% (0.100 g) as a catalyst. After uptake of
H.sub.2 (3 equiv; 0.0015 mol), the catalyst was filtered off and
the filtrate was concentrated by rotary evaporation and dried in
vacuo over 16 hours at 40.degree. C., yielding 0.15 g of
4-[[5-amino-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitr-
ile (84%); mp. >300.degree. C.
Example 2.B19
[0405]
4-[[4-[(2,4,6-trimethylphenyl)amino]-5-nitro-2-pyrimidinyl]amino]be-
nzonitrile (0.001 mol), Pd/C 10% (0.025 g), ethanol (20 ml), and
hydrazine (0.030 mol) were combined to form a slurry and stirred at
room temperature for 16 hours. The solvent was removed by rotary
evaporation. The residue was taken up in tetrahydrofuran (20 ml)
and methanol (1 ml). A second portion of hydrazine (0.5 g) was
added, and the reaction was stirred for 16 hours at room
temperature. A third portion of hydrazine (0.5 ml) was added and
the reaction was stirred for an additional 16 hours at room
temperature. The sample was concentrated by rotary evaporation onto
silica gel (1 g) and purified by flash chromatography (eluent: 0.5,
1.2% 10% (NH.sub.4OH in CH.sub.3OH) in CH.sub.2Cl.sub.2). The
desired fractions were purified by preparatory HPLC to yield 0.24 g
of
4-[[5-amino-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzo-
nitrile (70%); mp. 224-225.degree. C.
Example 2.B20
[0406] Compound (3) (0.001 mol), trimethyl silanecarbonitrile
(0.0012 mol), Pd(PPh.sub.3).sub.2Cl.sub.2 (0.020 g), CuI (0.010 g)
and CF.sub.3COOH/H.sub.2O (3 ml) were combined in a sealed tube and
heated to 110.degree. C. for 10 hours. Second portions of the
catalysts Pd(PPh.sub.3).sub.2Cl.sub.2 (0.020 g) and CuI (0.010 g),
and CF.sub.3COOH/H.sub.2O (3 ml) were added and the reaction
mixture was stirred for 10 hours at 110.degree. C. The material was
concentrated by rotary evaporation. The residue was purified by
preparative reversed-phase HPLC. The desired fractions were
concentrated and purified by reversed-phase preparative HPLC and
dried with a stream of N.sub.2, then in vacuo at 40.degree. C. for
16 hours. Yield: 0.011 g of
4-[[5-ethynyl-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzon-
itrile; mp. 165-175.degree. C.
Example 2.B21
[0407] Compound (3) (0.000906 mol), tributylphenyl stannane
(0.000906 mol), Pd(PPh.sub.3).sub.4 (0.002718 mol), and 1,4-dioxane
(3 ml) were combined under N.sub.2 in a sealed tube and heated to
110.degree. C. for 16 hours. The reaction mixture was cooled and
concentrated by rotary evaporation. The sample was purified by
Preparatory Reverse Phase HPLC, then dried under Ar stream. Drying
in vacuo yielded 0.0845 g of or
4-[[5-phenyl-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzoni-
trile; mp. 209-214.degree. C.
Example 2.B22
[0408] Compound (3) (0.001 mol), tetraethenyl stannane (0.22 ml),
1,4-dioxane (2 ml) and Pd(PPh.sub.3).sub.4 (0.112 g) were combined
in a sealed tube under Ar. The mixture was stirred and heated to
100.degree. C. for 16 hours. More tetraethenyl stannane and
Pd(PPh.sub.3).sub.4 were added. The reaction was placed under Ar,
stirred and heated. The reaction was concentrated by rotary
evaporation and purified on preparative HPLC. The material was
dried with a N.sub.2 stream, and dried under vacuum for 4 hours at
60.degree. C. to obtain 0.422 g of
4-[[5-ethenyl-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]-benzo-
nitrile; mp. 237-242.degree. C.
Example 2.B23
[0409] Compound (3) (0.001225 mol), CuCN (0.001470 mol) and
N,N-dimethylformamide (2 ml) were combined in a sealed tube under
Argon, then stirred and heated to 160.degree. C. for 16 hours. The
residue was purified by column chromatography (eluent:
CH.sub.2Cl.sub.2/hexane 1/1, then pure CH.sub.2Cl.sub.2). The
desired fractions were collected and the solvent was evaporated.
The residue was triturated under CH.sub.2Cl.sub.2 at room
temperature. The solid was dried (vacuum, 40.degree. C., 24 hours,
yielding 0.0864 g of
##STR00045##
(24%); mp. 254-259.degree. C.
[0410] Tables 2, 3, 4 and 5 list compounds of formula (I-B) which
were made analogous to one of the above examples.
TABLE-US-00002 TABLE 2 ##STR00046## Comp. No. Ex. No. Y Physical
data 1 2.Bla Cl -- 2 2.Bla Br mp. 227-228.degree. C. 22 2.B11
NO.sub.2 mp. 224-226.degree. C.
TABLE-US-00003 TABLE 3 ##STR00047## Comp. No. Ex. No. R.sup.a
R.sup.b R.sup.c X Y Q 3 2.Blb CH.sub.3 CH.sub.3 CH.sub.3 NH Br H
mp. 227-228.degree. C. 4 2.B2 CH.sub.3 CH.sub.3 CH.sub.3 NH Cl
NH.sub.2 mp. 241-242.degree. C. 5 2.B3 CH.sub.3 CH.sub.3 CH.sub.3
NH Cl H mp. 224-226.degree. C. 6 2.B5 CH.sub.3 CH.sub.3 CH.sub.3 O
Cl H mp. 218-219.degree. C. 7 2.B5 CH.sub.3 CH.sub.3 CH.sub.3 S Cl
H mp. 264-266.degree. C. 8 2.B5 CH.sub.3 Br CH.sub.3 O Cl H mp.
237-238.degree. C. 9 2.B3 CH.sub.3 Br CH.sub.3 NH Cl H mp.
217-219.degree. C. 10 2.B4 Br CH.sub.3 Br NH Cl H mp.
262-263.degree. C. 11 2.B4 Br Br F NH Cl H mp. 200-202.degree. C.
12 2.B4 CH.sub.3 C(CH.sub.3).sub.3 CH.sub.3 NH Cl H mp.
214-215.degree. C. 13 2.B4 CH.sub.3 CN CH.sub.3 NH Cl H mp.
281-283.degree. C. 14 2.B4 Cl Cl CH.sub.3 NH Cl H mp.
243-245.degree. C. 15 2.B5 Cl Br CH.sub.3 O Cl H mp.
244-247.degree. C. 16 2.B5 CH.sub.3 Cl CH.sub.3 O Cl H mp.
232-235.degree. C. 17 2.B6 CH.sub.3 CN CH.sub.3 O Br H mp.
288-289.degree. C. 18 2.B5 CH.sub.3 CN CH.sub.3 O Cl H mp.
283-284.degree. C. 19 2.B7 CH.sub.3 CN CH.sub.3 NH Cl NH.sub.2 mp.
266-268.degree. C. 20 2.B3 Cl Cl CH.sub.3 NH Br H mp.
253-254.degree. C. 21 2.B3 CH.sub.3 Br CH.sub.3 NH Br H mp.
243-245.degree. C. 23 2.B23 CH.sub.3 CN CH.sub.3 NH CN H mp.
275-290.degree. C. 24 2.B23 CH.sub.3 Br CH.sub.3 NH CN H mp.
291-299.degree. C. 25 2.B14 CH.sub.3 CN CH.sub.3 O Br NH--CH.sub.3
mp. 248-250.degree. C. 26 2.B14 CH.sub.3 CN CH.sub.3 O Br NH.sub.2
mp. 255-256.degree. C. 27 2.B14 CH.sub.3 CH.sub.3 CH.sub.3 O Br
NH.sub.2 -- 28 2.B14 CH.sub.3 CH.sub.3 CH.sub.3 O Br NH--CH.sub.3
mp. 213-214.degree. C. 29 2.B14 CH.sub.3 CN CH.sub.3 O Br
NH--C.sub.2H.sub.5 mp. 263-264.degree. C 30 2.B14 CH.sub.3 CN
CH.sub.3 O Cl NH.sub.2 mp. 272-274.degree. C. 31 2.B14 CH.sub.3
CH.sub.3 CH.sub.3 O Cl NH.sub.2 mp. 199-202.degree. C. 32 2.B11
CH.sub.3 CH.sub.3 CH.sub.3 NH NH.sub.2 H mp. >300.degree. C. 33
2.B5 CH.sub.3 CH.sub.3 CH.sub.3 O Br H mp. 207-215.degree. C. 34
2.B5 CH.sub.3 CH.sub.3 CH.sub.3 O Cl Cl mp. 225-226.degree. C. 35
2.B5 CH.sub.3 CN CH.sub.3 O Cl Cl mp. 273-276.degree. C. 36 2.B6
CH.sub.3 CN CH.sub.3 O Cl Br mp. 281-282.degree. C. 37 2.B5
CH.sub.3 CH.sub.3 CH.sub.3 O Cl Br mp. 214-215.degree. C.
TABLE-US-00004 TABLE 4 ##STR00048## Comp. No. Ex. No. R.sup.a
R.sup.b R.sup.c X Y Q Z 38 2.B17C CH.sub.3 CN CH.sub.3 O Br H
C(.dbd.O)--CH.sub.3 mp. 194-196.degree. C.
TABLE-US-00005 TABLE 5 ##STR00049## Comp. Ex. No. No. R.sup.a
R.sup.b X Y Q 39 2.B5 Cl Cl S Br H mp. 198-200.degree. C.
2.C. Pharmacological Example
Example 2.C.1
[0411] The same test as described above for the compounds of
formula (I-A) (example 1.C.1) was used for the in vitro evaluation
of the anti-HIV agents of formula (I-B). The compounds of formula
(I-B) were shown to inhibit HIV-1 effectively. Particular
IC.sub.50, CC.sub.50 and SI values of compounds of formula (I-B)
are listed in Table 6 hereinbelow.
TABLE-US-00006 TABLE 6 Co. IC.sub.50 CC.sub.50 No. (.mu.M) (.mu.M)
SI 2 0.030 82.6 2730 3 0.006 4.4 738 1 0.004 10.9 2787 4 0.002 10.0
5555 5 0.002 0.4 178 6 0.009 >100 >11049 7 0.084 >100
>1182 8 0.012 >100 >8298 9 0.003 1.2 376 10 0.005 0.4 92
11 0.002 0.4 183 12 0.020 48.5 2393 13 0.0005 0.4 860 14 0.002 0.4
191 15 0.010 >100 >9661 16 0.010 >100 >10416 17 0.002
>10 >6451 18 0.001 >10 >7142
3. Compounds of Formula (I-C)
[0412] Hereinafter, the term `RT` means room temperature, `THF`
means tetrahydrofuran and `EtOAc` means ethyl acetate.
3.A. Preparation of the Intermediates
Example 3.A1
[0413] Starting material 2,4-dichloro-1,3,5-triazine was prepared
in 34.8% yield by the method of Synthesis 1981, 907. A solution of
2,4-dichloro-1,3,5-triazine (0.0238 mol) in 1,4-dioxane (120 ml)
was prepared with vigorous stirring. 4-Aminobenzonitrile (0.0240
mol) was added in one portion, resulting in a suspension.
N,N-bis(1-methylethyl)ethanamine (0.0241 mol) was added. The
reaction mixture was stirred at RT for 48 hours. The reaction was
concentrated in vacuo to produce a viscous orange syrup which was
dissolved with EtOAc and treated with cold 1 M NaOH. The combined
aqueous phases were back extracted with EtOAc. The combined organic
extracts were dried over MgSO.sub.4, filtered and the filtrate was
evaporated to give 5.27 g of yellow powder that was subjected to
flash chromatography on silica gel (eluent: 100% CH.sub.2Cl.sub.2
to 90:10 CH.sub.2Cl.sub.2/Et.sub.2O). The pure fractions were
collected and the solvent was evaporated to give 3.87 g of off
white solid that was recrystallized from CH.sub.3CN, filtered off
and dried, yielding 3.57 g (64.8%) of
4-[(4-chloro-1,3,5-triazin-2-yl)amino]benzonitrile (Intermediate
1).
3.B. Preparation of the Final Compounds
Example 3.B.1
[0414] Intermediate (1) (0.00160 mol) was partially dissolved by
stirring in 1,4-dioxane (10 ml). Sequentially,
2,4,6-trimethylbenzenamine (0.00164 mol) and
N,N-bis-(1-methylethyl)ethanamine (0.00164 mol) were added, and the
resulting suspension was heated to reflux with stirring. The
mixture cleared at 40-50.degree. C. After 4.5 days at reflux, the
reaction was cooled to RT, diluted with Et.sub.2O, and treated with
cold 1 M NaOH. EtOAc was added to dissolve all of the material
between the 2 layers. The organic phase was separated and extracted
with cold 1 M NaOH. The combined aqueous fractions were washed with
EtOAc, adding solid NaOH to adjust the pH to >10. The combined
organic phases were dried (MgSO.sub.4), filtered and the solvent
was evaporated in vacuo to give 0.60 g brown waxy solid. This
fraction was purified by flash column chromatography over silica
gel (eluent: 100% CH.sub.2Cl.sub.2 to 80:20
CH.sub.2Cl.sub.2/Et.sub.2O). The pure fractions were collected and
the solvent was evaporated to give 0.40 g of white waxy solid that
was recrystallized from CH.sub.3CN. The precipitate was filtered
off and dried, yielding 0.24 g (45.4%) of
4-[[4-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazin-2-yl]amino]benzonitril-
e (compound 1).
Example 3.B.2
[0415] NaH (0.0025 mol) and THF (5 ml) were added to a flask
equipped with an addition funnel. A solution of
2,4,6-trimethylphenol (0.00206 mol) in THF (15 ml) was added
dropwise with stirring over 15 minutes. The reaction mixture was
stirred at room temperature for 45 minutes. Intermediate (1)
(0.00203 mol) was added in one portion. The reaction mixture was
stirred for 4 days. The reaction was quenched by pouring over ice
(75 ml). Upon melting, a minimal amount of precipitate formed. The
mixture was treated with Et.sub.2O and EtOAc and the fractions were
separated. The pH of the aqueous fraction was adjusted to >10 by
treatment with solid NaOH and extracted with EtOAc. The combined
organic phases were treated with cold 1 M NaOH. The organic phases
were dried over MgSO.sub.4. Concentration in vacuo afforded 0.65 g
white powder. This fraction was recrystallized from CH.sub.3CN,
filtered off and dried, yielding 0.50 g (74.4%) of
4-[[4-(2,4,6-trimethylphenoxy)-1,3,5-triazin-2-yl]amino]benzonitrile
(compound 2).
Example 3.B.3
[0416] Intermediate (1) (0.00203 mol) and 1,4-dioxane (15 ml) were
added to a flask and stirred. Sequentially,
2,4,6-trimethylbenzenethiol (0.00204 mol) and
N,N-bis(1-methyl-ethyl)ethanamine (0.00207 mol) were added and
stirred at ambient temperature. After stirring for one hour, THF
(10 ml) was added. The reaction mixture was heated to reflux for 64
hours and cooled to RT. The reaction mixture was diluted with EtOAc
and treated with cold 1 M NaOH. The aqueous phase was extracted
with EtOAc while maintaining the pH>10 with the addition of
solid NaOH. The combined organic phases were dried over MgSO.sub.4
and concentrated to afford 0.75 g yellow powder. The residue was
crystallized from CH.sub.3CN, filtered off and dried, yielding 0.64
g (90.7%) of
4-[[4-[(2,4,6-trimethylphenyl)thio]-1,3,5-triazin-2-yl]amino]benzonitrile
(compound 3).
[0417] Table 7 lists the compounds of formula (I-C) which were
prepared according to one of the above examples.
TABLE-US-00007 TABLE 7 ##STR00050## Comp. No. Ex. No. X R.sup.a
R.sup.b R.sup.c Physical Data 1 3.B1 --NH-- CH.sub.3 CH.sub.3
CH.sub.3 mp. 248-249.degree. C. 2 3.B2 --O-- CH.sub.3 CH.sub.3
CH.sub.3 mp. 220-221.degree. C. 3 3.B2 --O-- CH.sub.3 Br Cl mp.
221-222.degree. C. 4 3.B3 --S CH.sub.3 CH.sub.3 CH.sub.3 mp.
256-257.degree. C. 5 3.B2 --O-- Br CH.sub.3 Br mp. 255-257.degree.
C. 6 3.B1 --NH-- Br CH.sub.3 Br mp. 285-286.degree. C. 7 3.B1
--NH-- CH.sub.3 Br CH.sub.3 mp. 248-249.degree. C.
3.C. Pharmacological Example
Example 3.C.1
[0418] The same test as described above for the compounds of
formula (I-A) (example 1.C.1) was used for the in vitro evaluation
of the anti-HIV agents of formula (I-C). The compounds of formula
(I-C) were shown to inhibit HIV-1 effectively. Particular
IC.sub.50, CC.sub.50 and SI values of compounds of formula (I-C)
are listed in Table 8 hereinbelow.
TABLE-US-00008 TABLE 8 Co. IC.sub.50 CC.sub.50 No. (.mu.M) (.mu.M)
SI 1 0.0004 9.1 22722 2 0.0006 >100 >166666 3 0.0011 56.2
53536 4 0.0022 >100 >46511 5 0.0016 10.1 6452 6 0.0005 1.0
1901 7 0.0007 27.8 39722
4. Preparation of the Particles of the Present Invention
[0419] 8 g of compound 17 of formula (I-A) and 12 g hydroxypropyl
methylcellulose 2910 5 mPas (HPMC 2910 5 mPas) were mixed until the
mixture was homogenous. The mixture was fed into a Gimac single
screw extruder L/D 24:1 having the following operating
parameters:screw rate was 30 revolutions per minute, the
temperature ranged from 70.degree. C. to 235.degree. C. Yield was
17 g (85%). The melt extrudate was milled and fractions with
particle size below 150 .mu.m (condition I in point 6) and between
500 and 850 .mu.m (condition II in point 6) were collected.
5. Thermal Stability of the Antiviral Compound in the Melt
Extrudate
[0420] The thermal stability of compound 17 of formula (I-A) after
melt extrusion was determined by HPLC (high performance liquid
chromatography). No degradation of the antiviral compound could be
detected, which confirms the thermal stability of said compound
after melt extrusion.
6. Dissolution Study
[0421] In-vitro dissolution studies were performed on the melt
extrudate fractions described under point 4. 375 mg of each
fraction was directly added to the dissolution medium. The fraction
with particle size between 500 and 850 .mu.m was also filled in a
gelatin capsule nr. 0 EL, which was then added to the dissolution
medium (III). The dissolution medium was 900 ml of 0.1 N HCl at
37.degree. C. in Apparatus 2 (USP 23, <711> Dissolution, pp.
1791-1793) (paddle, 100 rpm). The concentration of the active
ingredient compound 17 of formula (I-A) dissolved in the test
medium was determined by removing a 3 ml sample at the indicated
time, filtering the sample over a millex-LCR filter, measuring its
absorbance at 286 nm and calculating the concentration
therefrom.
[0422] The following results were obtained:
TABLE-US-00009 Percentage dissolved active ingredient Time (min) I
II III 0 0.00 0.00 0.00 5 64.32 33.96 12.90 15 76.44 69.18 52.02 30
82.74 79.50 79.08 45 91.50 84.84 88.98 60 98.34 92.40 92.28 I:
compound 17 of formula (I-A):HPMC 2910 5 mPa s (1:1.5 (w/w));
fraction with particle size below 150 .mu.m II: compound 17 of
formula (I-A):HPMC 2910 5 mPa s (1:1.5 (w/w)); fraction with
particle size between 500 and 850 .mu.m III: compound 17 of formula
(I-A):HPMC 2910 5 mPa s (1:1.5 (w/w)); fraction with particle size
between 500 and 850 .mu.m filled in a gelatin capsule nr. 0 EL
[0423] The in vitro dissolution study from the melt extrudate
fractions and the fraction filled in a gelatine capsule shows that
the drug release reached at least 85% after 60 minutes.
* * * * *